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ABSTRACT
SMS is an enzyme belonging to the sphingolipid metabolic pathway.
Since the discovery and initial characterizations of sphingolipids (SLs) in
1884, extensive research has established that these molecules not only are
structural components of eukaryotic membranes but they are also critical
bioactive lipids involved in fundamental cellular processes such as
proliferation, differentiation,

apoptosis,

inflammation,

migration,

and

autophagy. In particular, SMS produces sphingomyelin (SM) in mammalian
cells by transfering the phosphorylcholine moiety from phosphatidylcholine
(PC) onto ceramide forming SM and diacylglycerol (DAG).

Both ceramide

and DAG are bioactive lipids with opposing functions, and SMS produces
sphingomyelin (SM) while consuming ceramide (negative regulator of cell
proliferation) and forming diacylglycerol (DAG) (a mitogenic factor).
Therefore enhanced SMS activity could favor cell proliferation.
To examine if disregulated SMS contributes to leukemogenesis, we
measured SMS activity in several leukemic cell lines and found that it is
highly elevated in K562 chronic myelogenous leukemia (CML) cells. The
increased SMS in K562 cells was caused by the presence of the BCR-ABL
oncogene, a hallmark of CML, as stable expression of BCR-ABL elevated
SMS activity in the BCR-ABL negative HL-60 cells while inhibition of the
tyrosine kinase activity of Bcr-abl with Imatinib mesylate, decreased SMS
activity in K562 cells. The increased SMS activity was the result of upregulation of the SMS1 isoform. Inhibition of SMS activity with D609 (a
pharmacological SMS inhibitor) or down-regulation of SMSl expression by
siRNA, selectively inhibited the proliferation of Bcr-abl positive cells. The

VIll

inhibition was associated with an increased production of ceramide and a
decreased production of DAG, conditions that antagonize cell proliferation.
A similar change in lipid profile was also observed upon pharmacological
inhibition of Bcr-abl (K526 cells) and siRNA-mediated down-regulation of
BCR-ABL (HL-60/Bcr-abl cells). These findings indicate that SMS1 is a
downstream target of Bcr-abl, involved in sustaining cell proliferation of
Bcr-abl positive cells.
The increased SMS 1 activity in bcr-abl positive cells was associated
with higher levels of the SMS 1 protein due to enhanced transcription, as
measured by quantitative real time PCR (QRT-PCR) of heteronuclear RNA
(hnRNA). In particular, the highest increase of SMSl transcript and mRNA
was observed when probing down-stream of exon 6, suggesting the
preferential utilization of an alternative transcription start site (TSS) in Bcrabl positive cells. Thus this study investigated the effect of Bcr-abl on SMSl
transcription. Indeed, RLM-RACE based analysis of Bcr-abl positive cells
identified multiple SMSl TSSs, including a TSS located within intron 6 in
close proximity and upstream to exon 7 (TSS C). Notably, in silica analysis
of the entire SMSl locus, including large areas of its 5' and 3' UTR, revealed
multiple putative promoter regions, including Promoter C located upstream
to TSS C. Further promoter-based studies corroborated the possibility of
Bcr-abl to mediate transcription of SMSl through the putative Promoter C
and the dependence of SMSI transcription on Bcr-abl was further confirmed
by demonstrating the inhibition of Promoter C activity upon inhibition of
bcr-abl activity with Imatinib. A series of deletions from the 5' end of
promoter C revealed a core promoter region from -110 to -113 from TSS C
suggesting that the cis-element(s) needed for Bcr-abl mediated SMSl
regulation was located within this area. Overall, these results provide strong
IX

evidence of Bcr-abl's regulation of SMSl expreSSIon through enhanced
transcription via a promoter switch.

x

Introduction
Sphingomyelin synthase (SMS) is the class of enzymes responsible
for production of sphingomyelin (SM) in mammalian cells. In particular,
SMS transfers the phosphorylcholine moiety from phosphatidylcoline (PC)
onto ceramide forming SM and diacylglycerol (DAG) (1-7). Since SMS can
up- and down-regulate levels of ceramide, a negative regulator of cell
growth and promoter of differentiation, and DAG, a well-established
mitogenic factor (8) (Figure 1), SMS activity may play an important role in
the regulation of pathologies associated with aberrant cell proliferation and
differentiation, such as leukemia. In mammalian cells SMS activity is
encoded by two recently identified genes, SMSl and SMS2 (9).

Figure 1. Enzymatic Reaction of SMSI
Other bioactive
{
.]
lipids
<J •.••• -- Ceramlde + Phos~hatidy~ (J
choline

SMS

[>

SM +

( DAG

)-----t> Other.bi.oactive
lipids

Figure 1. SMS is a bi-directional transferase that uses ceramide and phosphatidlycholine
to produce SM and DAG. Ceramide and DAG can be further processed by other
members of the sphingolipid metabolic pathways to become or act upon other bioactive
lipids.

1

Previous studies have shown increased SMS activity and decreased
ceramide levels in a pool of chemoresistant versus chemosensitive patients
with different leukemias (10). This study led to an in vitro screening of
SMS activity in various leukemia cell lines revealing an upregulation of
SMS activity in K562 cells compared to all other screened leukemia cell
lines. K562 cells are known to express the Bcr-abl oncogene, a hallmark of
95% of chronic myelogenous leukemia (CML) cases.

CML is a

myeloproliferative disorder of the hematopoietic stem cells and is clinically
characterized by three phases: chronic, accelerated and blast phase. The
most aggressive and refractive phase is the blast phase which is clinically
defined as an up to 30% increase of highly undifferentiated blast cells in the
bone marrow and peripheral blood. K562 cells were originally isolated from
a patient with CML in blast crisis; consequently these cells have an
undifferentiated blast-like phenotype.
In our preliminary results, we demonstrated that increased SMS
activity observed in K562 cells (compared to other leukemia and lymphoma
cells lines) could be recapitulated by stable expression of the Bcr-abl
oncogene In otherwise Bcr-abl negative cells.

Furthermore, expression

analysis by quantitative reverse real time RT-PCR (QRT-PCR) and
modulation of gene expression by siRNA treatment suggested that enhanced
expression of SMS1, and not SMS2 was responsible for increased SMS
activity in Bcr-abl-positive versus negative cells.

Additional studies

suggested that elevated SMS 1 expression, in Bcr-abl positive versus
negative cells, resulted from increased transcription and was most likely
regulated by an alternative transcriptional start site.
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Therefore based on these observations and given the opposing roles of
ceramide

and

DAG

on

proliferation

and/or

differentiation,

we

HYPOTHESIZED that enhanced transcription of SMSI contributes to
the undifferentiated, pro-proliferative phenotype of Bcr-abl positive
cells. To test this hypothesis the following specific aims were proposed:

Specific Aim 1: Determine the function o(SMSl in maintaining
the cancerous phenotype exhibited by Bcr-abl positive blast cells.
The over-all goal for Specific Aim 1 was to elucidate the role and
function of SMS in the regulation of cellular functions such as proliferation,
differentiation, and stress response in Ber-abl positive cells.
Rationale for Specific Aim 1:

Preliminary results demonstrated that Bcr-abl drives SMSl expression
and activity and that inhibition of SMS 1 resulted in a significant reduction of
proliferation that coincided with an induction of differentiation of Ber-abl
positive cells.

Bcr-abl's role in regulating SMS activity was further

substantiated by experiments using Imatinib, a catalytic inhibitor of Bcr-abI.
These experiments revealed both a time and dose dependent decrease of
SMS activity following Bcr-abl inhibition.
modulating

bioactive

lipids

was

Furthennore, SMS's role in

confirmed

measurements subsequent to SMS inhibition.

by

mass

spectrometry

These results showed that

pharmacological inhibition of SMS activity in K562 cells resulted in
increased ceramide and decreased DAG levels.

SMS inhibition, in both

K562 and HL-60/Bcr-abl cells did not provide evidence for increased cell
death as measured by trypan blue exclusion. Based upon these observations,
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we proposed that inhibition of SMS/SMS 1 expression would result in
decreased cellular proliferation and increased cellular differentiation and that
this modulation does not affect cellular toxicity_ Furthermore, we proposed
that inhibition of SMS/SMS 1 would produce an alteration of the levels of
the bioactive lipids, cerami de and DAG, resulting in a lipid profile consistent
with cell growth arrest (high ceramide and/or low DAG).
Therefore, in order to further consolidate the specific hypothesis, the
following sub-aims were proposed: 1) confirm SMSI 's role in maintaining
the undifferentiated phenotype in Bcr-abl cells, 2) verify absence of cellular
cytotoxicity upon inhibition of SMS activity and 3) validate modulation of
ceramide and DAG levels upon SMS 1 inhibition.
Specific Aim 1 resulted in an accepted publication with 1ll1nor
revisions in the Journal of Lipid Research, titled "Sphingomyelin synthase 1
activity is regulated by the Bcr-abl oncogene." Full details in manuscript
format can be found in Chapter 1, with the exception of ex vivo experiments
from CML patients which are included in Appendix A (Chapter 1).

Specific Aim 2: Determine if there is transcriptional activation of
SMSl upon Bcr-abl expression

The over-all goal for Specific Aim 2 was to provide an in depth
investigation of Bcr-abl-mediated regulation of SMSI transcription.

Rationale for Specific Aim 2:

Preliminary data strongly suggested that Bcr-abl promotes a 33-38fold increase of SMSl expression above levels seen in Bcr-abl negative
leukemia cell lines. In fact, experiments studying SMSl expression indicated
4

that Bcr-abl regulates SMSl via transcription. Notably, these investigations
also revealed the presence of an additional putative transcription start site
preferentially utilized upon BCR-ABL expression. Therefore the following
sub aims were proposed in order to examine the mechanism by which Bcrabl regulates SMSl transcription: 1) verify increased SMSl expression and
transcription upon Bcr-abi expression 2) identify the transcriptional start site
located within SMSl that is activated upon Bcr-abi expression, and 3)
characterize SMSl 's promoter utilized upon Bcr-abl expression.
Results obtained while addressing Specific Aim 2 are being organized
In a manuscript in preparation with a tentative title, "Transcriptional
regulation of SMSl by the Bcr-abl oncogene." This aim is covered in its
entirety in Chapter 2. Moreover, additional preliminary results indicating the
potential transcription factor responsible for Bcr-abl-dependent SMSI
enhanced transcription are presented in Appendix B (Chapter 2).
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Review of Literature

Overview of sphingolipid metabolism and signaling.
Introducing sphingolipids.
Sphingolipids (SL) are a diverse class of lipids originally identified as
integral structural components of eukaryotic membranes (11). The first SL
was isolated from the human brain and described in 1884 by the German
physician and biochemist, J.L. Thudichum (12). Due to its enigmatic
characteristics, this newly found lipid was termed sphingomyelin (SM) in
reference to the Greek mythological Sphinx who asked riddles for mortals to
answer to gain entrance into Thebes. Since the discovery and initial
characterization of SLs, extensive research has established that these
molecules not only act as structural components of eukaryotic membranes
but also they are bioactive lipids, regulators of essential biological processes
such as cellular proliferation, differentiation, apoptosis, inflammation,
migration and autophagy, (for excellent reviews, see (11,13-18).
Simple mammalian SLs are characterized by the presence of an
amine-containing

lipid

backbone

either

(dihydrosphingosine or sphingosine) (Figure 2).
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saturated

or

unsaturated

Figure 2. Ceramide Structure
Primary hydroxyl for linkage
of head group in complex SLs

o

OH

Double bond in position 4-5, absent in
dihydroceramide
Sphingoid backbone

Figure 2. Ceramide Structure. Ceramide as an example of a sphingolipid. Contains a
fatty acid linked via an amine-containing lipid backbone, and a primary hydroxyl for
possible linkages of head groups in complex sphingolipids.

A fatty acid can be linked via an amide-bond to this "sphingoid"
backbone, generating dihydroceramide or ceramide (saturated or unsaturated
backbone, respectively), considered to be the central block of the SL
pathway (Figure 2). The presence of a variable polar head group (from a
simple phosphate to very complex sugars, for example) connected to the
primary hydroxyl of ceramide characterizes complex SLs (17). Overall, SL
nomenclature is derived from the nature of the different groups attached to
the sphingoid backbone, and, so far, hundreds of SL species have been
identified.

SL metabolism and its regulation.

Since the discovery of SLs and their metabolism, the highly regulated
nature of this pathway has become apparent. SL metabolism presents several
7

levels of complexity: 1) the pathway proceeds through a number of
interconnected reactions,

some of which are reversible, potentially

redirecting certain steps of the pathway (Figure 3); 2) the pathway is a
reservoir of bioactive (signaling) lipids, often with opposing roles (i.e.
ceramide, sphingosine, and sphingosine-I-phosphate); 3) ceramide (and the
derived complex SLs) represents an array of molecular subspecies, each
characterized by the presence of a different fatty acid (Figure 2), often with
opposing biological functions; 4) different segments of the pathway reside in
different cellular compartments, thus the regulation of the modes by which
one SL produced in one organelle reaches another organelle (where it
functions as substrate for the next reaction) significantly affects the pathway
itself; 5) several SL-metabolizing enzymes are represented by different
isoforms, sometimes distributed in different cellular compartments, splitting
the pathway into multiple mini-modules; and 6) in one of the SL pathway
reactions, diacylglycerol (DAG) is produced, establishing the potential for
cross-talk between the sphingo- and glycero-lipid pathways (Figure 3).
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Figure 3. Schematic of SL metabolism
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Figure 3. Schematic of SL metabolism. SL metabolism is characterized by a complex
network of interconnected reactions, each regulated by one or more enzymes. Some of
the enzymes have birectional activity (SMSs, nCDases and Acers), and many of the
enzymes that catalyze the reaction reside in distinct intracellular compartments (Refer to
introduction for details). Different bioactive lipids are formed through the SL pathway,
SPT:serine palmitoyl
such as ceramide, sphingosine, SIP, Ceramide-l-P, DAG.
synthase;
DES:dihydroceramide
desaturase;
transferase;
CerS:ceramide
SMS:Sphingomyelin synthase; aSMase:acid sphingomyelinase; nSMase:neutral
sphingomyelinase; Cer 1P-P:ceramide-l-phosphate phosphatase; Cerk:ceramide kinase;
synthase;
Glyases: glycosidases;
GalCS :galactosylceraide
GCS :glucosylceramide
synthase; aCDase:acid ceramidase; SK:sphingosine kinase; SPP:sphingosine-l-phosphate
phosphatase;
FA: fatty
acid;
SM:sphingomyelin;
DAG:diacylglycerol;
PC:phosphatidylcholine; ceramide-l-phosphate. * in vitro, SMS 1 and SMS2 catalyze
bidirectional reactions. (9 ,19)

In the sections that follow, these aspects will be discussed in addition
to the fundamental concepts important for appreciating the specific role of
SLs in leukemia.
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The SLpathway: a complex network o/interconnected reactions.

The biosynthetic branch of the SL pathway generally begins with the
condensation of a serine and a palmitoyl-CoA to generate 3-ketodihydrosphingosine, catalyzed by the serine palmitoyl transferase (SPT)

(Figure

3).

The

3-keto-dihydrosphingosine

then

IS

reduced

to

dihydrosphingosine (also called sphinganine) by 3-keto-dihydrosphingosine
reductase.

Subsequently,

dihydrosphingosine

IS

N-acylated

to

dihydroceramide by ceramide synthase (CerS, also known as Lass) and
dihydroceramide

IS

desaturated to form ceramide by dihydroceramide

desaturase (DES). These initial steps of de novo SL synthesis occur in the
ER. Once ceramide is formed, it is transferred to the Golgi apparatus where
it can be used as a substrate for formation of complex SLs, namely
sphingomyelin (SM) through the action of SM synthase (SMS), glucosyl- or
galactosylceramide through the action of glucosylceramide synthase (OCS)
or galactosylceramide synthase respectively, and ceramide-l-phosphate
through the action of ceramide kinase (CERK). Complex SLs then reach the
plasma membrane, where they accumulate, via vesicular trafficking.
Breakdown of SLs occurs at the expense of complex SLs and
ceramide. The bulk of SL breakdown occurs in the lysosomes (via enzymes
with an acidic optimal pH) whereas a number of isoforms for the same
reactions (with neutral or alkaline optimal pHs) intervene to modulate SL
levels in response to specific stimuli in other organelles (Figure 3). A group
of enzymes named sphingomyelinases (SMases, characterized by acidic,
neutral or alkaline pHs), hydrolyse SM into ceramide (20). In addition,
glucosyl- and galactosyl-ceramide are catabolized by their own glycosidases,
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and ceramide-l-phosphate is dephosphorylated by the ceramide phosphate
phosphatase. Once produced, ceramide can, in tum,

b~

converted to

sphingosine through fatty acid cleavage via several ceramidases (CDases,
characterized by acidic, neutral or alkaline optimal pHs). Sphingosine can
then be converted into spingosine-I-phosphate (SIP) by the addition of a
phosphate group via sphingosine kinase (SK) (21). SIP is then broken down
by a lyase into hexadecenal and ethanolamine phosphate (22). Also,
sphingosine can be converted back to ceramide by CerS or by the neutral or
alkaline CDases since they operate bidirectionally (23-25). In spite of the
number of interconnected reactions within the SL pathway, it is important to
point out that there is only one way in (through the SPT) and one way out
(through the SIP lyase).

The SL pathway as a reservoir of bioactive lipids.

Considering SL metabolism and its effect on cell function
regulation, a complication arises in that SL metabolism produces several
bioactive lipids, such as ceramide and dihydroceramide, sphingosine, SIP,

ceramide-lP, GD3 ganglioside, and DAG. Depending on their specific
biochemical and biophysical properties, each of these lipids likely has its
own set of cellular targets (please refer also to the discussion on the
compartmentalization of the SL metabolism). Different downstream targets
may elicit specific cellular responses, which may eventually elicit totally
different effects on the fate of the cell. In this regard, ceramide and
sphingosine, for instance, have been shown to transduce signals generally
associated with growth arrest, and/or differentiation, and/or apoptosis,
whereas SIP and ceramide-lP mostly transduce pro-proliferative and
11

prosurvival signals (11,26-28). Thus, it is important to keep in mind that the
ultimate balance among all these bioactive lipids is the true final determinant
of the observed phenotype (29). To this end, the "lipidomic" analysis
(measurements of a large number of SLs from the same sample) is currently
the most effective approach to precisely model how a specific stimulus
interferes with SL metabolism and which of the SLs is most likely to be
involved in downstream signaling.
In leukemia, most of the evidence linking SL metabolism with
regulation of this cancer has focused on ceramide and SIP. Thus, we present
a brief overview of the biological effects, regulatory pathways, and
downstream targets for these two bioactive lipids.

Ce ram ide

The "signaling" function of ceramide was first proposed more than
twenty years ago. This discovery arose from studies showing that SL
metabolism can be regulated in response to extracellular agents in HL-60
leukemic cells. Specifically, after exposure to lu,25-dihydroxyvitamin D3
(Vitamin D 3), SM was hydrolyzed into ceramide, the proposed mediator of
vitamin D3-induced differentiation (30,31). Regulated SM hydrolysis was
subsequently observed in response to a variety of different cytokines, such
as tumor necrosis factor (TNF) u, interferon y, and interleukin-l (IL-I).
Other cellular functions in addition to differentiation appeared to also be
affected by ceramide. Indeed, ceramide was found to induce a cytotoxic
effect consistent with the apoptotic phenotype (32). Currently, cerami de is
thought to be involved in a variety of cellular processes such as apoptosis,
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differentiation, terminal differentiation, cell proliferation, and autophagy
(5,11,13-18,26,28,33-37). Of note, the bioactive functions of ceramide are
not only observed in connection with stress agents but are also observed
during physiological processes. For instance, ceramide's contribution to
apoptosis was also investigated in an ex-vivo setting using neutrophils
isolated from human blood. Neutrophils spontaneously undergo apoptosis 68 hours after entering the bloodstream, so ceramide's relationship to
apoptosis can be analyzed during this process. In this model, a substantial
increase in intracellular ceramide derived from de novo generation prior to
apoptosis was observed. Inhibition of the de novo pathway significantly
reduced caspase activation and spontaneous apoptosis, whereas ceramide
accumulation (either by exogenous addition or by inhibiting the synthesis of
complex SLs) resulted in increased apoptosis and caspase activation (38).
Ceramide accumulation in response to stress signals or during
physiological processes occurs due to one or more of these events: induction
of de novo synthesis (as in spontaneous apoptosis of neutrophils),
stimulation of SMases, and inhibition of complex SL synthesis (Figure 3).
Accumulation of ceramide through the de novo pathway via induction
of SPT (initial enzyme of SL metabolism) or CerSs has been shown to occur
in response to various stimuli such as UV radiation, palmitate overload
(implicating the involvement of SLs in diabetes or metabolic syndrome),
chemotherapeutic agents (etoposide, doxorubicine, daunorubicine and
gemcitabine), cytokines (TNF and IL-I), heat stress, hypoxia/reoxygenation,
and N-hydroxyphenyl retinamide (39-48). Moreover, de novo ceramide
synthesis has been linked to the onset of several diseases (49) such as cystic
fibrosis, diabetes, and chronic obstructive pulmonary disease (50-54).
Historically, two inhibitors, Myriocin and Fumonisin Bl have been
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instrumental in establishing a critical role for ceramide generated by this arm
of the pathway and to discriminate between SPT (inhibited by Myriocin) and
CerS (inhibited by Fumonisin B 1), when the enzymes had not been yet
identified (41,55,56). Now that the CerS family has been identified, progress
can be made on dissecting the specific molecular mechanisms through which
ceramide is generated by these enzymes.
Extensive literature documents the generation of ceramide VIa
activation of SMases, which are a family of enzymes consisting of several
isoforms characterized by different pH optima and subcellular localization.
This group includes one acidic SMase (acid pH), localized in the lysosomes;
four different neutral SMases (neutral pH), localized in different cellular
compartments (neutral SMase 1 in the ER, neutral SMase 2 in the Golgi and
plasma membrane, neutral SMase 3 in ER and Golgi and neutral SMase 4 in
the ER and mitochondria); and one alkaline SMase exclusively expressed
and secreted in the gut (57-64). The majority of the studies addressing the
regulation of ceramide production via this pathway and its implications refer
to acid SMase and neutral SMase 2. In fact, neutral SMase 1, although
possessing SMase activity in vitro, does not seem to be a major nSMase in
human cells and in mice. Neutral SMase 3 and 4 were only recently
identified (60,61,63,65).
The study of acid SMase (aSMase) as a modulator of ceramide has
exploited the existence of both a human disease, Niemann Pick type A and B
(characterized by aSMase gene deficiency) and a knock out mouse model
(66,67). With these tools, it has been convincingly shown that activation of
aSMase occurs in response to a variety of stimuli such as bacterial and viral
infections, ionizing and UV radiations, CD95 treatment, chemotherapeutic
agents and nitrosative stress in a variety of cell types including leukemia
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cells (5,68-80). Interestingly, the same aSMase gene gives fise to two
distinct isoforms, one targeted to the lysosomes and one zinc-dependent,
secreted in the extracellular space. Most studies investigating the signaling
role for aSMase have referred to the lysosomal enzyme. A current model for
regulation of aSMase in response to both receptor stimulation (CD95, CD40
or EGFR) (81,82) and cytotoxic agents (such as cisplatin) (83) involves
translocation to the plasma membrane and formation of ceramide enriched
microdomains which coalesce to form large platforms and amplification of
the signaling cascade.
ASMase was also found to signal through the lysosomes via activation
of cathepsin D (84). In fact, cathepsin D was found to bind ceramide and, as
a consequence, to mature into the active 32kDa form. Upon TNF treatment,
it was observed that mature cathepsin D (after aSMase activation) cleaved
and activated the proapoptotic factor, bid, suggesting a role for aSMase in
TNF-dependent cell death (85). Several mechanisms have been reported for
aSMase activation. In particular, aSMase was found to be activated by
reactive oxygen species, potentially through disruption of protein disulfide
bridges (86-89), by phosphorylation of serine 508 through protein kinase C
delta (an event critical for the translocation of the enzyme to the plasma
membrane), (73,90) and by direct proteolytic cleavage through caspase 7
(91).

Neutral SMase (nSMase) activation has also been reported in response
to

a

variety of treatments

such as

cytokines

(TNF

and

IL-l (3),

chemotherapeutic agents, serum deprivation, amyloid J3 petide, hydrogen
peroxide, and upon ageing and cell confluence (92-94). The study of the role
of nSMase in ceramide-mediated signaling has suffered from a lack of
specific inhibitors and late identification of the genes. Thus for years,
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nSMase was just a biochemical activity that changed upon varIOUS
treatments. The recent identification of several isoforms represents a
milestone for SL investigations and current efforts are placed on revisiting
the involvement of specific nSMases under various experimental conditions.
Currently nSMase2 is the best characterized isoform. Regulation of
nSMase2 may occur through different mechanisms, and like aSMase,
nSMase2 has been localized to various intracellular compartments such as
the Golgi, nucleus, and plasma membrane, and cellular localization has been
shown to change upon treatment. For example, in subconfluent MCF-7 cells,
nSMase2 is found predominantly intracellularly and at cell-to-cell contact
sites, but as cells reach confluency, the enzyme is found almost exclusively
at the plasma membrane (95). Moreover, under oxidative stress, nSMase2
was found at the plasma membrane, whereas the addition of reduced
glutathione promoted its translocation to the perinuclear region (96).
Importantly, the plasma membrane localization of nSMase2 may be
regulated by the presence of two palmitoylation cystein clusters present in
proximity of the protein N-terminus and nSMase2 action in- this
compartment may also depend on the presence of phosphatidylserine, an
activator of the enzyme naturally enriched in the inner leaflet of the plasma
membrane (97,98). Translocation to the plasma membrane after TNF
stimulation of lung epithelial cells was also shown to be dependent on p38
mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) 8
(99,100). Increased transcription of nSMase2 was observed in response to
the chemotherapeutic agent, daunorubicine and this event was characterized
as a critical step for the cytotoxic action of the drug (101).
A

strong

link

exists

between

nSMase2

and

regulation

of

inflammation. In fact, nSMase2 activation after TNF treatment has been
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reported in a variety of cell lines, such as A549, HUVEC, smooth muscle
cells (100,102,103), and a model has been proposed in which, at the plasma
membrane, a complex forms containing the TNF receptor, FAN (the factor
associated with N-SMase activation), the FAN interacting protein RACKI
and the polycomb group protein EED, and this leads to nSMase2 activation
(104,105). Compelling evidence for nSMase2 regulation by

IL-l~

also

exists. In fact, hepatocytes from aged rats have been reported to have
increased nSMase activity and hypersensitivity to IL-l f3 stimulation;
nSMase2 inhibition in these cells significantly reduced the IL-l b response
(93). In line with these observations, over-expression of nSMase2 in primary
hepatocytes from young rats exacerbated the IL-l f3 response, mimicking the
phenotype observed in aged rats.
Ceramide accumulation can also be prompted by inhibition of the
synthesis of complex SLs. Indeed a decrease in SMS activity before the
onset of apoptosis has been observed in Kym-l cells after treatment with
TNF (which also inhibited glucosylceramide synthase), and in Jurkat cells
after CD95 stimulation or photodynamic therapy (106-109).
Several ceramide downstream targets have been identified, and in
addition to cathepsin D, ceramide has been reported to activate protein
phosphatases PPI and PP2A. The first has been proposed to be a mediator of
ceramide-induced

cell

cycle

arrest

via

dephosphorylation

of

the

retinoblastoma (Rb) protein (105,110,111), and the second has been linked
to c-jun N-teminal kinase (JNK) dephosphorylation and ubiquitination of the
IL-l f3-receptor-associated kinase (IRAK) (both involved in IL-1 ~ signaling),
and Akt dephosphorylation (112,113). Interestingly, ceramide seems to
activate PP2A in two ways, by directly activating the protein as shown by in
vitro assays (114) and by binding to the inhibitor of PP2A (IPP2A), inducing
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its dissociation from PP2A and consequent loss of inhibitory activity (115).
Other targets of ceramide include PKCa,

PKC~

and the kinase suppressor of

Ras (116-119).

Sphingosine-l-P (Sl P)

SIP is the best characterized bioactive SL and it is thought to
counteract the actions of ceramide. SIP is produced by phosphorylation of
sphingosine which, in

tum~

is formed from ceramide hydrolysis by one of

several CDases (Figure 3). On the other hand, given the large difference in
cellular content between sphingosine and SIP (approximately 100:1),
activation of CDases is not theoretically necessary for acute intracellular
increases in SIP. Nevertheless, activation of CDases has been observed in
response to a variety of stimuli, such as cytokines, dexamethasone,
doxorubicin, gamma radiation, serum deprivation, interestingly many of the
same stimuli also found to activate SMases (for a comprehensive review on
CDases see (27)).
Similar to ceramide, sphingosine has been associated with a negative
effect on cell proliferation and induction of apoptosis, thus the balance of the
"ceramide-CDases-sphingosine-SK-S IP" branch of the SL pathway is often
critical for treatment outcomes.
Sphingosine can be converted to SIP by either one of two sphingosine
kinases, SKI or SK2, and once formed, SIP may act intracellularly or
extracellularly. SIP has been found to be a ligand for the SIP (1 to 5)
receptor family (previously named EDG receptor family),

and its

extracellular functions proceed through the activation of one or more of
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these receptors (120). Specific cellular effects of extracellular SIP are likely
due to the tissue-specific expression patterns of the receptors and their
coupling to specific G proteins (121).
Addition of extracellular SIP generally has pro-proliferative and prosurvival effects, which can be recapitulated by over-expression of SKI.
Moreover, activation of SKI and production of SIP has been shown to occur
in response to cytokines, chemokines, growth factors, and hormones, to
name a few [reviewed in (28)]. Because SIP is charged, once formed, it is
actively transported from inside the cells to the extracellular milieu, possibly
through the ABCCI and ABCAI transporters (122,123). When outside the
cell, SIP may act in an autocrine or paracrine fashion via the SIP receptors.
Most SIP induced effects (either after extracellular addition of SIP or in
response to agonist stimulation) have been found to depend upon SIP
receptors. After an early acute activation of SKI, many agonists later induce
a sustained increase of SKI expression as a result of increased transcription
(124-128).
SKI and SK2 are primarily cytosolic enzymes but their localization
changes in response to certain stimulations. For example, after treatment
with TNF, SKI translocates to the plasma membrane [via extracellular
signal-regulated kinases 1/2 (ERKI/2)-mediated phosphorylation of serine
225 and interaction with the calcium- and integrin-binding protein 1] to
produce SIP locally (129,130). Recently, it was reported that SIP generated
by SKI in response to TNF binds to the TNF receptor associated factor 2
(TRAF2), stimulating its E3 ligase activity and the ubiquitination of the
receptor interacting protein 1 (RIPl), a critical step in the activation of the
pro survival transcription factor Nuclear Factor kappa B (NF-kB) (131).
These events were shown to occur independently from SIP receptors, thus
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demonstrating an intracellular role for SIP. Another potential intracellular
target for SIP is represented by thapsigargin-sensitive calcium channels in
the ER. Specifically, SIP elicited inositol triphosphate receptor-independent
calcium release from subcellular fractions enriched in rough ER (132). In
addition to the plasma membrane, SKI has been found to translocate into the
nuclear envelope, in the phagosome or extracellularly, whereas SK2 has
been also localized in the ER and inside the nucleus (21,133-135). It has
been shown that nuclear SK2 and SIP associate with the histone
deacetylases 1 and 2 (136), preventing deacetylation of lysines within
histone tails, and thus affecting their DNA binding and gene expression.
Activation of SK2 is induced by fewer agonists than SKI, and
overexpression of SK2, in contrast to SKI, generally induces cell growth
arrest and apoptosis, and it sensitizes cells to chemotherapeutic agents (with
few exceptions) (137,138). Although it appears that SKI and SK2 functions
are significantly different, SK2 can, in part, compensate for SKI and vice
versa because the single knock out mouse for SKs are viable, whereas the
double knock out mouse model is not (139).
Overwhelming evidence supports a role for SKI and SIP in
carcinogenesis. In fact, SKI overexpression has been shown to be sufficient
for inducing transformation of 3T3 cells as it promotes focus formation and
colony formation in soft agar, and tumors in immunodeficient mice,
suggesting that SKI may act as an oncogene. Moreover, SKI was found to
be involved upstream of H-Ras-dependent transformation (140). SKI is also
a positive regulator of cell growth and survival of human glioblastoma cells
because its inhibition hinders growth in a xenograft model (141).
Additionally, SKI was found to be involved in colon carcinogenesis by
regulating cyclooxygenase 2 expreSSIon and prostaglandin E2 formation
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(142,143), and in head and neck squamous cell carcinoma, for which its
expression was up-regulated and found to be necessary for disease
development (144,145). Interestingly, not only SKI is up-regulated in
various cancers (acute leukemia, breast, colon, lung, ovary, stomach, uterus,
kidney, and rectum) compared with normal tissue from the same patient but
SKI expression often correlates with more malignant phenotypes and/or
chemotherapy resistance (28,142,146-149). Involvement of SKI in cancer is
not only due to SKI-mediated regulation of cell growth and survival but also
due to migration, invasion, andangiogenesis (21,139,150-156). Importantly,
a monoclonal antibody for SIP that sequesters and neutralizes extracellular
SIP unequivocally demonstrated the requirement of SIP for endothelial cell
migration and capillary and blood vessel formation in various human
xenograft tumors (157).

Location,
location,
location:
the
compartmentalization of the SL pathway

importance

of

Understanding the effects of SL metabolism is further complicated by
the fact that both SLs and their associated enzymes have distinct sub-cellular
localizations. The subcellular localization of SLs depends upon their
inherent biochemical characteristics.

For example, the

simple SLs,

sphingosine and dihydrosphingosine are sufficiently amphipatic, that they
are able to freely diffuse from the membrane where they were produced, and
to travel through the cytosol to other cellular compartments or the
extracellular space (158). In contrast, the respective phosphorylated lipids,
sphingosine-l-P and dihydrosphingosine-l-P cannot diffuse through the
membranes thus, unless actively pumped, they remain in the hydrophilic
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compartment in which they are formed (122,123). Different from simple
SLs, ceramide does not freely diffuse through the membranes and it only
moves between cell compartments via vesicular trafficking or via protein
transport with the ceramide transfer protein (CERT) (159). However,
ceramide can still flip from one leaflet of the membrane to the other, thus it
can access the catalytic sites of enzymes localized on either leaflet (160162). This action contrasts to more complex SLs such as SM and
glucosylceramide,

which cannot readily flip

because of the

steric

impediment of their head-groups. So, they remain in the leaflet in which
they were produced. For glucosylceramide though, it is possible that a
flippase may help the lipid to reach the opposite leaflet for further
modifications.
Localization of SLs that do not readily diffuse through membranes
mostly depends upon the localization of the enzymes that produce them. De
novo synthesis of SLs, up to the formation of ceramide, takes place in the
ER and from there ceramide is transported to the Goigi apparatus via
vesicular trafficking for glucosylceramide synthesis and mostly through
protein transport (CERT) for SM synthesis. Therefore, SL levels are not only
determined by regulation of the enzymes through which they are
metabolized but also by regulation of the processes that connect different
branches of the pathway residing in different organelles.
Several reactions may be catalyzed by different isoforms of the same
enzyme. For instance, CerS is represented by six isoforms (CerS 1-6) that
have been localized in the ER (for a review please see (163)), as are the two
dihydroceramide desaturase isoforms, DESI and DES2 (164). The situation
is further complicated by the fact that for some enzymes, different isoforms
are localized in different organelles, as is the case for SMS 1 which is present
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in the Golgi, and SMS2, which is present in the Golgi and plasma membrane
(9,165). Likewise, acid CDase is found in lysosomes, neutral CDase is found
in the mitochondria and plasma membrane, and alkaline COase (Acerl) is
localized to the ER, Acer2 is found in the Golgi, and Acer 3 in the ER and
Goigi (for a comprehensive discussion on CDases please refer to (27)).
Thus, it follows that distinct enzymes that regulate the same reaction
may coexist in the same organelle and that same reactions are carried out in
different organelles. Modes by which each enzyme accesses its substrate (in
particular for different isoforms within the same organelle) and the way each
substrate accesses its enzyme (in particular for different isoforms in different
organelles) become determining factors in the regulation of specific
functions of the different enzymatic isofonns.

Not all ceramides are created equal.

With the advancement of techniques that permit characterization and
quantification of SLs, a significant finding of the last 15 years is that
ceramides consist of a diverse class of molecules. In fact, via mass
spectrometry, it has been shown that different fatty acid moieties may be
naturally linked to the sphingoid backbone, mainly long fatty acids (with 14
to 18 carbons) and very long fatty acids (with 20 carbons and above)
(Figure 2).
The significance of such ceramide variety may lie within specific
functions of each species. In support of this hypothesis, in head and neck
squamous cell carcinoma (HNSCC), C I6 and C I8 ceramides have been
shown to exert opposing effects: accumulation of C I8 ceramide by
overexpression of CerS 1 induced apoptosis and potentiated the cytotoxic
23

effect of chemotherapeutic agents (42), whereas accumulation of C 16
ceramide via CerS6 was essential for HNSCC survival (166). Of note, the
same ceramide species may exert different effects in different cell types. In
fact, in Ramos B cells, the specific increase of C I6 ceramide contributed to
apoptosis induced by IgM cross-linking (167), and, in colon cancer cells, C 16
ceramide produced by CerS6 restored sensitivity to tumor necrosis factorrelated apoptosis-inducing ligand, TRAIL(168), thus exerting a proapoptotic function in both cell types. In HEK 293 T cells, unlike HNSCC,
CIS

ceramide generated by CerSI overexpression did not cause apoptosis

(169). In addition to specific functions for C 16 and C I8 , it was also observed
that an increase of C 24 :0 and C 24 : 1 ceramides via activation of nSMase2
induced cell growth arrest in the breast cancer cell line, MCF-7 (95).
The possibility that different ceramide species may exert different
functions perhaps justifies the presence of many different enzyme isoforms.
The most eloquent example is represented by the CerS family. Strikingly,
each family member has a clear substrate preference for specific fatty acylCoAs, which determines the specific molecular ceramide species produced.
For example CerSl utilizes mostly C 1S - and C 18 : I -CoA; CerS2 utilizes CoAs
carrying very long chain fatty acids; and CerS5 and CerS6 utilizes mostly
C I6 -CoA (163). Therefore, this substrate preference ensures that CerS are not
redundant when more isoforms are expressed at the same time. It is tempting
to speculate that different substrate specificity may be shared also by other
enzymes of SL metabolism for which different isoforms are present in the
same cellular compartment, such as neutral SMases or SMSs. However,
experimental evidence to support this is presently lacking.
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Crosstalk between the SL and glycerolipid pathways .. Role of
Sphingomyelin Synthase.

The enzyme that synthesize SM, SMS, do so by transferring a
phosphocholine moiety from PC onto the primary hydroxyl of ceramide (6).
Therefore in the course of the reaction, a DAG molecule is also produced
(Figure 3). DAG is a well-established bioactive glycerolipid associated with
pro-proliferative and prosurvival phenotypes and with several important
cellular targets such as PKCs, protein kinase D, RasGRP, and chimaerins
[for reviews, see (170-173)]. Thus, it is apparent that SMS can regulate in
opposing directions levels of two bioactive lipids with opposing cellular
effects, ceramide and DAG.
The SMS family has have only been recently molecularly identified
(174,175). In mammals, two genes SMSl and SMS2 are responsible for
encoding two SMS isoforms, SMS 1 and SMS2. At the protein level, human
SMS1 and SMS2 consists of 413 and 365 amino acids, respectively, with an
apparent molecular weight slightly above 37kD. SMS 1 and SMS2 share
50% identity and 64% similarity. Significant divergence is found in the
amino termini of the proteins where SMS 1 carries a sterile alpha motif
(SAM) missing in SMS2. SMSI and SMS2 are both integral membrane
proteins with 6 predicted transmembrane domains (174). Importantly, SMS1
and SMS2 differ for their sub-cellular localization. SMS 1 is localized in the
Goigi and SMS2 in Goigi and plasma membrane. Importantly, this
localization pattern is in agreement with early biochemical studies that found
the bulk of SMS activity in the Goigi and residual activity in other cellular
compartments including plasma membrane (176-181). Recent studies have
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established that the SAM domain is not important for SMS 1 localization
since it neither changes localization of SMS2 when a SAM-SMS2 chimaera
was studied (182). On the other hand, 4 palmitoylation sites present on the
C-terminus of SMS2, and absent on SMS 1, seem to be instrumental for
SMS2localization to the plasma membrane (183).
In vitro biochemical characterization of the two proteins, using a yeast
expression system, showed that both enzymes work as bidirectional
transferases potentially able to synthesize either SM or PC (174). In addition
to PC, SMS2 can also convert Phosphatidylethanolamine (PE) into
phosphorylethanolamine-ceramide (EPe) (5).

In Hela and macrophage cell

lines, studies conducted by Luberto, et al. (165) and others (184,185) have
shown that down-regulation of either SMS 1 or SMS2 causes a decrease in
SM and a concomitant increase of ceramide, lipid changes that suggest a
basal SM synthetic activity. Moreover, it was shown that both SMSI and
SMS2 are active in the Goigi and contribute to de novo SM synthesis. The
effect of modulation of SMSs on DAG are less apparent. Down-regulation
of both SMSs slightly reduces DAG levels in macrophages (185), but it does
not exert a net effect in Hela cells (165,184). On the other hand, subcellular
localization studies conducted by our laboratory in Hela cells (165), have
revealed as modulation of both SMSs induces a relocalization of DAG
subcellular pools. These studies suggest as both SMSs have the ability to
modulate also DAG cellular levels. Modulation of SMS 1 or SMS2 in
macrophages, HEK 293, and lymphoma have demonstrated the importance
of either SMS in the maintenance of proper homeostasis of lipid rafts and
consequently proper lipid-raft-mediated receptor signaling, as for CD95,
TNFR and TCR (186-188).
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Furthermore, in addition to direct regulation of DAG levels, SMSs
may also affect levels of other bioactive glycerolipids derived from DAG,
such as phosphatidic acid or glycerolipids with metabolic functions such as
monoacylglycerol or triacylglycerol. Importantly, SMS1 knock out mice
have been recently characterized as having significant neonatal lethality,
smaller size, reduced body weight, loss of fat tissue mass, and impaired
insulin secretion (189), thus, whether these phenotypes are related to
alteration of glycerolipid metabolism will be of interest.
Evidence for the regulation ofSMS

The following are key studies that helped to elucidate SMS' role
within regulated cellular processes. These studies are limited since there
was a great deal of difficulties in the past identifying the proteins or genes
that are responsible for SMS activity and its regulation. Nevertheless, SMSs
role in addition to SM biosynthesis has been validated by a number of nicely
crafted studies. These studies were performed, for the most part, in
experimental conditions characterized by altered proliferation and/or
transformation. Miro-Obradors and colleagues showed that SMS activity is
increased during rat liver regeneration compared to non-proliferating cells
(190). In a different study, SMS activity was increased in quiescent primary
astrocytes after stimulating the cells with J3-fibroblast growth factor, a
cellular proliferation stimulus (191). Other studies demonstrated elevated
SMS activity in transformed phenotypes (such as hepatocellular carcinoma
versus normal liver and SV -40 transformed fibroblasts versus their normal
counterpart)(192,193). Alternatively, a decrease of SMS activity preceded
the onset of apoptosis induced by either TNF or FAS ligand (108,194). The
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decrease of SMS was an early event concurrent with early accumulation of
ceramide. Importantly, the loss of SMS activity was found to be a caspasedependent event thus suggesting that inhibition of SMS could be a regulated
process required for the full development of the apoptotic program.
In spite of the great biological potential of SMS, its role and function
In important cellular processes, such as proliferation, apoptosis and
differentiation is still poorly understood. The recent identification of
candidate SMSs genes provides us with a unique and long awaited
opportunity to start shedding some light on these important enzymes.

General concepts of leukemia.
Classification and incidence of leukemia.

Leukemia can be broadly classified as a malignant neoplasm arising
from the transformation of a hematopoietically derived blood cell. Like other
cancers, leukemia is characterized by abnormal and uncontrollable cell
division. Most leukemias fall into four different classes: acute myelogenous
leukemia

(AML),

acute

lymphoblastic

leukemia

(ALL),

chronic

myelogenous leukemia (CML), and chronic lymphocytic leukemia (eLL)
(195). Each of these leukemias include numerous sub-types, so a uniform
classification system does not exist at this time. Currently, designations of
different leukemia subtypes are made according to either the FrenchAmerican-British (FAB) system or the World Health Organization (WHO)
classification. The F AB system represents a more classical approach that
uses

morphological,

cytochemical,

and

to

a

lesser

degree,

immunophenotyping analysis for classification (196-200). The WHO
classifications are gradually replacing the more traditional FAB groups. Like
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the F AB designations, WHO classifies different leukemia types according to
morphology, but also relies heavily on cytogenetic and genetic features.
According to the WHO classification system, leukemia can be initially
classified based on lineage, namely:

myeloid neoplasms, lymphoid

neoplasms, mast cell disorders, and histiocytic neoplasms. In addition, each
category is further narrowed according to a combination of diagnostic
features including morphology, genetic abnormality, clinical symptoms, and
immunophenotype (195,201).
ALL and AML are clinically characterized by sudden onset and, if not
treated, the progression of these diseases is rapid. Patient signs and
symptoms are related to depressed bone marrow function. ALL is the most
common leukemia, representing about 80% of all acute leukemias and is far
more common in children than in adults. In fact, ALL is the cause of 75% of
childhood cancers, with AML accounting for most of the remaining cases
(202). AML is mostly a disease that occurs in adults although, occasionally,
AML arises in children and young adults (203).
In general, the chronic leukemias, eLL and CML, are initially
characterized by increased proliferation of more differentiated myeloid and
lymphoid cells. Both CML and eLL are mainly adult-onset diseases and
thus are rarely seen in children. CLL is responsible for 30% of all leukemias
and occurs mostly in older adults with an average age at diagnosis around 72
years-of-age. Finally, CML accounts for 10-15% of all leukemias, with the
average age of onset at 67 years-of-age at the time of diagnosis. (203).

29

Leukemia as a stem cell disorder.

Leukemia is thought to be the result of a neoplastic transformation of
the hematopoietic stem cell (HSC). Normal HSCs, and their partially
differentiated progenitor cells (collectively called blast cells) are an
important reservoir for short-lived, mature blood cells. HSCs are classified
into

compartments

according

to

their

distinct,

laboratory-based

characteristics. The three compartments are the stem, progenitor, and
precursor compartments, and although each of these compartments includes
a number of different cell types, each compartment is distinctive. All cells in
the different compartments have self-renewal capabilities for maintaining a
stable HSC population. Determination of the differentiation status is based
upon the detection of a variety of unique surface antigens (204-207). The
stem cell compartment contains the least number of cells. These cells are
molecularly defined by antigens expressed on the surface, such as Thl-l, the
Flk-l/KDR receptor as well as the expression of CD34 (205,208,209). The
next compartment is the progenitor cell compartment; these cells are not
morphologically distinguishable. Progenitor cells have become partially
differentiated to initiate a lineage specific pathway and are more copious
than those within the stem cell compartment. The molecular pathway
committing these cells to lineage dependence is not completely understood.
Within the progenitor compartment, cells are at different differentiation
stages, which are defined based upon a variety of different criteria including
proliferative potential, maturation time, response to a variety of cytokines,
and the ability to produce partially differentiated progeny. The final
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compartment is the precursor cell compartment in which cells can be
distinguished based on their morphological characteristics (207).
The most compelling evidence establishing leukemia as a stem cell
disease comes from experiments using AML cells isolated from human
patients. These cells, after transplantation into an immuno-compromised
mouse, gave rise to AML, establishing a novel mouse model for the disease
(210). These studies reveal similarities between hematopoietic stem cells
and leukemic stem cells, including properties of multi-potency and selfrenewal that were maintained even upon serial transplantation of AML cells
into mice. Interestingly, upon transplantation, few AML cells (estimated at
1x105 to 1x106 mononuclear cells in the marrow) had complete self-renewal
capabilities and multi-potency. Further immunophenotypic analysis of this
population demonstrated that these AML cells displayed known HSC
markers (CD34+/CD38-) consistent with the least differentiated stem cell
state. In contrast, AML cells that exhibited a slightly more differentiated
immunophenotype, CD34+/CD3S+ were unable to proliferate effectively.
These data strongly suggest that the heterogeneous population of blast cells
exhibiting various stages of maturation, as seen in leukemia patients, can be
derived from a single leukemic stem cell (LSe) which, in tum, can sustain
the leukemic disease. Importantly, this hierarchical LSC population
organization in terms of both numbers and levels of maturity mirrors the
commonly accepted paradigm of normal adult hematopoiesis. In addition,
the slow rate of proliferation, which is characteristic of HSCs, is also
exhibited by LSCs. In fact, LSCs slow proliferation rate is thought to be a
contributing factor to the overall refractiveness of leukemic disease to
conventional chemotherapy strategies targeting rapidly dividing cells (210213).
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SLs and Leukemia
Acute myelogenous leukemia (AML)
AML is mostly associated with acquired genetic alterations that
inhibit terminal differentiation and result in replacement of normal marrow
elements with largely undifferentiated blast cells. The traditional in vitro
cellular model to study this disease is the HL-60 cell line (203), which was
obtained by leukopheresis from a patient with acute promyelocytic leukemia
(214). Many early studies using HL-60 cells revealed that alterations of SL
metabolism in leukemic cells can induce cellular processes such as apoptosis
and differentiation which can be further exploited for therapeutic benefit.
Early studies showed that increased ceramide correlated with HL-60
cells differentiation induced by vitamin D3 treatment (30). In these studies,
ceramide was shown to be derived from SM hydrolysis; equal masses of
ceramide and phosphorylcholine were produced after vitamin D3 treatment,
and increased neutral SMase activity in cell extracts was detected. Similar to
the behavior of "signaling" molecules, ceramide returned to basal levels by 4
hours. These observations suggested the existence of a "SM cycle", a
mechanism of SM hydrolysis and regeneration intimately linked to cellular
processes such as differentiation.
Subsequent

studies

corroborated

ceramides'

role

in

HL-60

differentiation by illustrating enhanced vitamin D-mediated differentiation
upon addition of cell-permeable ceramide (synthetic ceramide with a shorter
fatty acid chain) or purified soluble bacterial neutral SMase (31). Ceramide
has also been shown to recapitulate the ability of TNF-a or interferon y to
induce monocytic differentiation in HL-60 cells (215). Mechanistic studies
later established that TNF-a stimulation (leading to ceramide generation)
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resulted in de-phosphorylation of Rb (216) due to PPI activation (217).
Ceramide accumulation during differentiation is not only observed in HL-60
cells (30,31,215), but also is seen in a number of other cell types, such as
EL4 thymoma cells (218), cerebral Purkinji cells (219), and U937
monoblastic leukemia cells (220).
Subsequent experimentation revealed that ceramide could induce a
cytotoxic effect consistent with the apoptotic phenotype (32). The fact that
SL modulation can induce apoptosis was substantiated by additional studies
showing SM hydrolysis followed by apoptosis in response to a variety of
different cytokines and known stress-inducers such as TNF -u, interferon y,
and IL-l in numerous cell types. Furthermore, the biological effect of many
of these agents was reproduced upon exogenous addition of either cellpermeable ceramide analogues or bacterial SMase [for excellent reviews on
this topic please refer to (92,221,222)].
Because AML is characterized by the inability of stem cells to
properly differentiate, the ability of ceramide to either revert the
undifferentiated phenotype of AML blasts or suppress them (alone or in
combination with chemotherapeutic agents) has prompted investigators to
consider SL metabolism manipulation as a novel therapeutic approach.
Moreover, recent developments have established a link between drug
resistance and alterations of the SL pathway. It has long been established
that treatment of parent HL-60 cells with doxorubicin results in increased
ceramide and subsequent apoptosis (223). In contrast, HL-60 cells positive
for the multidrug resistance genes MDR1 or MRPI(224), failed to respond
to doxorubicin or etoposide and did not accumulate ceramide (225). It was
proposed that the key difference in SL metabolism between parent and MDR
HL-60 cells was SKI expression, which was low in parent HL-60 and
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significantly elevated in MDR HL-60 cells. Importantly, forced SKI
expression in sensitive parent cells resulted in blockade of apoptosis whereas
inhibition of SKI activity in MDR HL-60 by the pharmacological inhibitor
F-12509a overcame this resistance by inducing mitochondrial-dependent
apoptosis. In another study, granulocyte macrophage colony-stimulating
factor (GM-CSF) fused to the catalytic and translocation domains of the
diphtheria toxin (DT388-GM-CSF) induced cell death in MDR HL-60 cells.
DT388-GM-CSF

treatment

induced

a

strong

ceramide

accumulation

concomitant to SM hydrolysis (226). Because the GM-CSF receptor is only
present on AML blasts, the engineered diphtheria toxin is preferentially
delivered to AML cells, thereby killing them, likely by affecting SL
metabolism. The effectiveness of DT388-GM-CSF as a novel therapeutic
approach for AML was initially determined in a phase I clinical trial
conducted on drug-resistant AML patients. In this trial, DT388-GM-CSF was
found to promote partial or complete remission, although hepatotoxicity
prevented widespread drug use (226).
Recently, the therapeutic potential of the modulation of bioactive SLs
as a way to potentiate other therapies was investigated in conjunction with
resveratrol (3,5,4'-trans-trihydroxystilbene), a natural compound known to
exhibit anti-tumor activities through an undetermined mechanism. It was
observed that elevation of endogenous ceramide in HL-60 cells promoted by
either cell permeable C 8-ceramide treatment, pharmacological inhibition of
glucosylceramide synthases with l-phenyl-2-decanoylamino-3-morpholinoI-propanol (PDMP) or SKI inhibition in combination with resveratrol was
followed by significantly greater apoptosis compared to any of the
treatments given in isolation (227). These observations support the idea that
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induction of ceramide accumulation might be a viable avenue for sensitizing
cells to other cytotoxic agents.

Acute lymphoblastic leukemia (ALL).

ALL represents a group of neoplasms defined by accumulations of
precursor B or T-Iymphocytes commonly called lymphoblasts (203). In
particular, T-ALL is a highly aggressive leukemia and represents 15% of
childhood ALL and 25% of adult ALL (228). Model systems of lymphoidderived cell lines have allowed reseachers to uncover the potential of SLs as
mediators of chemotherapeutics through apoptosis. For example, cytarabine
(Ara-C) and fludarabine induced apoptosis in lymphoid leukemia cell lines
by increasing ceramide via SM hydrolysis as well as de novo ceramide
synthesis (229). The correlation between ceramide and apoptosis is also
supported by ceramide accumulation in ALL cells in response to
doxorubicin (230) and the vinca alkaloid, vincristine (VCR) (231,232).
Ceramide accumulation-driven apoptosis is a proposed pathway to
cytotoxicity in addition to the ones originally described for these agents. In
T -ALL cells, the apoptotic mechanism invoked for doxorubicin depends
upon ceramide upregulation, specifically through stimulation of the CD9S
(APO-l/Fas) death receptor as demonstrated by increased CD9S-ligand,
cleavage of caspases and apoptosis, and by activation of the tyrosine kinase,
Lck (233). Likewise, inhibition of the CD95 death pathway either by antisense-mediated downregulation

of CD95-L,

dominant

negative

Fas

Associated protein via Death Domain (FADD), or by using cells deficient in
aSMase (Niemann-Pick A [NPA] fibroblasts) inhibited ceramide-induced
apoptosis. Finally, ceramide's role in this process was also supported by the
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observations that upon exogenous ceramide addition in NPA fibroblasts, a
restoration of apoptosis and CD95-L expression was observed. Collectively,
these results provide a link between doxorubicin-stimulated ceramide and
C095 death signaling (230).
The relationship between CD95 activation and ceramide has been the
topic of intense investigation and one of the most popular cellular models
employed has been the T -ALL cell line, Jurkat. Although not without
controversy (76,230,234-245), the current model for this relationship
involves the activation of aSMase (246). In particular, upon initial
stimulation of the CD95 receptor, the recruitment and activation of a small
percentage (--2%) of the adaptor protein FADD and caspase 8 to the receptor
is sufficient to induce translocation of aSMase to the plasma membrane.
ASMase, in tum, produces ceramide which coalesces into ceramide-rich
platforms, favoring CD95 oligomerization and the assembly of the DISC for
the full activation of the CD95 signaling cascade. The importance of this
process is demonstrated in experiments with lurkat cells in which
pharmacological inhibition of raft formation (by cholesterol extraction or
chelation), inhibition of aSMase activation, or sequestration of surface
ceramide with anti-ceramide antibody caused resistance to CD95-induced
apoptosis (243-245). Finally, inhibition of nuclear SMS activity has been
shown to be an additional contributing factor to ceramide accumulation and
apoptosis in response to CD95 stimulation (108). Inhibition of SMS activity
was found to be a caspase-dependent event (109). Cleavage and inactivation
of SMS1 occurred early in the signaling cascade and caused the relocalization of the enzyme from the Golgi, where it normally resides, to the
cytoplasm.
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In line with the importance of activation of aSMase for CD95signaling, recent observations have also demonstrated the fundamental role
for plasma membrane SM in this process. In fact, a mutant line of murine T
cell lymphoma WR19L devoid of SMS1 (hence of SM in the outer leaflet of
the plasma membrane where SM naturally is concentrated), failed to
undergo apoptosis in response to CD95 ligation because of the inability of
the receptor to cluster. Restored expression of SMS 1., and thus of SM in the
plasma membrane, enabled formation of the CD95-initiated death-inducing
signaling complex., allowing caspase 3 and 8 activation and the full
execution of the apoptotic program (175,187,247).
Over the years, lurkat cells have been a popular model for studying
the relationships between SLs and T-cell ALL, in particular. In fact, in
addition to investigations to address the role of SLs as signaling molecules
downstream of CD95 activation, lurkat cells have been employed to study
the SL response after a variety of other stimuli, such as gamma and UV-C
radiations, photodynamic therapy (PDT), cannabinoids, and galectin-l
(107,248-254). Apoptosis is the most common ceramide-mediated response
observed in these cells., although necrosis due to loss of mitochondrial
membrane potential, formation of reactive oxygen species, and loss of
intracellular ATP has also been observed (255,256). For instance, apoptosis
has been observed after treatment with gamma radiation, and ceramide
accumulation, resulting initially from SM hydrolysis and subsequently from
de novo synthesis, preceded the onset of caspase-dependent death.
Interestingly, after irradiation, ceramide accumulated in different cellular
compartments at different times: an early peak was observed in the plasma
membrane (minutes), followed by an Increase of ceramide In the
mitochondria (hours) (249,250,254). Importantly, the addition of SL
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metabolism inhibitors which favor the accumulation of endogenous
ceramide maximized mitochondrial dysfunction and apoptosis (251).
Modulation of ceramide metabolism by inhibition of ceramidases or GCS
potentiated apoptosis also in response to the cationic antimicrobial peptide
bovine lactoferricin (257) and in lurkat cells, as in AML blasts, SKI
inhibition with BML-258 was sufficient for inducing caspase-dependent cell
death (258). Similar to CD95 stimulation, exposure of lurkat cells to UV-C
induced a rapid translocation of aSMase to the plasma membrane where it
promoted ceramide formation and raft fusion (244). Different from CD95
stimulation, the UV -C-induced aSMase activation was caspase independent,
but nevertheless critical to UV -C-induced cell death. Activation of aSMase
in these cells has been observed in response to a number of apoptotic stimuli
such as the histone deacetylase inhibitor LAQ824 and the B-galactosidasebinding protein galectin-l (78,253).
Exposure to PDT was also found to be cytotoxic for lurkat cells, and
after PDT, ceramide was found to accumulate due to inhibition of SMS and
GCS . (107).

Indeed,

over-expression of SMS 1 decreased ceramide

accumulation and apoptosis after PDT treatment (259) whereas RNAimediated down-regulation of SMS 1 resulted in the opposite effect,
potentiating apoptosis through caspase activation (260).
In Jurkat cells, ceramide-induced apoptosis generally proceeds in a
caspase-dependent fashion although the precise ordering of the signaling
cascade is unclear. For example, caspase 8 has been proposed to act
upstream of mitochondrial damage upon treatment with ceramide or
etoposide (261) whereas it was shown to be downstream of the mitochondria
after ceramide accumulation in response to cannabinoid treatment (252).
Recently, research into the effects of ceramide on gene transcription
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indicated the tumor suppressor gene thioredoxin-interacting protein (Txnip)
as a novel distal effector (262). Similar to ceramide, etoposide induced
Txnip expression and apoptosis, and both events were prevented by
inhibition of ceramide production. According to this study, Txnip, by
binding to thioredoxin, promotes its dissociation from the apoptosis signalregulating kinase 1 (ASKl) which, in tum, gets activated. Active ASK!
promotes phosphorylation of p38 mitogen-activated protein kinase and JNK
and induces ER stress, events that collectively lead to apoptosis.
In addition to Jurkat,

Molt~4

cells have been employed as an

additional model for T -ALL, and they have been instrumental for the
discovery of the functional link between ceramide and cell cycle arrest. Prior
to cell cycle arrest induced by serum withdrawal, sustained cerami de
accumulation due to SM hydrolysis through the action of an nSMase was
observed. Addition of C6-ceramide recapitulated the serum withdrawal
phenotype (263). Later studies in other cell types showed that ceramideinduced cell cycle arrest was caused by dephosphorylation of Rb (217) and
inactivation of the eyelin-dependent CDK2, but not CDK4 (264).
Chemotherapeutics and their ability to activate apoptosis have also
been studied in this cell line. Etoposide was shown to induce apoptosis
through activation of SPT (41), and increased ceramide due to activation of
aSMase and nSMase prior to caspase 3 activation was observed after
treatment with the folate analog and thymidylate synthase inhibitor,
GW1843 (265).
Molt-4 cells were also used to investigate the relationship between
p53, a known tumor suppressor, and ceramide; this relationship was
analyzed based upon the seemingly functional similarities of these two
molecules. These studies revealed that upon treatment with either
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actinomycin D or gamma-irradiation, there was an induction of p53dependent ceramide accumulation followed by cell death (266). The
biochemical pathways responsible for ceramide accumulation after p53 upregulation were recently revisited, and it was shown that gamma-irradiation
of Molt-4 cells and consequential p53-upregulation led to de novo ceramide
synthesis of primarily C]6-ceramide due to increased activity of ceramide
synthase (267).

Evidence for in vivo regulation of SLs in AML, ALL and Large
Granular Lymphocytic Leukemia

SKI and nSMase2 expression (measured by quantitative peR) were
found to be altered in bone marrow specimens collected from patients with
acute leukemia (148). Corresponding to signaling functions of these two
enzymes, SKI expression was IO-fold greater in leukemic specimens
compared to normal bone marrow, whereas nSMase2 expression was 10fold lower in leukemia when compared to normal counterparts.
In line with these observations, the nSMase2 gene was reported to be
the target of inactivating mutations in human ALL and AML specimens
(268). In fact, 11 different mutations were reported., targeting the nSMase2
gene in 8 of 131 (6%) ALLs and 5 of 92 (5%) AMLs examined, but no
mutations on nSMase2 were found in other cancers examined. Of these
mutations, 9 corresponded to amino acids conserved in all known vertebrate
animal sequences of nSMase2, with 2 recurrent mutations. Functional
analysis of two mutations revealed lower nSMase2 protein expression and/or
its mislocalization; the effect of the other mutations was not readily evident
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(148). Support for SKI '8 contribution to AML is validated by investigations
demonstrating a potent induction of apoptosis upon SKI specific inhibition
in AML leukemic blasts isolated from patients (258). Importantly., this study
identified and subsequently utilized the first potent and water-soluble
pharmacological inhibitor specific for SKI (BML-258). Results revealed
that BM-258 treatment and subsequent apoptosis were specific to leukemic
blasts because they were relatively non-cytotoxic to normal peripheral blood
mononuclear leukocytes. Furthermore, BM-258 was suggested to be a
potential therapeutic agent for ameliorating AML because its use in an AML
xenograph model suppressed tumor growth, and decreased cell proliferation
and induced apoptosis within the tumor (258). Based on the evidence
previously presented for the regulatory functions of SLs and ceramide in cell
culture models for AML and ALL, these results substantiate the potential
targeting of the SL pathway as an effective therapeutic intervention.
Promise for manipulating ceramide levels to induce apoptosis of
leukemic cells is impressively demonstrated in a recent investigation with
large granular lymphocytic leukemia (LGL) cells derived from natural killer
(NK) cells (269). NK-LGL can be an extremely aggressive disease, with
survival upon diagnoses limited to only days or weeks. Notably, NK-LGL
pathogenesis is relatively unknown and no therapeutics exist for this disease.
In this study, high expression of survivin., a member of the inhibitor of the
apoptosis protein (lAP) family, was reported in both chronic and aggressive
NK leukemia cells isolated from patients (but not in normal tissues), and this
demonstrated the dependence of primary human NK-LGL on this protein for
survival. Treatment of the RNK-16 cell line, a rat model for NK-LGL, with
cell permeable C 6-ceramide administered in nanoliposomes resulted in
inhibition of constitutive phosphorylation of ERK and a time- and dose41

dependent decrease of survivin protein. The relevance of these studies to in
vivo NK-LGL was validated because systemic, intravenous delivery of
nanoliposomal ceramide induced complete remission of aggressive NK-LGL
leukemia in a rat model (transplantation of spleen cells from aged F344 rats
with spontaneous LGL leukemia in young syngeneic rats). In addition, C 6 ceramide induced caspase-dependent cell death in human primary NK-LGL
but not in the normal counterparts. Collectively, these data suggest that
effective ceramide delivery can target leukemia mediators that are
dysregulated, such as sUfvivin, serving as a unIque approach for specific
therapy directed to leukemic versus normal cells.
Disrupted SL signaling during LGL derived from T-cells (T-LGL)
was also demonstrated (270) with an approach that utilized microarray data
and "theme-based" bioinfonnatics such as Expression Analysis Systematic
Explorer (EASE) and Gene Set Enrichment Analysis (GSEA) collected from
mononuclear cells in peripheral blood (PBMC) of normal versus T -LGL
patients. This analysis revealed a dramatic dysregulation of apoptotic gene
expression in PBMCs of T-LGL patients. Additionally, there was evidence
of a balance shift between SL-mediated pro-apoptotic signaling versus antiapoptotic signaling, with a critical role for acid ceramidase and SKI, both
upregulated in PBMCs of T-LGL patients. Upon validation of the
bioinformatic results, it was discovered that inhibition of acid ceramidase
(by NO E) and of SIP-mediated signaling with the SIP antagonist FTY720,
resulted in significantly higher apoptosis in T -LGL PBMCs versus normal
PBMCs.
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Chronic myelogenous leukemia (CML).

Myelogenous neoplasms are hematopoietic stem cell disorders
resulting from the clonal expansion of one or more of the myeloid stem or
precursor cells (201). CML is one of the best characterized myelogenous
leukemias and one of the first malignancies known to result from a specific
genetic abnormality, the Philadelphia chromosome (Ph). This abnormality
arises from the reciprocal translocation between the long arms of
chromosome 9 and 22 creating a fusion gene between BCR (breakpoint
cluster region) and ABL (Abelson leukemia virus-derived kinase). BCRABL is subsequently transcribed and translated into a constitutively active
tyrosine kinase protein similarly named, Bcr-abl (Figure 4) (271-274). Bcrabl encodes three different Bcr-abl proteins depending upon the location of
the translocation breakpoint located on chromosome 22: p190 kD, p210 kD
(the most common), and p230 kD [reviewed in (275-278)].
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Figure 4. Reciprocal translocation ofBcr-abl
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Figure 4.
Reciprocal translocation of Bcr-abl.
Reciprocal translocation of
chromosomes 9 and 22 resulting in der 9 and the Philadelphia chromosome.
Translocation results in the fusion gene between BCR (breakpoint cluster region) and
ABL (Abelson Leukemia virus-derived kinase), Bcr-abl.

In the clinical setting, CML is characterized by three distinct phases: a
chronic phase, an accelerated phase, and a blast phase (or blast crisis). The
chronic phase is characterized by expansion of the granulocytic cell lineage
and, if untreated, it lasts two to five years. The accelerated phase is
characterized by an increase of basophils or blasts, abnormality of platelet
counts, and the presence of clonal evolution, and it may last up to one year.
Disease progression from the accelerated phase to the blast phase is
associated with an increase in cytogenetic mutations and a block of cell
differentiation that results in the presence of 30% or more myeloid blast
cells in peripheral blood or bone marrow, and eventually the presence of
infiltrates outside the bone marrow. The survival time for patients in blast
phase is 3 to 6 months (276,278,279).
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The fusion of the Ber and Abl genes produces a protein that retains
the tyrosine kinase activity of Abl, but it has lost its regulation and is now
constitutively active. At early stages of CML, the kinase activity of Bcr-abl
is necessary for its oncogenic function, and a number of factors have been
identified as potential direct or indirect targets of its disregulated kinase
activity. Bcr-abl promotes the formation of a multicomplex via binding to
GRB2 (growth factor receptor-bound protein 2) that in turn binds to SOS (a
guanine-nucleotide exchanger of RAS) which activates Ras. GRB2 also
binds to Gab2 (GRB2-associated binding protein 2) which is phosphorylated
by Bcr-abl and activates the PI3K1AktJMAPK pathway (274,280,281). Other
targets of Bcr-abl are the RAe GTPases (RAe1, 2, and 3) and janus kinase
2. Ultimately, a number of transcription factors are activated by Bcr-abl such
as STATs, c-Myc, NF-kB, c-Jun and c-Fos. Activation of these factors
promotes transcription of anti-apoptotic genes, such as bel2 and bel-xl, and
of positive regulators of cell cycle progression, such as cyclin D (for a
review (273,275,277)). It has been postulated that the anti-apoptotic effect of
Bcr-abl favors inaccurate DNA repair whereas in normal cells DNA damage
would induce apoptosis. As a result, genetic changes (occurring in 50-75%
of patients) would accumulate on p53, c-myc, ras, Rb and p16, further
favoring enhanced proliferation, survival, and arrest of differentiation. These
events are thought to promote progression to the blast phase in a newly
acquired Bcr-abl-independent manner.
With the identification of Bcr-abl as a CML initiator and the
uncovering of its kinase activity, targeted therapy followed, and Bcr-abl is
the prototype for such pharmacological approaches . Indeed a competitive
inhibitor of the A TP-binding site of Ber-abl was developed by Novartis
(imatinib mesylate; Gleevec, Glivec, or STI571) (282-284). Imatinib was
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first administered to patients In 1998, and SInce that time has been
remarkably successful in patients with chronic phase CML (80% complete
cytogenetic response in newly diagnosed chronic phase patients) (285). In
contrast, imatinib treatment does not cure the disease because it does not
eradicate Bcr-abl-positive hemopoietic stem cells. So, long-term treatment
with imatinib favors relapse due to acquired resistance arising from point
mutations in the Bcr-abl A TP-binding site, overexpression of Bcr-abl itself
or mutations of the p-glycoprotein pump (286). Imatinib treatment for
patients in the advanced phase of the disease has been far less beneficial than
for patients in the chronic phase, probably due to an acquired independence
from Bcr-abl arising from additional genetic mutations. These patients are
given standard chemotherapy (anthracycline, anthracenedione, cytarabine,
etoposide, carboplatin, hydroxyurea alone or in combination) and they have
a response rate, in myeloid blast crisis, of less than 30% (287-291).

SLsandCML

Lately the role of SLs in Bcr-abl-mediated signaling is becoming
more apparent. In fact, initial evidence has led to contrasting conclusions. In
particular, whereas Bcr-abl expression was shown to impart total or partial
resistance to treatment with exogenous short chain ceramide analogues (C 2
or C 6 -ceramide), Bcr-abl also accelerated ceramide-mediated apoptosis by
these same analogues (292-295). In contrast, the consensus opinion appears
to converge on the role of SKI in Bcr-abl positive cells. Increased basal SKl
activity was observed in Bcr-abl positive, compared to negative cells,
suggesting that the expression of Bcr-abl is sufficient to drive SKI activity
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(296). Moreover, it was shown that an SKI target seemed to be Mcl-l
because inhibition of SKI in CML lead to decreased Mel-I. An additional
target of SKI in CML cells might be the anti-apoptotic protein bel2;
overexpression of neutral CDase in K562 cells induced up-regulatioll of bel2
via SIP (297). Recently, in two important studies, accumulat.ion of
endogenous ceramide and decreases in the anti-apoptotic SL, SIP, were
shown to be partly responsible for the cytotoxic effect exerted by imatinib
treatment in CML-derived cell lines. Also, a balance shift between
endogenous ceramide and SIP in favor of SIP was purported to be critical in
the acquisition of imatinib resistance to CML cells (298,299). The first of
these studies employed K562 cells as an in vitro model of CML and
demonstrated that. imatinib treatment resulted in a substantial and timedependent increase of C 18-ceramide, most likely generated via CerSI. The
importance of ceramide in inducing apoptosis after imatinib treatment was
further exemplified by results showing that inhibition of CerS 1 caused a
complete block of C]8-ceramide generation which was, in turn, followed by
decreased apoptosis. To understand the mechanism of imatinib resistance,
K562 cells were continuously exposed to increasing amounts of imatinib
followed by selection of apoptotic resistant clones, termed K562IIMA 0 . 2 or

-1.. Interestingly, these imatinib-resistant clones failed to increase C 18ceramide after imatinib treatment and CerS lover-expression in K562/IMA
cells successfully restored C 18-ceramide accumulation and enhanced
sensitivity to imatinib.

Moreover, detection of enhanced SKI expression

and SIP generation in K562/IMA cells further suggested an imbalance of the
C]8-ceramide/SlP ratio in favor of SIP, thus promoting cell survival in these
cells (298).

47

The role of SKI as an indicator of chemoresistance of CML cells has
also been explored using the CML cell model LAMA84 (300). In contrast to
imatinib-resistant LAMA84 cells, imatinib-sensitive LAMA84 displayed
marked SKI inhibition paired with decreased SIP and increased ceramide
content.

Furthermore, it was demonstrated that SKI over-expression

protected LAMA84 cells from imatinib-induced cytotoxicity, by blocking
the release of cytochrome c and Smac/Diablo from mitochondria.

The

potential relationship between SKI and the anti-leukemic drug Ara-C, was
also investigated. Ara-C was shown to induce cell death by inhibiting SKI,
suggesting that cell death induced by either imatinib or Ara-C may converge
on SKI as a regulatory checkpoint. Additionally, these studies identified a
rapid and transient increase in ceramide, not only following imatinib
treatment but also upon treatment with Ara-C as well as other anti-leukemic
therapeutics such as farnesyltransferase (FTI), UOI26 (a MEK inhibitor),
and F-12S09a (an SKI inhibitor) supporting the idea that an increase in
ceramide is a common event in response to several chemotherapeutics also
in CML-derived cells.

Notably,

pharmacological or RNAi-mediated

inhibition of SKI resulted in increased ceramide and decreased SIP in
imatinib-resistant LAMA84 cells, followed by apoptosis as measured by
caspase-3 activation and strong nuclear fragmentation.

Interestingly,

treatment with F-I2509a in both resistant and sensitive clinical patient
samples resulted in significant decreases in cellular viability indicating the
potential of this type of therapeutic in the future. A concurrent study
conducted in a different laboratory, while failing to quantify lipids upon SKI
inhibition, still demonstrated that with pharmacological inhibition of SKI,
there was an early and substantial SKI inhibition in K562 cells, followed by
impaired cell cycle progression and apoptosis, further supporting the
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therapeutic potential of SKl(301). Ilnportantly, the combination of imatinib
and SKI inhibition resulted in a strong synergistic effect on cellular growth
and survival (302).
Interestingly, the link between ceramide and Bcr-abl may involve
PP2A. It has been demonstrated that the cytotoxic effect of the SIP
antagonist FTY720 to CML cells occurs through activation of PP2A (303).
Interestingly, it was recently shown that FTY720 treatment induces
accumulation of ceramide (304) and, as previously discussed, ceramide is
known to activate PP2A by binding to IPP2A and dissociating it from PP2A
(115).

Therefore

a

novel

link

between

FTY720/ceramide

accumulation/activation of PP2A and inhibition of Bcr-abl may exist.
For a summary of the roles of different SLs and SL-nletabolizing
enzymes in CML cells, please see Figure 5.

Figure 5. Roles of the different SLs and SL-metabolizing enzymes
in CML cells.
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Figure 5. Roles of the different SLs and SL metabolizing enzymes in CML cells. A.
Bcr-abl increases the expression of the SL-metabolizing enzymes SKI and SMS 1 causing
an increase of the pro-proliferative lipids, SIP and DAG and the decrease of ceramide
levels. The particular SL profile contributes to the proliferative advantage and prosurvival characteristics of CML cells. B. Pharmacological inhibition of BCT-abl by
Imatinib activates CerS 1 and inhibits SMS and SKI with consequent accumulation of
C 18-ceramide levels and decrease of DAG and SIP levels. This particular profile
contributes to the cytotoxic effect of this drug in CML cells (See text for details).

DAGandCML

It is very surprising that the relationship between Bcr-abl and DAG
has not been documented in the literature. Indirect evidence of the
involvement of DAG as a downstream signaling molecule of Bcr-abl come
from reports showing that activation of phospholipase C (PLC) yl and of the
PI3K1Akt pathway are required for Bcr-abl signaling through mTOR/p70S6kinase (305,306). The regulation of mTOR/p70S6-kinase by PLCyl seems
to occur via modulation of both calcium signaling (CaMKII) (presumably
through formation of IP 3) and classical and novel protein kinase C (likely
through production of DAG). In our system, we observed a very significant
drop of DAG levels when either Bcr-abl or SMS/SMS 1 were inhibited.
Being SMS 1 regulated by Bcr-abl, it is possible that part of the observed
drop of DAG levels after inhibition of Bcr-abl is due to the decrease of
SMS/SMSI

activity,

In

addition
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to

inhibition

of

PLCyl.

Chapter 1
Specific Aim 1: Determine the function ofSMSl in maintaining the
cancerous phenotype exhibited by Bcr-abl positive blast cells

Manuscript 1:
"Sphingomyelin Synthase 1 activity

IS

regulated by the Bcr-abl

oncogene."
Tara Ann Burns I, Marimuthu Subathra 1, Paola Signorelli 3, Young Choi 1, Xiaofeng
Yang2 , Yang Wang2 , Maristella Villani lA , Kapil Bhallas,Daohong Zhou6, and Chiara
LUbertol.
Departments of 1Biochemistry and Molecular Biology, and 2Pathology and Laboratory
Medicine, Medical University of South Carolina, Charleston, South Carolina, USA;
3Laboratory of Biochemistry and Molecular Biology, San Paolo University Hospital,
Medical School, University of Milan, Italy; 4 Polispecialistica Bios, 88900 Crotone, Italy;
5The University of Kansas Cancer Center, Kansas City, KS, USA; 6Division of Radiation
Health, Department of Pharmaceutical Sciences, and Winthrop P. Rockefeller Cancer
Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Abbreviated Title: SMS 1 expression is regulated by Bcr-abl
Abbreviations: SMS, sphingomyelin synthase; DAG, diacylglycerol; SM,
sphingomyelin; PC, phosphatidylcholine~ TNF, tumor necrosis factor; CML, chronic
myelogenous leukemia; NBD, N-(7-nitrobenz-2-oxa-l,3-diazol-4- yl)amino; FACS,
fluorescence activated cell sorter; PARP, Poly (ADP-ribose) polymerase; SIP,
sphingosine-I-phosphate; PP2A, protein phosphates 2A; PLC, phospholipase C.

Supplementary key words: sphingomyelin synthase, ceramide, diacylglycerol, Bcr-abl,
imatinib mesylate.

INTRODUCTION
Sphingomyelin synthase (SMS) represents an important class of
enzymes responsible for the biosynthesis of sphingomyelin (SM), a critical
structural component of the plasma membrane. While producing SM from
ceramide and phosphatidylcholine (PC), SMSs also form diacylglycerol
(DAG) (307-313). Therefore the biological importance of SMSs may reside
not only in the biosynthesis of SM but also in the regulation, in opposing
directions, of the levels of ceramide, a bioactive molecule which mainly
exerts a negative effect on cell proliferation, and DAG, a well-established
mitogenic lipid (314).
Indeed, increased SMS activity was observed in conditions of
enhanced cell proliferation (such as regenerating rat liver or stimulation of
quiescent

astrocytes

with

basic

FGF)

(192,193)

and

during

cell

transformation (such as hepatocellular carcinoma versus normal liver and
SV-40 transformed fibroblasts versus their normal counterpart) (314,315).
Vice versa, inhibition of SMS activity, in a caspase-dependent manner, has
been shown to precede the onset of apoptosis induced by either TNF in
Kym-1 cells or FAS ligand in lurkat T-cells (108,194).
Two genes have been identified as responsible for SMS activity in
mammalian cells, SMS1 and SMS2 (174,175). The amino acidic sequence of
the proteins encoded by these two genes mainly differs in their N-termini,
with SMS 1 carrying a sterile alpha motif that is absent in SMS2. In
agreement with previous biochemical studies assessing the intracellular
distribution of SMS activity, SMS 1 localizes at the Goigi whereas SMS2
localizes at the Golgi and plasma membrane (165,174,182,183). Modulation
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of SMS1 or SMS2 activity In most tested cell types has resulted in an
alteration of ceramide levels whereas changes in DAG levels have been
elusive (165,184,185,259,260,316). On the other hand, in Hela cells it has
been shown that, in spite of the absence of significant changes of total DAG
levels upon modulation of SMSs, intracellular DAG pools (in particular at
the Golgi) appeared to be altered (165).
Whereas inhibition of SMS 1 by direct caspase cleavage has been
shown after treatment with Fas ligand in lurkat cells (317), no molecular
factors that are able to stimulate SMS1 or SMS2 expression/activity have
been identified so far. One of the conditions in which total SMS activity was
found to be increased, was a pool of samples isolated from patients with
acute lymphoblastic leukemia,

acute myeloid leukemia and chronic

myelogenous leukemia (CML) (10).
CML is a myeloproliferative disorder of hemopoietic stem cells and
occurs in 1 to 1.5 per 100,000 accounting for 15-20% of adult leukemia.
CML is directly linked to a chromosomal abnormality caused by the
reciprocal translocation of chromosomes 9 and 22 resulting in a shortened
chromosome 22, termed the Philadelphia chromosome. This chromosomal
translocation generates a fusion product between the breakpoint cluster
region (Bcr) and the Abelson kinase (Abl) genes (275-278). The chimera
now encodes for a constitutively active tyrosine kinase, Bcr-abl which
initiates the leukemic transformation (273,274). In the clinical setting, CML
is identified by three distinct phases: chronic phase, accelerated phase, and
blast phase (279). The chronic phase is characterized by a slight increase of
granulocytic progenitors and a substantial increase of granulocytes in the
peripheral blood. At this stage, pharmacological inhibition of the Bcr-abl
tyrosine kinase activity by Imatinib mesylate has proven key for the
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containment of the disease (282,283,318). Nevertheless, the insurgence of
mechanisms of resistance to current therapy, most commonly mutations in
the A TP-binding pocket of Bcr-abl after long-term treatment with tyrosine
kinase inhibitors, are causing disease progression from the chronic phase to
the terminal blast phase (286). The blast phase is characterized by a block of
differentiation resulting in 30% or more myeloid or lymphoid blast cells in
the peripheral blood or bone marrow, from where the blast cells eventually
infiltrate other organs such as spleen, liver, or lymph nodes (276). These
blast cells are refractory to current treatments and the survival time for
patients affected by blast crisis CML is 3 to 6 months (287,288,291). In this
study, we provide evidence of a link between the expression of the BCRABL oncogene, its activity and elevated SMS activity. We show that
elevated expression of SMS 1 and not SMS2 is responsible for the elevated
SMS activity and that elevated SMS 1 is important for sustaining
proliferation of Bcr-abl positive cells. Inhibition of Bcr-abl, SMS activity or
SMSl expression results in an alteration of the ceramide to DAG ratio

consistent with a negative effect on cell proliferation. All together these
results establish the first molecular link between a well-established oncogene
and SMS 1 expression.
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MATERIALS AND METHODS
Materials

RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and
Trypan Blue dye solution were from Gibeo/Invitrogen Corp., Carlsbad, CA.
NBD-C 6-Ceramide and NBD-C 6 -sphingomyelin were purchased from

Molecular Probes. All other lipids were purchased from A vanti Polar Lipids
(Alabaster, AL). D609 was purchased from Biomol International; and
Imatinib Mesylate was obtained from Novartis.

Cell culture
K562, HL-60, U937, Jurkat, and MCF-7 cell lines were originally
purchased from the American Type Culture Collection (Rockville, MD).
Human acute myeloid leukemia HL-60 cells stably expressing p18S Bcr-abl
(HL~60/Bcr-abl)

or the empty vector (HL-60 ct) were a generous gift from

Dr. K. Bhalla (Medical College of Georgia, Augusta, Georgia, USA) (292).
Human leukemic SupT13 T cells were obtained from Dr. J.S. Thompson at
the University of Kentucky. All cell lines were grown in RPMI-1640
supplemented with 10% FBS, 100 Vlml penicillin and 100 J.lg/ml
streptomycin, and were maintained at 37°C at 5% CO 2 . Cells were routinely
counted after staining with the Trypan blue dye. Pharmacological inhibition
of SMS and Bcr-abl was achieved by incubation of cells with D609 and
Imatinib mesylate as indicated in the individual experiments in complete
growth medium (in absence of antibiotics) using O.lxl06 cells/ml cultures.
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Methods
Downregulation of SMSl and SMS2 with siRNA

The siRNA for human SMSI targeted the sequence CAe ACT ATG

Gee

AAT CAG CAA (165) and the one for SMS2 targeted the sequence

ACe GTe ATG ATe ACA OTT GTA (316). In preliminary experiments,

the effects on SMSs RNA expression, SMS activity, and cell viability of the
AIIStars Negative Control siRNA (Qiagen) was compared to that of the
transfection reagent by itself and found no difference, therefore the Alistars
Negative Control was used in subsequent experimentation as baseline. K562
were transfected with siRNAs by electroporation using the Amaxa
Nucleofector device (Amaxa) according to the manufacturer's instructions.
The protocol was optimized regarding the concentration of SMS 1 siRNA,
transfection and post-transfection conditions in preliminary dose-response
experiments (1-10 ).lg SMS 1 siRNA). Consequently, the following optimal
conditions were employed. Cells (lxl06 K562 cells or 2xl0 6 HL-60 cells)
were transfected with 2-5 Ilg of siRNA. After 30 minutes of incubation at
37°C, 5% CO 2 in 500 J.lI of complete growth medium, cells were initially
seeded at O.5x 106 cells/ml, and subsequently diluted 1:4 once control cells
reached 1.3xl06 cells/ml concentration. At the indicated time points after
transfection, cells were washed twice with ice cold PBS and processed
according to the required analysis.

RNA isolation and reverse transcription for real time peR.

To analyze the expression of SMS 1 or SMS2 in U937, HL-60/ct, HL60IBcr-abl, and K562 cells, total RNA was first isolated from Ix10 6 cells
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using the RNeasy Mini Kit according to manufacturer's protocol, including
optional DNase digestion (Qiagen, Gmbh, Hilden, Germany). Further DNase
digestion was performed using the Turbo DNA free kit according to
manufacturer's protocol (Applied Biosystems).

The first strand eDNA

synthesis was prepared from 1 f.lg of RNA using Superscript III (Invitrogen)
according

to

the

manufacturer's

recommendations.

Real-time

peR

amplification was carried out as described by Villani et a1. (165).

Lentiviral-mediated downregulation of SMSl

For lenti-viral experiments, K562 cells were transduced with either
non-targeting control particles (shRNA-NTCP) or Mission lentiviral
transduction particles (both from Sigma-Aldrich) that contained the
pLKO.l-puro vector including the SMSI targeting sequence, 5'-CCG

Gee

AAC TGC GAA GAA TAA TGA ACT eGA GTT CAT TAT TCT TCG
CAG TTG GTT TTT TG-3' (sh-RNA-SMSl). During transduction, 3xl04
K562 cells/ml fe-suspended in RPMI-1640 containing 10% FBS and 10
J..lg/ml of Hexabromide (Sigma) were infected at a Multiplicity of Infection
(MOl) of 10 with the appropriate lenti-viral particles. Cells were incubated

at 37°C, 5% CO 2 and 3 days post-transduction, 10 f.lg/ml of puromycin
(Sigma) was added to the media to select for pLKO.1-puro positive clones
and fe-added every 3-4 days to maintain selection. The concentration of
puromycin needed to select for vector expressing clones was based on a killcurve analysis showing 70-80% cell death after 3 days in non-transduced
K562 cells (data not shown). SMSI down-regulation (approximately 50%)
was confirmed by quantitative real time peR.
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[3H]-Thymidine incorporation assay

K562 cells stably transduced with either shRNA-SMS 1 or shRNANTCP lentivirus particles were used for transient siRNA transfections.
K562/shRNA-SMSl and K562/shRNA-NTCP were transiently transfected
with SMSI siRNA or Allstars Negative control respectively, and their
cellular proliferation rates were compared by thymidine incorporation. The
transient transfections were accomplished by the same electroporation
protocol as described above and were diluted 48 hours post transfection by
1.25 dilution factor in complete medium. The thymidine incorporation assay
was optimized for K562 cells to determine the cell concentration and total
cell number, as well as the amount of [3 H ]_ Thymidine (American
radiolabeled chemicals; 1JJ.Ci/J..lI specific activity) needed for maximum
[3 H]_ Thymidine incorporation within the linear range of the assay (data not

shown). At the indicated time points after transient transfection, IJ.lCi of
[3 H]-Thymidine was added to 500 J.!ls serum free RPMI-1640 containing

2xl05 K562 cells in each of the experimental groups (as above) and
incubated for 4 hours at37°C and 5% CO 2 -

After incubation, cells were

centrifuged at lOOOg for 5 minutes at 4°C and the supernatant was removed.
The cell pellets were washed twice with ice-cold PBS to remove all excess
of unincorporated [3 H ]-Thymidine followed by a 30 minute incubation in
5% ice cold trichloroacetic acid (TeA, 700 f.lls).

The suspensions were

centrifuged as above, TeA removed, and pellets were subsequently
solubilized in O.SN NaOH containing 0.5% SDS (500 f.!ls).

For analysis,

150 J.!ls of the solubilized pellets were counted in 4ml of scintillation fluid
(MP Biomedicals) and incorporated [3 H ]_ Thymidine was measured as
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counts per minute in a Beckman-Coulter scintillation counter. CPM values
were normalized to the total 500 Ills of solubilized pellets.

Downregulation of BCR-ABL

Bcr-abl was transiently down-regulated with a validated siRNA,
targeting the sequence 5'-AAG CAG AGT TeA AAA Gce CTT-3' (319).
HL-60/Bcr-abl cells were electroporated with 2 J.!g of either BCR-ABL
targeting siRNA or the Allstar Negative Control siRNA according to the
conditions described for SMS 1 and SMS2 down-regulation with the
following modifications. Twelve hours post transfection, cells were diluted
to O.2xl06 cells/ml in complete medium and 36 hours post transfection, cells
were harvested, washed twice with ice cold PBS and processed for lipid
analysis. Effective down-regulation of Bcr-abl was determined by western
blotting and an aproximate 70% reduction of Bcr-abI in BCR-ABL siRNA
treated cells was observed (data not shown).

Sphingomyelin synthase activity assay

SMS activity was performed as previously described with few
modifications (165). Briefly, three to four million cells were harvested on
ice, washed in PBS and resuspended in 150 III of homogenization buffer
containing 250 mM Tris, 50 mM EDTA pH 7.4, Pierce Halt phosphatase
inhibitor, Pierce Halt protease inhibitor (Pierce, Rockville, 11) and 5 mM

PMSF. Cells were then lysed by sonication at 11 % power for 20 seconds
(preliminary optimization experiments showed 95% cell lysis with these
conditions). Unbroken cells were pelleted by centrifugation at 400g for 5
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minutes at 4°C and supernatant was collected and assayed for protein
concentration using the Bio-rad protein determination assay reagent (BioRad, Hercules, CA). Fifty micrograms of proteins were used for SMS
activity which was carried out and analyzed as previously described (165).

Total membrane preparation and SMSI western blotting

Twenty million cells were harvested on ice, washed in PBS and
resuspended in 800 J.lI of homogenization buffer containing 250 mM Tris, 50
mM EDT A pH 7.4, Pierce Halt phosphatase inhibitor, Pierce Halt protease
inhibitor (Pierce, Rockville, 11) and 5 mM PMSF. Cells were then lysed as
indicated for SMS activity and centrifuged at 1000g for 10 minutes at 4°C.
Supernatants were collected and centrifuged at 120,000g for 1 hour at 4°C.
Membrane pellets were re-suspended in 200 J-!l of homogenization buffer
and passed through a 21 gauge needle until uniform.

Membrane protein

concentration was determined using the Bio-fad protein determination assay
reagent (Bio-rad, Hercules, CA). Membranes were diluted with 4X sample
buffer and incubated at 37°C for 30

minutes~

Cell membrane proteins (80

J-!g) were separated by 10% SDS-PAGE under reducing conditions and
transferred to nitrocellulose membranes. Membranes were blocked with 5%
milk PBS-Tween 0.1 % for 1 hour at room temperature. Membranes were
then incubated with SMS 1 antibodies raised against the full-length protein
(1:1000) (Ex-alpha Biologics, Maynard, Ma) for 4 hours at room
temperature in 5% milk PBS-Tween 0.1 %. After extensive washings,
membranes were next incubated with peroxidase-conjugated goat-anti-rabbit
(1:3500, Santa Cruz) in 5% milk PBS-Tween 0.1% for 1 hour at room
temperature. Signals were visualized using Super Signal (Pierce Chemical
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Co) and exposure to Kodak BioMax MR Film (Eastman Kodak Co.,
Rochester, NY).

Detection of PARP cleavage as an indicator of apoptosis

Analysis of PARP cleavage was conducted on totallysates (20 J.lg) on
a

7.5%

SDS-PAGE

under

reducing

conditions.

After

transfer

to

nitrocellulose membranes and blocking as indicated above, PARP and its
cleaved fragment were visualized using primary rabbit polyclonal antibodies
(Santa Cruz, 1: 1500) and secondary peroxidase-conjugated goat-anti-rabbit
(1:10000, Santa Cruz) both in 5% milk PBS-Tween 0.1 %. Signals were
visualized using EeL (GE Healthcare) and exposure to Kodak BioMax MR
Film (Eastman Kodak Co., Rochester, NY).

Lipid Analysis

Ceramide, DAG and SM species were measured by the Lipidomics
Core

Facility

at

(http://www.musc.edu/BCMB/lipidomics/index.shtml).

MUSe

For

the

lipid

measurements, lxl0 6 K562 cells or 2x10 6 HL-60/ct or HL-60IBcr-abl cells
were used for each experimental condition. Aliquots of lipid extracts were
used to measure inorganic phosphate which was used as normalization factor
(320).

Statistical Analysis

Statistical analysis of the data was performed using Student's t-test,
and p<0.05 was considered statistically significant.
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RESULTS

Expression ofBcr-abl increased SMS activity

In a published report, it was shown that a pool of mononuclear cells
isolated from peripheral blood or bone marrow of chemoresistant patients
with different leukemias presented elevated SMS activity along with
decreased ceramide levels (10). Therefore to assess if increased SMS
activity was associated with specific hematological malignancies, a
screening was carried out in different leukemic cell lines in vitro. As shown
in Figure 6A, K562 cells exhibited a significantly higher SMS activity (by
approximately lO-fold) compared to the other cell lines.

The enzymatic

activity of SMS was linear with the amount of cell lysates and time of
reaction (data not shown), indicating that the differences were not an artifact
of the assay conditions. Notably, K562 cells originate from a pleural
effusion of a patient with chronic myelogenous leukemia (CML) in blast
crisis, and are characterized by the expression of the BCR-ABL oncogene,
whose expression is present in 95% of cases of CML.
Therefore in order to determine if the increase of SMS in K562 was a
direct result of BCR-ABL expression, SMS activity was then measured in
HL~60

cells stably transfected with the BCR-ABL gene (HL-60/Bcr-abl) in

comparison to cells transfected with the empty vector (HL-60/ct) (292,316)
(Figure 6B). It was found that the expression of Bcr-abl in HL-60 cells
induced a 9-fold increase of SMS activity, not due to the assay experimental
conditions (data not shown). As a complementary approach, the effect of
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inhibition of Bcr-abl tyrosine kinase activity on SMS activity was
determined in K562 cells. As shown in Figure 6C, inhibition of Bcr-abl
activity by Imatinib mesylate induced a dose- and time-dependent inhibition
of SMS activity which became significant by 24 hours of incubation, and
continued through 36 hours of treatment. Importantly, the inhibition of SMS
activity by Imatinib at 24 and 30 hours was observed when no significant
effect of the drug on cell proliferation could be observed. Inhibition of cell
proliferation by Imatinib started at 36 hours of treatment with all
concentrations tested (Supplementary Figure 1), and it was accompanied
by the presence of 3.7% of dead cells at O.2J.lM, 8.3% at O.4J.lM, and 10% at

1 ~M (versus 2% of dead cells in the vehicle control sample).
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Figure 6A-C. Expression of Bcr-abl increased SMS activity
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Figure 6. Expression of Bcr-abl increased SMS activity. (A) In vitro SMS activity
was measured in a panel of exponentially growing leukemic cell lines as described in the
"Materials and Methods" section. The SMS activity was normalized to that of HL-60
cells. (B) In vitro SMS activity was measured in exponentially growing HL-60 cells
stably expressing the BCR-ABL oncogene (p185) (HL-60 Bcr-abl) and control cells
carrying the empty vector (HL-60 ct) as described in the "Materials and Methods"
section. (C) K562 cells (0.1 x 106 cells/ml) were incubated in the presence of the
indicated concentrations of Imatinib (1m) or vehicle control (CT) for different periods of
time. At the reported time points, 3x 106 cells were collected for SMS activity. Data
represents the average and standard deviation of at least 3 separate experiments. Where
standard deviations are not visible, the standard deviation is too small compared to the
scale of the y-axis. Asterick indicates significant to HL-60/ct or to control (CT) (pvalue).
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All together these results suggest that, in K562 cells, SMS activity is
regulated by the tyrosine kinase activity of Bcr-abl.

Bcr-abl-induced increase of SMS activity is attributable to the upregulation ofSMSl

Two SMSs have been identified in mammalian cells. In order to
determine which of these SMSs is responsible for the observed increase in
SMS activity, the effect of Bcr-abl on the expression of SMSl and SMS2 was
determined by Real Time peR. Interestingly, as shown in Figure 7A, the
expression of SMSl mRNA in K562 and HL-60/Bcr-abl was significantly
higher than that in Bcr-abl negative cells (HL-60/ct or U937). The results
obtained by real-time peR were also confirmed by northern blot analysis of
total RNA collected from HL-60/ct and HL-60/Bcr-abl cells, using the fulllength SMSl eDNA as probe (data not shown). On the other hand, the
expression of Bcr-abl caused a reproducible and significant drop of SMS2
mRNA level (Figure 7A). Notably, the absolute expression level of SMS2
mRNA in HL-60/ct is significantly lower than that of SMSl (1.32xlO-3
versus 6.24xlO-4 MNE) and, by dropping in Bcr-abl-positive cells, it became
almost undetectable.
To confirm that increased expression of SMSl in Bcr-abl positive cells
led to elevated SMS 1 protein, western blotting was performed on the total
membrane fraction isolated from Bcr-abl-negative and positive cell lines. As
shown in Figure 7B and in line with the mRNA expression pattern (Figure
7A), the levels of SMS 1 in Bcr-abl negative cells were barely detectable
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whereas they were significantly elevated in Bcr-abl positive cells (K562 and
HL-60/Bcr-abl). The identification of the SMS 1 band in leukemia cells was
based on the comparison with Hela cells treated with SMSl siRNA (Figure
7C). On the other hand, no commercially available antibodies for SMS2
(ExAlpha or Santa Cruz) were able to detect any band in any of these cell
lines (whereas they were able to detect SMS2 in Hela cells, data not shown).
All together these data suggest that SMS 1 may indeed be responsible for the
increase in SMS activity observed in Bcr-abl-positive cells.
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Figure 7A-C. Bcr-abl induced upregulation of SMSI
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compared to Bcr-abl negative cells (HL 60 CT and U937) whereas it caused a drop of
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Asterisk indicates significance to HL-60/CT (p<0.05). MNE:Mean of Normalized
Expression.
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To further test if Bcr-abl regulates SMS activity by promoting SMSl
expression and activity, SMSl was down-regulated by transient treatment
with siRNA in

K562

cells.

Down-regulation was

achieved

by

electroporation of SMSl specific siRNA followed by both expression and
activity analysis at various time points. As shown in Figure 8A, downregulation of SMSl caused a significant reduction of the expression of SMSl
mRNA already after 24 hours (Figure 8B). Importantly, the SMSl siRNA
showed target specificity since no change of SMS2 mRNA expression was
observed (Figure 8e). Similarly, treatment of K562 cells with a validated
SMS2 siRNA (316) caused SMS2 expression to reach levels below detection

(data not -shown) while not affecting SMSI expression (data not shown).
Differently from SMSl, down-regulation of SMS2 did not affect SMS
activity (Figure SD).
All together these observations demonstrate that SMS 1 is the main
contributor to Bcr-abl-induced increase of SMS activity.
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Figure SA-D. SMSI is the main contributor to SMS activity in K562
cells
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Figure 8. SMSI is the main contributor to SMS activity in K562 cells. SMSl (SMS 1-)
and SMS2 (SMS2-) were down-regulated in K562 cells by treatment with siRNA (40nM
up to 72 hours). Treatment with SMSl siRNA significantly decreased SMSl expression as
measured by Real-Time peR (A) without significantly affecting SMS2 expression (C).
The siRNA-induced SMSl decrease caused a decrease of total in vitro SMS activity (B).
SMS2 siRNA did not affect in vitro SMS activity (D). These results are representative of
at least 3 separate experiments. AU: Arbitrary Fluorescence Units. MNE: Mean of
Normalized Expression. Asterisk indicates significance to SCR control (p<O.05).

Inhibition of SMS activity caused accumulation of ceramide and
decrease ofDAG

Since SMS promotes the formation of DAG by consuming ceramide,
and DAG sustains cell proliferation whereas ceramide has generally a
negative effect on cell growth (32,42,95,167,168,170,321-325), lipid
analysis upon modulation of SMS activity was conducted to determine its
impact on the levels of these bioactive lipids. To this aim, lipid levels were
determined upon inhibition of SMS activity by either treatment with the
SMS pharmacological inhibitor, D609 (50j.lg/ml) (Figures 9A and 9B) or
siRNA-mediated down-regulation of SMSl (Figure 9C and 9D) in K562
cells. Cells for each experimental condition were collected after 24 and 48
hours of treatment. Since the basal levels of the lipids (for these and all
subsequent lipid measurements) were variable among separate experiments
whereas the pattern of changes for each experiment was similar as compared
to other repeat experiments, results are reported as fold of time-matched
controls. Absolute values of all detected ceramide, SM and DAG molecular

specIes for a representative experiment are provided in Supplementary

Tables 1 and 2. As shown in Figure 9A, pharmacological inhibition of
70

SMS induced a significant accumulation of representative ceramide species
C18:0 and e22:1 at both 24 and 48 hours of treatment. On the other hand,

the levels of representative DAG species C14:0/C18:0 and C16:0/C18:0
significantly decreased upon inhibition of SMS after both 24 and 48 hours
of treatment (Figure 9B). The overall lipid changes cause a shift of the ratio
between total ceramide levels over total DAG levels from 0.11 of control
cells to 0.45 of D609 treated cells at 24 hours and from 0.09 of control cells
to 0.50 of D609 treated cells at 48 hours (Supplementary Table 1).
Similarly, although in a less pronounced manner, C18:0 and C22: 1 ceramide
levels accumulated after 48 hours of down-regulation of SMSl (Figure 9C)
whereas C14:0/C18:0 and C16:0IC18:0 DAG levels decreased significantly
already after 24 hours (Figure 9D). In this case, the ratio between total
ceramide levels over total DAG levels goes from 0.17 in control cells to 0.26
in SMS 1- cells after 24 hours and from 0.46 to 0.64 after 48 hours
(Supplementary Table 2).
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Figure 9A-D. Effect of inhibition of SMS on ceramide and DAG
levels
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Figure 9. Effect of inhibition of SMS on ceramide and DAG levels. K562 cells were
treated either with D609 (50 ).lg/ml) (A and B) or with control siRNA (SCR) or SMSl
siRNA (SMS 1-) (C and D) for 24 and 48 hours. One million cells were collected for each
time point and experimental condition and analyzed by mass spectrometry for ceramide
(A and C) and DAG (B and D) levels and species by the Lipidomics Core Facility at
MUSC. Reported in the graphs are representative ceramide and DAG species. Levels are
reported as fold changes versus time-matched control. Where standard deviations are not
visible, the standard deviation is too small compared to the scale of the y-axis. CT:
vehicle control. Asterisk indicates significance to time-matched control (p<0.05).
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All together these results indicate that inhibition of SMS/SMSI
induced changes in some ceramide and DAG molecular species that shift the
ceramide/DAG ratio in favor of ceramide.

Modulation of Bcr-abl expression and activity caused lipid changes
consistent with down-stream regulation ofSMSl

If Bcr-abl promotes SMS 1 expression and activity, then modulation of
Bcr-abl activity should cause lipid changes consistent with changes in SMS
activity. To investigate this relationship, we first determined the effect of
Bcr-abl expression on basal levels of DAG, ceramide and SM by mass
spectrometry. HL-60/ct and HL-60/Bcr-abl cells (Figure 10) were grown
under standard conditions and collected once the cells reached the
logarithmic phase of growth.

Importantly, cells with similar passage

numbers were used to control for lipid changes resulting from cell culture
aging, potentially disguising the lipid changes specifically mediated by Bcrabl expression. The levels of several DAG and SM species were found
increased in HL-60IBcr-abl cells as compared to HL-60/ct (Figure 10 and

Supplementary Table 3). In particular, the same representative DAG
species that were decreased upon down-regulation of SMSl, C14:0/C16:0
and C14:0/C18:0, were also elevated in BCR-ABL expressing cells (Figure
lOA). Moreover, the majority of SM species were significantly elevated in

HL-60/Bcr-abl

cells

as

compared

to

HL-60/ct

(Figure

lOB

and

Supplementary Table 3C). This is in agreement with the enhanced SMS
activity observed in HL-60/Bcr-abl cells as compared to HL-60/Ct (Figure
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6B). Interestingly, Bcr-abl expression did not decrease ceramide levels
(Supplementary Table 3A).

Figure lOA+B. Effect of overexpression of Bcr-abl in HI-60 cells
on the lipids regulated by SMSI
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Figure 10. Effect of overexpression of Bcr-abl in HL-60 cells on the lipids regulated
by SMSI. Two million HL-60IBcr-abl or HL-60/ct cells of similar passage were allowed
to reach the logarithmic phase of growth and were harvested at the same time for lipid
analysis. The levels and species of DAG (A) and SM (B) were analyzed from two
independent experiments by mass spectrometry at the Lipidomics Core Facility at
MUSC. Reported in the graphs are representative DAG and SM species. Levels are
reported as fold change versus time-matched control (HL-60/ct). Asterisk indicates
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of
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control
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calculated.
fold
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Next, in a complementary approach, the effect of siRNA-mediated
down-regulation of BCR-ABL was determined on SMS-regulated lipids. The
amount of siRNA, time of incubation, and cell culture conditions were
optimized in preliminary experiments and conditions were selected based

upon both maximum BCR-ABL down-regulation, as measured by western
blotting, and decreased SMS activity (data not shown). HL-60/Bcr-abl cells
were either treated with siRNA targeting BCR-ABL (Bcr-abl-) or with the
scrambled siRNA Allstar control (SCR) and cells from each experimental
condition were harvested 36 hours post siRNA treatment for lipid analysis.
Absolute lipid levels from one representative experiment are reported in

Supplementary Table 4 and representative lipid species are reported in
Figure 11. These results showed that reduction of BCR-ABL expression
induced a significant increase of the levels of representative ceramide
species, C 18:0 and e22: 1 and a decrease of representative DAG species,
C14:0IC18:0 and C16:0/C18:0 (Figures l1A and lIB and Supplementary

Table 4). These changes resulted in an overall shift of the total ceramide
over total DAG ratio from 0.34 of control cells to 1.34 of BCR-ABL downregulated cells. Furthermore, Bcr-abl inhibition resulted in a significant
decrease of total SM levels, as the levels of several molecular species were
affected (Supplementary Table 4C).
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Figure llA-D. Inhibition of Bcr-abl induced accumulation of
ceramide and reduction of DAG levels
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Figure 11. Inhibition of Bcr-abl induced accumulation of ceramide and reduction of
DAG levels. Panels A and B: HL-60IBcr-abl cells were treated with either scrambled
siRNA control (SCR) or BCR-ABL siRNA (Bcr-abl -) for 36 hours. Two million cells
were collected from each experimental condition and the levels and species of cerarnide
(A), and DAG (B) were analyzed from three independent experiments by mass
spectrometry by the Lipidomics Core Facility at MUSC. Panels C and D: K562 cells
were treated with Imatinib (1m, 0.4 or 1 I-lM) for 24 and 30 hours and the levels of
different species of ceramide (C) and DAG (D) were measured by mass spectrometry at
MUSC. Levels are reported as fold changes versus time-matched control (SCR or CT).
Where standard deviations are not visible, the standard deviation is too small compared to
the scale of the y-axis. Asterisk indicates significant difference between HL-60/Bcr-abl( -)
and SCR control or Imatinib-treated and control cells (p< 0.05). CT: control~ 1m:
Imatinib-treated cells. Reported in the graphs are representative ceramide and DAG
speCIes.

The effect of loss of active Bcr-abl on DAG, ceramide and SM levels
was also determined in K562 cells after pharmacological inhibition of Bcrabl with Imatinib. K562 cells were treated with O.4Jj.M and If.lM Imatinib for
24 and 30 hours (concentrations of Imatinib and time of incubation which
effectively inhibited SMS activity prior to affecting cell proliferation,

Supplementary Figure 1). Cells for each experimental condition were
collected and lipids extracted for mass spectrometry analysis. As shown in

Figure IIC, accumulation of the representative C18:0 and e22:1 ceramide
species was observed already after 24 hours and more pronouncedly after 30
hours of treatment with both concentrations. On the other hand, C14:0/C18:0
and C16:0IC18:0 DAG levels were greatly suppressed already after 24 hours
of treatment with both Imatinib concentrations and they remained low after
30 hours of incubation. In the presence of 1JlM Imatinib, the reported lipid
changes cause a shift of the ratio between total ceramide over total DAG
from 0.64 of control cells to 1.21 of Imatinib treated cells after 24 hours and
from 0.34 to 1.03 after 48 hours. Absolute lipid values from one
representative experiment are reported in Supplementary Table 5.
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All together these results are consistent with modulation of SMS
activity by Bcr-abl.

Inhibition ofSMSl caused a significant defect in cell growth ofBcrabl-positive cells

Since down-regulation of SMSI caused a decrease of DAG and an
increase of ceramide, and DAG and ceramide are involved in regulation of
cellular proliferation and/or cell death (32,42,95,167,168,170,321-325), the
effect of SMS 1 inhibition was next determined on these cellular processes.
K562 cells were first treated with D609, and its effect on cell proliferation
was tested by measuring incorporation of tritiated thymidine (Figure 12A).
A significant inhibitory effect of D609 was observed already after 24 hours
and it continued after 48 and 72 hours of treatment. Next, the effect of
specific down-regulation of SMSl was determined. Initially, transient downregulation of SMS 1 with siRNA produced variable results depending on the
extent of SMSI reduction (inhibition of cellular proliferation was only
observed in case of suppression of SMSl by more than 75%). We reasoned
that this might be due to the high basal SMSl expression in these cells and to
a possible threshold effect. Thus, to obtain a more reproducible effect, we
aimed at achieving maximal down-regulation of SMSI. To this aim, K562
cells were first transduced with viral particles containing short hairpin RNA
targeting SMSl (shRNA-SMSI) followed by selection of stably expressing
cells (this ensured a basal 50% reduction of SMSl expression, data not
shown). Subsequently, to further down-regulate SMSl, K562 cells stably
transduced with shRNA-SMS1 were transfected with SMSl siRNA (shRNASMS1/SMSI) and those transduced with control shRNA (shRNA-NTCP)
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were transiently transfected with Allstar Scrambled siRNA

(shRNA-

NTCP/SCR). As shown in Figure 12B, sustained inhibition of SMSl in
K562 cells (shRNA~SMSI/SMSI) resulted in reduced [3 H ]-thymidine
incorporation as compared to control cells (shRNA-NTCP/SCR) already at
24 hours, and significantly after 48 and 72 hours. On the other hand
inhibition of SMSl expression by more than 75% in HL-60/ct cells did not
affect their cell growth (Supplementary Figure 2).These results suggest
that sustained inhibition of SMSI expression/activity in K562 cells
significantly impairs cell proliferation.
On the other hand, down-regulation of SMSl
cytotoxicity or apoptosis.

did not cause

In fact no significant increase in trypan blue

positive cells and no positivity to propidium iodide was detected by FACS
analysis (data not shown). Moreover, no evidence of caspase-induced
apoptosis was observed in K562 cells upon treatment with D609 or after
downregulation of SMSl (Supplementary Figure 3).
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Figure 12A +B. Inhibition of SMS activity in K562 cells
significantly reduced cell proliferation
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Figure 12. Inhibition of SMS activity in K562 cells significantly reduced cell
proliferation. Changes in proliferation after pharmacological (A) or siRNA~mediated
inhibition of SMS 1 (B) were measured by 3H-Thymidine incorporation after 24, 48, and
72 hours. A: 3H_Thymidine incorporation was determined after inhibition of total SMS
with D609 (50 ~g/ml). B: cells were transduced with lenti-virus containing either control
particles (shRNA-NTCP) or viral particles containing sequences to induce partial stable
down-regulation of SMSl (shRNA-SMSl). 3H-Thymidine incorporation was then
measured in shRNA-NTCP transiently transfected with Allstar scrambled siRNA control,
(shRNA-NTCP/SCR) and shRNA-SMS 1 cells transiently transfected with SMSl siRNA.
Results represent the average and standard deviation of a minimum of 4 separate
experiments. Where standard deviations are not visible, the standard deviation is too
small compared to the scale of the y-axis. Asterisk indicates significant difference versus
Control or shRNA-NTCP/SCR (p< 0.05). ShRNA: short-hairpin RNA. NTCP: NonTransducing Control Particles. CPMs: Counts Per Minute.
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All together these results implicate SMS 1 in specific regulation of cell
proliferation, and not cell death, of Bcr-abl-positive cells.

DISCUSSION
In this study, we provide evidence of a link between the expression of
the Bcr-abl oncogene, its activity and elevated SMS activity. We further
show that enhanced expression of SMS 1 and not SMS2 is responsible for the
elevated SMS activity and that elevated SMS 1 is important for sustaining
proliferation of Bcr-abl positive cells. Moreover, modulation of Bcr-abl,
SMS activity or SMS 1 expression results in a similar alteration of the ratio
of the bioactive lipids ceramide and DAG. Finally, inhibition of SMSI
significantly affects cell proliferation of Bcr-abl positive cells consistent
with the shift of the ceramide to DAG ratio in favor of ceramide.
These results are significant since up to date no molecular factors that
are able to stimulate SMS 1 or SMS2 expression/activity have been
identified. In particular, increased SMS activity has been associated with
some transformed phenotypes (10,314,315), thus the herein reported
regulation of SMS 1 by Bcr-abl represents the first molecular link between a
well-known oncogene and an SMS to support that association.
Up to date, the involvement of SMS 1 as a potential downstream target
of Bcr-abl was unknown, and in general the role of ceramide in Bcr-ablmediated signalling was unclear. In particular, whereas Ber-abi expression
was shown to impart total or partial resistance to treatment with exogenous
short chain ceramide analogues (C2 or C6-ceramide), Bcr-abl was also
found to accelerate ceramide-mediated apoptosis by these same analogues
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(292-294). Recently., accumulation of endogenous ceramide and decrease of
the antiapoptotic sphingolipid, sphingosine 1 phosphate (SIP) was shown to
be in part responsible for the cytotoxic effect exerted by imatinib treatment
in CML derived cell lines (298). Moreover, it was also shown that a shift of
the balance between endogenous ceramide and SIP in favor of SIP might be
of critical relevance for imparting imatinib resistance to CML cells
(298,299). In our experimental model, we observed similar changes in
ceramide levels after treatment with Imatinib as those reported in the
literature (298), and these lipid changes were also observed in case of
pharmacological or siRNA-mediated inhibition of SMSI. Together with the
fact that inhibition of Bcr-abl causes a significant block of SMS activity

(Figure 6C), this suggests that, at least in part, ceramide accumulation upon
inhibition of Bcr-abl might be due to inhibition of SMS 1 activity.
Interestingly, down-regulation of SMSl induced accumulation of specific
ceramide molecular species such as C16:0, C18:0, C20:0 and e22:1 which
were also accumulated upon pharmacological inhibition with D609
(Supplementary Tables lA and 2A). D609 treatment also caused
accumulation of other ceramide species, and this maybe due to either or both
the more rapid and sustained inhibition of SMS activity compared to siRNA
and the activation of other ceramide-generating pathways, such as the de
novo pathway (326). Importantly, C18:0., C20:0 and e22: 1 ceramides were
also increased upon pharmacological inhibition of Bcr-abl., and this is
consistent with SMS 1 being a down-stream target of Bcr-abl. Also in the
case of Bcr-abl inhibition, other ceramide species were also increased and
this maybe the result of activation of certain ceramide synthases, such as
CerS 1 (298).
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The fact that ceramide accumulation upon inhibition of Bcr-abl might
be in part due to SMS 1 inhibition is also supported by the analysis of both
SM and DAG levels. Indeed, we found that upon inhibition of Bcr-abl or
SMS/SMS 1, there was a tendency for several species of SM to decrease,
although some changes were not statistically significant (Supplementary
Tables Ie, 2C, and 5C). Additionally, over-expression of Bcr-abl in HL-60
cells induced a significant accumulation of various species of SM

(Supplementary Table 3C) and siRNA-mediated downregulation of the
oncogene significantly lowered SM levels (Supplementary Table 4C).
Notably, inhibition of Bcr-abl or SMS/SMS 1 induced a significant
drop of several DAG species, and these changes were even more
pronounced than those in ceramide levels (Supplementary tables IB, 2B
and 3B). Pharmacological and siRNA-mediated inhibition of SMS 1 induced
a significant decrease of specific DAG molecular species, such as low
abundant C14:0/C16:0 and C14:0/18:0 DAGs, and highly represented
C16:0/18:0, C16:0/18:1, C18:0/18:1 and Di-C16:0 DAGs. These same

species were also decreased upon inhibition of Bcr-abl (Supplementary
Table SB), suggesting that there might be a specific pattern of DAG changes
induced by modulation of SMS1. These results were also observed upon
siRNA mediated down-regulation of BCR-ABL in HL-60/Bcr-abl cells

(Supplementary Table 4B).
As already mentioned In the general introduction, the relationship
between Bcr-abl and DAG has not been documented in the literature.
Indirect evidence of the involvement of DAG as a downstream signaling
molecule of Bcr-abl come from reports showing that activation of
phospholipase C (PLC) yl and of the PI3KJAkt pathway are required for
Bcr-abl signaling through mTOR/p70S6-kinase (305,306). The regulation of
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mTOR/p70S6-kinase by PLCyl seems to occur

VIa

modulation of both

calcium signaling (CaMKII) (presumably through formation of 1P3) and
classical and novel protein kinase C (likely through production of DAG). In
our system, we observed a very significant drop of DAG levels when either
Bcr-abl or SMS/SMS 1 were inhibited. Being SMS 1 regulated by Bcr-abl, it
is possible that part of the observed drop of DAG levels after inhibition of
Bcr-abl is due to the decrease of SMS/SMS 1 activity, in addition to
inhibition of PLCy 1.
Importantly the changes of cerami de (accumulation) and DAG
(decrease) levels observed upon inhibition of Bcr-abl or SMS/SMS 1 are
both consistent with the inhibition of cell proliferation observed in response
to these treatments, and these concomitant lipid changes may work in
concert to cause this phenotype. Interestingly, down-regulation of SMSl did
not cause a change in proliferation of the Bcr-abl negative cell line HL-60

(Supplementary Figure 2), indicating a specific role for SMS 1 in
supporting proliferation of Bcr-abl positive K562 cells. The difference in the
requirement of SMSl expression for proliferation between Bcr-abl positive
and negative cells may be linked to the expression of SMS2 and the ability of
SMS2 to compensate for the loss of SMS 1. In fact, SMS2 is almost
undetectable in Bcr-abl positive K562 but expressed in HL-60 to a similar
level as SMSI (data not shown). This scenario would imply that whenever
SMS 1 is the only SMS expressed in a certain cell type, then its activity is
crucial for survival of those cells.
An interesting observation is the fact that SMSl mRNA is increased in
Bcr-abl positive cells opening up the question of the mechanism by which

SMSl expression is stimulated by Bcr-abl (transcriptional regulation or
mRNA stability). Preliminary results support the first mechanism thus in the
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near future it is our intention to characterize the transcriptional regulation of
SMSI by Bcr-abl in order to elucidate the signaling pathway, down-stream

of Bcr-abl, responsible for up-regulation of SMS1.
Interestingly, even if K562 cells are blast phase CML, and therefore
characterized by a block of differentiation potentially due

to the

accumulation of mutations in addition to the formation of the Bcr-abl
chimaera, SMS 1 activity is still under the control of the Bcr-abl tyrosine
kinase activity. Therefore it is unlikely that SMS 1 may represent a
"druggable" target to contain newly diagnosed blast phase CML. On the
other hand, in spite of the success obtained in controlling the chronic phase
of CML, the increase in resistance to Bcr-abl inhibitors is starting to
represent a significant medical challenge. Thus, establishing SMS 1 as an
important down-stream regulator of Bcr-abl may provide the basis for future
work set to test SMS 1 as a potential novel pharmacological target for CML,
in particular for those cases that arise from resistance to Bcr-abl inhibitors.
In summary, the discovery of the Bcr-abl/SMSl connection provides
the first molecularly-characterized model for a better understanding of
potential modes of regulation and down-stream functions of the elusive
SMSI.
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Supplementary Figures
Supplementary Figure 1. Effect of Imatinib on cell number
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Supplementary Figure 1. Effect of Imatinib on cell number. K562 cells (O.Ix 106
cell/ml) were incubated in the presence of the indicated concentrations of Imatinib (1m)
or vehicle control (CT) for different periods of time. At the reported time points, cells
were counted and cell viability was determined by Trypan blue staining. The cell number
reported in the Figure represents total cells (Trypan blue positive + Trypan blue negative
cells). Data represent the average and standard deviation of at least 3 separate
experiments. Where standard deviations are not visible, the standard deviation is too
small compared to the scale of the y-axis. Asterisk indicates significant difference to
control cells (CT) (p<0.05).
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Supplementary Figure 2. Down-regulation of SMSI did not affect
cell proliferation
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Supplementary Figure 2. Down-regulation of SMSI did not affect cell proliferation
of HL-60/ct cells. HL-60/ct cells were transfected with either the All Star Scrambled
control siRNA (SCR) or SMSl siRNA (SMSl-). Aliquots of cells were counted and
stained with Trypan blue after 24, 48, and 72 hours. Treatment with SMSl siRNA
induced an average 70-80% down-regulation of SMSl expression after 48 hours. Data
represent the average and error bars of two separate experiments. CT: mock transfection
control.
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Supplementary Figure 3. Inhibition of SMS activity in K562 cells
did not induce apoptosis
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Supplementary Figure 3. Inhibition of SMS activity in K562 cells did not induce
apoptosis. Treatment of K562 cells with either D609 (50 ~g/ml) or SMSl siRNA
(SMS 1-) for 72 hours did not induce PARP cleavage (as determined by western blotting).
MCF-7 cells treated with InM TNFa for 18 hours were used as positive control for
PARP cleavage and ~ - actin as control for equal loading within samples of the same
treatment group.
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Supplementary Tables
Supplementary Table 1. Effect of inhibition ofSMSl by D609 treatment on lipid levels

Effect of inhibition of SMSI by D609 treatment on lipid levels. Reported are the levels of individual species of cerami de (A),
DAG (B) and SM (C) as measured by mass spectrometry during treatment with D609 (50 J..!g/ml) after 24 and 48 hours. Since basal
levels of lipids were variable among the different experiments whereas the pattern of changes between experimental conditions was
similar (Figure 13A and B), reported are the absolute values of one representative experiment. In bold are the values that were
significantly different compared to the time-matched control once the fold change versus the appropriate control was calculated
among three independent experiments (p<O.05 versus CT). CT: Control cells.

Supplementary Table lA. Ceramide species (pmoleslnmole of Pi)
Samples

I C14-Cer

C16-Cer

C18-Cer

C18:1-Cer

C20-Cer

C20:1-Cer

C22-Cer

C22:1-Cer

C24-Cer

C24:1-Cer

C26-Cer

C26:1-Cer

Total Cer

CT24h

0.018

0.117

0.020

0.007

0.014

0.003

0.082

0.030

1.13

0.445

0.015

0.035

1.92

D60924h

0.097

0.323

0.073

0.025

0.082

0.008

0.213

0.073

1.15

0.502

0.042

0.053

2.64

CT48h

0.012

0.063

0.017

0.003

0.010

0.002

0.047

0.018

0.73

0.300

0.013

0.015

1.23

D60948h

0.093

0.277

0.043

0.020

0.080

0.012

0.158

0.082

0.90

0.420

0.020

0.023

2.13
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Supplementary Table lB. DAG species (pmoleslnmole of Pi)
C16:0/24:1-

C16: 1/18:0-

DAG

C16:0/20:0DAG

DAG

DAG

CI6:1/18:1DAG

3.82

5.39

0.182

0.217

0.072

0.393

0.080

0.84

1.32

0.005

0.008

0.115

0.602

0.298

0.142

3.59

3.14

0.275

0.267

0.022

0.285

0.050

0.075

0.69

0.78

0.020

0.020

0.003

0.237

C14:0/16:0·

C14:0/18:0·

C14:0/18:1·

DAG

C16:0/18:0·
DAG

DAG

DAG

CT24h

0.620

0.225

0.127

D60924h

0.177

0.050

CT48h

0.497

D60948h

0.068

Samples

C16:0/18:1·
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Supplementary Table lB. DAG species (pmoleslnmole of Pi), continued
Total

C18:0118:1-

C18:0118:2·

C18:0/20:4·

Di·C14:0·

Di·C16:0-

Di·C18:0·

Di·C18:1-

DAG

DAG

DAG

DAG

DAG

DAG

DAG

CT24h

0.92

0.28

1.08

0.080

2.54

0.207

0.121

16.27

D60924h

0.65

0.48

0.66

0.060

0.45

0.178

0.225

5.89

CT48h

2.05

0.16

0.58

0.068

2.01

0.093

0.288

13.77

D60948h

0.61

0.14

0.90

0.022

0.23

0.197

0.195

4.24

Samples

Supplementary Table

Ie.

DAG

SM species (pmoleslnmole of Pi)

Samples

C14·SM

C16~SM

C18~SM

C18:1~SM

C20~SM

C20:1~SM

C22-SM

C22:1·SM

C24·SM

C24:1-SM

C26-SM

C26:1-SM

Total SM

CT24h

0.505

21.25

3.16

2.23

1.07

0.28

6.67

2.86

7.59

16.59

0.09

0.37

62.67

D60924h

0.735

22.23

2.71

1.62

0.98

0.22

3.93

1.80

4.56

8.37

0.25

0.41

47.82

CT48h

0.725

27.02

3.31

3.09

0.81

0.14

7.14

2.40

7.68

17.01

0.07

0.20

69.60

D60948h

0.885

23.19

2.97

2.85

0.87

0.13

7.67

2.44

9.41

16.80

0.28

0040

67.90
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Supplementary Table 2. Effect of inhibition ofSMSl by siRNA treatment on lipid levels

Effect of inhibition of SMSI by siRNA treatment on lipid levels. Reported are the levels of individual species of ceramide (A),
DAG (B) and SM (C) as measured by mass spectrometry during down-regulation of SMSl (SMSI-) with siRNA as compared to a
scrambled control sequence (SCR) after 24 and 48 hours. Since basal levels of lipids were variable among the different experiments
whereas the pattern of changes between experimental conditions was similar (Figure 13C and D), reported are the absolute values of
one representative experiment. In bold are the values that were significantly different compared to the time-matched control once the
fold change versus the appropriate control was calculated among three independent experiments(p<O.05 versus SCR).

Supplementary Table 2A. Ceramide species (pm oIe sinm ole of Pi)
Samples

I C14-Cer

C16-Cer

C18-Cer

C18:1-Cer

C20-Cer

C20:1-Cer

C22-Cer

C22:1-Cer

C24-Cer

C24:1-Cer

C26-Cer

C26:1-Cer

Total Cer

SCR24h

0.008

0.140

0.155

0.012

0.021

0.001

0.072

0.043

1.137

0.907

0.038

0.026

2.56

SMSl- 24h

0.001

0.118

0.160

0.004

0.014

0.001

0.070

0.042

0.802

0.904

0.015

0.021

2.15

SCR48h

0.036

0.307

0.124

0.021

0.026

0.004

0.112

0.065

1.532

1.427

0.053

0.067

3.77

SMSl- 48h

0.044

0.463

0.204

0.046

0.065

0.011

0.127

0.108

1.246

1.555

0.029

0.053

3.95
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Supplementary Table 2B. DAG species (pmoleslnmole of Pi)

DAG

CI6:0/18:1DAG

DAG

CI6:0/24: 1DAG

DAG

C16:1/18:1DAG

0.062

7.208

2.132

0.288

0.090

0.087

0.060

0.146

0.036

3.172

1.695

0.095

0.077

0.051

0.045

0.277

0.122

0.053

2.908

1.766

0.105

0.061

0.060

0.048

0.178

0.062

0.037

1.856

1.499

0.080

0.058

0.044

0.052

CI4:0/16:0-

CI4:0/18:0-

C14:0/18:1-

CI6:0/18:0-

DAG

DAG

DAG

SCR24h

0.774

0.399

SMSl- 24h

0.559

SCR48h
SMSl· 48h

Samples
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C16:0/20:0·

CI6:1/18:0-

Supplementary Table 2B. DAG species (pmoleslnmole of Pi), continued

Samples

C18:0/18:1DAG

C18:0/18:2DAG

C18:0/20:4DAG

Di-C14:0DAG

Di-C16:0DAG

Di-C18:0DAG

Di-C18:1DAG

Total DAG

SCR24h

1.102

0.034

0.072

0.041

2.534

0.106

0.103

15.09

SMSl- 24h

0.567

0.019

0.037

0.028

1.637

0.028

0.086

8.28

SCR48h

1.413

0.082

0.432

0.019

0.667

0.064

0.120

8.20

SMSl- 48h

1.262

0.103

0.351

0.014

0.452

0.029

0.134

6.21
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Supplementary Table 2C. SM species (pmoleslnmole of Pi)
Samples

I CI4-SM

C16-SM

CI8-SM

CI8:I-SM

C20-SM

C20:I-SM

C22-SM

C22:I-SM

C24-SM

C24:I-SM

C26-SM

C26:I-SM

Total SM

SCR24h

1.17

22.0

2.96

0.301

0.687

0.195

2.94

1.50

3.98

8.38

0.035

0.204

44.35

SMSI-24h

1.06

19.0

2.69

0.305

0.702

0.224

2.64

1.46

3.04

7.39

0.042

0.174

38.73

SCR 48h

1.22

22.5

2.77

0.260

0.681

0.186

2.34

1.31

3.77

7.18

0.077

0.197

42.49

SMSl-48h

0.96

13.0

1.84

0.249

0.663

0.172

2.28

1.31

2.86

6.21

0.027

0.118

29.69
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Supplementary Table 3. Effect of overexpression ofBCR-ABL in HL-60 cells on lipid levels.

Effect of overexpression of BCR-ABL in HL-60 cells on lipid levels. Reported are the levels of individual species of ceramide (A),
DAG (B), and SM (C) extracted from HL-60/ct and HL-60IBcr-abl cells as measured by mass spectrometry. Cells from each
experimental condition were harvested after the same amount of time in culture and during the logarithmic stage of growth. Since
basal levels of lipids were variable among the different experiments whereas the pattern of changes between experimental conditions
were similar (Figure 14), reported are the absolute values of one representative experiment. In bold are the values that were
significantly different compared to the time-matched control once the fold change versus the appropriate control was calculated
among two independent experiments (p<O.05 versus HL-60/ct). BDL: below detection limit.

Supplementary Table 3A. Ceramide species (pmoleslnmole of Pi)

Samples

C14-Cer

C16-Cer C18-Cer

C18:1-Cer

C20-Cer

C20:1-Cer

C22-Cer C22:1-Cer

C24-Cer

C24:1-Cer

C26-Cer

C26:1-Cer Total Cer

HI-60/ct

.08

0.83

0.07

0.03

0.02

BOL

0.08

0.02

1.81

1.39

0.07

0.16

4.56

HL601Bcrabl

.09

0.97

0.10

0.05

0.04

0.01

0.25

0.10

3.68

3.71

0.13

0.28

9.41
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Supplementary Table 3B. DAG species (pmoleslnmole of Pi)

C14:0/16:0AG

Samples

HL60/ct
HL60lBcr-abl

11.53

C14:0/18:0DAG

C14:0/18:1DAG

C16:0/18:0DAG

C16:0/18:1DAG

C16:0/20:0-

C16: 1/18:0-

C16: 1/18:1-

DAG

DAG

DAG

CI8:0/18:1DAG

0.11

0.49

0.83

3.22

0.02

0.08

1.60

1.03

0.52

0.26

5.95

8.53

0.32

0.25

0.45

2.87

Supplementary Table 3B. DAG species (pm o Ie sinm ole of Pi), continued

C18:0/20:4-

Di-C14:0

Di-C16:0-

DAG

DAG

HL60/ct

0.09

HL60/Bcr-abl

0.35

IC18:0/18:2Samples

AG

DAG

Dj-18:1DAG

DAG

0.17

0.08

0.51

10.47

0.05

0.13

0.48

30.60

DAG

Di-C16:1DAG

0.06

1.55

0.15

8.59
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Di-18:0-

Total

Supplementary Table 3C. SM species (pmolelnmole of Pi)

Samples

HI-60/ct
HL-60IBcr-abl

C14-SM

C16-SM

CI8-SM

C18:1-SM

C20-SM

C20:l-SM

e22-SM

C22:1-SM

C24-SM

C24:1-SM

Total 8M

.16

69.34

1.33

0.17

0.21

0.01

2.41

0.89

2.03

23.95

100.5

1O~23

59.52

4.89

3.69

1.36

0.28

6.72

3.55

6.82

18.24

105.3
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Supplementary Table 4. Effect of down-regulation ofBCR..ABL on lipid levels ofHL-60IBcr-abl cells.

Effect of down-regulation of BCR-ABL on lipid levels of HL-60IBcr-abl cells. Reported are the levels of individual species of
ceramide (A), DAG, (B), and SM (C) from HL-60IBcr-abl cells after down-regulation of BCR-ABL. HL-60fBcr-abl cells were treated
with either BCR-ABL targeting siRNA [HL-60/Bcr-abI/Bcr-abl( -)] or scrambled Allstar RNAi control [HL-60IBcr-abl/SCR] and cells
from each condition were collected after 36 hours and lipids were extracted for analysis. Since basal levels of lipids were variable
among the different experiments whereas the pattern of changes between experimental conditions was similar (Figure 13A and B),
reported are the absolute values of one representative experiment. In bold are the values that were significantly different compared to
the time-matched control once the fold change versus the appropriate control was calculated among three independent experiments
(p<O.05 versus HL-60IBcr-abI/SCR). BDL: below detection limit.

Supplementary Table 4A. Ceramide species (pmoleslnmole of Pi)

Samples

C14-Cer C16-Cer C18-Cer C18:1-CerC20-Cer C20:1-Cer C22-Cer

C22:1-Cer C24-Cer C24:1-Cer C26-Cer C26:1-Cer Total Cer

.10

0.72

0.07

0.03

0.07

0.01

0.24

0.11

2.42

2.27

0.08

0.13

6.25

HL-60IBcr-abllBcr-abl( -) 10.15

0.53

0.11

0.07

0.07

0.03

0.18

0.15

1.12

1.78

0.03

0.06

4.28

HL-60/Bcr-abUSCR
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Supplementary Table 4B. DAG species (pmoleslnmoZe of Pi)

C14:0/16:0

C14:0/18:0

C14:0/18:1

C16:0/18:0

C16:0/18:1

C16:0/20:0

C16:1/18:0

C16:1/18:1

C18:0/18:1-

DAG

DAG

DAG

DAG

DAG

DAG

DAG

DAG

1.24

0.56

0.20

7.09

4.48

0.26

0.06

0.40

0.61

HL-60IBcr-abllBcr-abl (-) 0.05

0.02

0.01

0.58

0.57

0.23

0.48

0.50

0.32

AG

Samples
HL-60IBcr-abl/SCR

Supplementary Table 4B. DAG species (pmoZeslnmoZe of Pi), continued

Total DAG

C18:0/20:4-

Di-CI4:0-

Di-C16:0-

Di-C16:1-

Di-CI8:0-

Dj-CI8:1-

DAG

DAG

DAG

DAG

DAG

DAG

HL-60IBcr-abIlSCR

0.06

0.08

3.11

0.01

0.06

0.12

18.36

HL-60IBcr-abIIBcr-abl (-)

0.22

BOL

0.09

BOL

0.03

0.06

3.19

C18:0/18:2Samples

AG
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Supplementary Table 4C. SM species (pmoleslnmole of Pi)

Samples

C14ISM

C16SM

C18SM

CI8:1SM

C20SM

C20:1SM

C22SM

C22:ISM

C24SM

C24:1SM

SM

C26:I-Total
SM SM

HL-60IBcr-abI/SCR

10.72

55.52

3.56

1.27

1.16

0.33

5.87

3.28

4.97

16.00

0.01

0.33

93.02

HI-60IBcr-abllBcr-abl(-)

\0.70

39.47

2.92

1.15

0.83

0.24

4.33

2.70

3.25

12.80

0.02

0.22

68.63
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C26-

Supplementary Table 5. Effect of inhibition of BCR-ABL activity with Imatinib on lipid levels in
K562cells.
Effect of inhibition of Bcr-abl activity with Imatinib on lipid levels in K562 cells. Reported are the levels of individual species of
ceramide (A), DAG (B) and SM (C) as measured by mass spectrometry during pharmacological inhibition of Bcr-abl in K562 cells
with different concentrations of Imatinib (0.4 and 1 JlM, 1m) after 24 and 30 hours of incubation. Since basal levels of lipids were
variable among the different experiments whereas the pattern of changes between experimental conditions was similar (Figure 13C
and D), reported are the values of one representative experiment. In bold are the values that were significantly different compared to
the time-matched control once the fold change versus the appropriate control was calculated among three independent experiments
(p<O.05 versus CT). BDL: below detection limit.

Supplementary Table SA. Ceramide species (pmoleslnmole of Pi)

Samples

C14I Cer

C16Cer

C18Cer

CI8:1Cer

C20Cer

C20:1Cer

Cer

C22:1 ..
Cer

C24·
Cer

C24:1
Cer

C26·
Cer

C26:1·
Cer

Total
Cer

e22-

CT24h

0.051

0.56

0.038

0.02

0.043

0.004

0.19

0.062

2.63

2.18

0.049

0.111

5.94

1m (O.4uM) 24h

0.089

0.57

0.051

0.087

0.061

0.008

0.24

0.107

2.36

2.83

0.038

0.1

6.54

1m (tuM) 24h

0.107

0.65

0.061

0.073

0.071

0.009

0.20

0.102

2.24

2.80

0.033

0.067

6.41

CT30h

0.068

0.99

0.031

0.026

0.053

0.003

0.26

0.080

3.15

2.73

0.058

0.115

7.56

1m (O.4uM) 30b

0.170

1.02

0.109

0.119

0.106

0.017

0.34

0.202

2.85

3.89

0.045

0.120

8.99

1m (luM) 30h

0.181

0.92

0.109

0.118

0.089

0.019

0.27

0.163

2.53

3.75

0.038

0.092

8.28
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Supplementary Table SB. DAG species (pmoleslnmole of Pi)
I CI4:0/16:0-

CI4:0/18:0-

C14:0/18:1-

DAG

DAG

DAG

CI6:0/18:0DAG

CI6:0/18:1DAG

C16:0/20:0DAG

C16: 1/18:0DAG

C16: 1/18:1DAG

CT24h

0.29

0.23

0.024

4.15

1.60

0.19

0.12

0.07

Illl (O.4uM) 24h

0.03

0.04

0.015

1.49

0.83

0.03

0.03

0.02

1m (luM) 24h

0.02

0.03

0.01

1.14

0.62

SOL

0.02

0.02

CT30h

0.69

0.65

0.073

10.61

3.03

0.57

0.30

0.19

1m (O.4uM) 30h

0.07

0.20

0.015

3.73

1.12

0.12

0.06

0.05

1m (luM) 30h

0.02

0.06

0.013

1.45

0.97

0.03

0.04

0.03

-,amples

103

Supplementary Table SB. DAG species (pmoleslnmole of Pi), continued

DAG

C18:0/20:4DAG

Di-C14:0DAG

Di-C16:0DAG

Di-C18:0DAG

Di-C18:1DAG

Total DAG

0.72

0.08

0.35

0.007

1.07

0.16

0.24

9.30

1m (Op4uM) 24h

0.53

0.04

0.84

0.002

0.21

0.08

0.19

4.38

1m (luM) 24h

0.73

0.20

2.01

0.001

0.10

0.13

0.26

5.29

CT30h

1.75

0.21

0.74

0.013

2.36

0.39

0.47

22.05

1m (O.4uM) 30h

1.09

0.36

1 .. 96

0.003

0.35

0.23

0.36

9.72

1m (luM) 30h

1.15

0.45

3.07

0.002

0.13

0.13

0.49

8.04

Samples

C18:0/18:1DAG

CT24h

C18:0/18:2-
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Supplementary Table

8M

Cl6SM

CT24h

0.056

1m (O.4uM) 24h

se.

SM species (pmoleslnmole of Pi)

8M

CI8:ISM

C20SM

C20:lSM

e22SM

e22:1SM

C248M

C24:ISM

C26SM

C26:lSM

Total SM

15.7

3.42

0.33

0.67

0.063

4.75

2.38

4.34

12.8

0.009

0.043

44.56

0.059

11.9

1.95

0 . 16

0.14

0.040

2.47

1.42

2.36

9.0

0.002

0.027

29.53

1m (luM) 24h

0.075

14.5

2.35

0.23

0.17

0.052

3.25

1.90

3.15

11.3

0.001

0.034

37.01

CT30h

0.074

21.5

4.18

0.39

0.80

0.071

6.02

2.85

5.47

15.9

0.012

0.055

57.32

1m (O.4uM) 30h

0.093

19.7

3.04

0.32

0.29

0.067

4.22

2.58

4.07

14.8

0.005

0.047

49.23

1m (luM) 30b

0.091

19.2

3.00

0.28

0.21

0.060

3.95

2.29

4.13

14.1

0.001

0.043

47.36

Samples

Cl4-

C18-
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APPENDIX A: Effect of pharmacological inhibition ofSMS on the
differentiation ofK562 cells, and SMS profile in circulating CD34+
blasts isolated from CML patients.

The following results are included as part of Specific Aim 1, but were not
included for either manuscript, "Sphingomyelin synthase 1 activity is regulated by
the BCR-ABL oncogene," or "Transcriptional regulation of SMSI by the Bcr-abl
oncogene", because more clinical samples including control blasts are necessary
for adequate statistical analysis and significance.

Materials and Methods
Materials
RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and Trypan
Blue dye solution were from Gibeo/Invitrogen Corp., Carlsbad, CA. K562 was
originally purchased from the American Type Culture Collection (Rockville, MD).
Cells were routinely counted after staining with the Trypan blue dye.
Phannacological inhibition of SMS was achieved by incubation of cells with D609
in complete growth medium needed per cell line. Peripheral Blood Mononuclear
Cells (PBMC) isolated from two patients with CML during the blast stage of the
disease were obtained from the Hollings Cancer Center Biorepository.

CD34(+) cell culture

CD34(+) and (-) cells were maintained at 37°C at 5% CO 2. CD34(+) and (-)
cells were grown in complete media containing the following: StemSpam serum
free expansion medium (SFEM) (StemCell Technologies, Vancouver, Canada),
including 200/0 FBS, StemSpan cytokine cocktail (1 ml added for each 99mls of
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media) (StemCell Technologies, Vancouver, Canada), 8ull O.5mls of low density
lipoprotein (0.032-0.068 mg protein/ml) (Sigma-Aldrich, St. Louis, MO) and 1%
of penicillin/streptomycin.

CD34(+) cell isolation

CD34( +) cells were separated from frozen PBMCs uSIng the CD34
microbead kit according to the suggested manufacturer protocol (Milltenyi
Biotech, Aubom, CA). Specifically, 1 x 10 8 frozen PBMCs containing 20% blast
cells were used.

One ml of 1 mg/ml DNAse 1 (1000-1500 U) (Stem cell

technologies, Vancouver, Canada) was added to cells upon thawing. Dead cells
were removed from the preparation using Ficoll-Plaque Premium according the
manufacturer's protocol (Pharmacia, New Yark, NY) and fe-suspended in degassed CD34 buffer [PBS (no Mg+2 or Ca+ 2) pH 7.2,0.5% BSA and 2 mM EDTA].
Subsequently, further removal of dead cells was obtained by using pre-separation
filters (Milltenyi Biotech, Auborn, CA) followed by centrifugation at 300g for 10
minutes at 4°C.

The supernatant was completely removed and cells were re-

suspended in 600ul of CD34 buffer.

To this cell suspension, 200ul of

crystallizable fragment receptor (FeR) blocking reagent and 200ul of CD34
phycoerythrin (PE) conjugated microbeads were added. The above mixture was
subsequently incubated for 30 minutes at 4°C. Cell were washed in 20mls of cold
CD34 buffer, centrifuged at 300g for 10 minutes at 4°C, supernatant was aspirated
completely and each pellet was resuspended in 500ul of CD34 buffer.

Cell

mixture was added to the prepared column placed in a magnetic field (autoMACS
separator) and processed according to the manufacturer's recommendation.
CD34( +) cells remain in the autoMACs separator when they are within the
magnetic field and flowthrough of cells represent CD34( -).
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CD34( -) cells are

stored at -20°C for further assays of mRNA expression or SMS activity. Column
is then removed from the magnetic field and the flowthrough contains CD34( +)
cells. These cells are then stored at -20°C for further assays of mRNA expression
or SMS activity.
In some cases, following elution of either CD34( -) or CD34( +) cells from
the magnetic column as described above, cells were subsequently centrifuged at
300g for 10 minutes at 4°C and resuspended in 200ul of complete medium for cell
growth experiments.

Flow cytometry

Standard flow cytometry procedure was used according to manufacturer's
suggested protocol (Becton Dickinson) with I x 105 cells using CDI1b conjugated
to fluoresceine isothiocyanate (FITC), CD14 conjugated to allophycocyanin
(APC), and CD34 conjugated to phycoerythrin (PE).

Flow cytometry was

analyzed using the FACSCaliber (Becton Dickinson) and results were provided by
the flow cytometry core facility at MUSC.

SMS activity and D609

For experiments testing optimal CD34( +) growing conditions or for D609
experiments, CD34( +) or CD34( -) cells purified as above were resuspended in 1ml
of complete media in a 12 well plate at a concentration of 5 x 104 cells/ml. Cells
were cultured for 24 hours before testing SMS activity or treating with D609. To
inhibit SMS activity, D609 was added and cellular proliferation was determined by
cell counting with trypan blue exclusion at 24 and 72 hours post-treatment.
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QRT-PCR and SMS activity assay

SMS activity assay, mRNA and QRT -peR were performed as described in
the "Materials and Method" section in Chapter 1.
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Results

Effect of pharmacological inhibition ofSMS on differentiation ofK562
cells.

To further characterize the biological implications of the effect of SMS
inhibition on K562 cells, the effect of D609 was determined on K562 cellular
differentiation. To this aim, K562 and control cells (vehicle only treatment) were
treated with 50ug/ml D609 for 96 hours and were analyzed for expression of the
myeloid/monocytic surface antigen markers, CD 14, and CD 11 b by flow
cytometry. As shown in Figure 13, D609 treatment caused a significant shift from
CDllb/CD14 negative K562 control cells to approximately 15% eDI1b and 60%

CD 14 positive cells. These results illustrate that pharmacological inhibition of
SMS not only decreases cellular proliferation but is capable of causing cellular
differentiation towards the myeloid/monocytic lineage.
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Figure 13. Inhibition of SMS activity induces myelocytic/monocytic
differentiation in K562 cells
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Figure 13. Inhibition of SMS activity induces myelocytic/monocytic differentiation in K562
cells. Differentiation markers are characterized by immunophenotypic analysis by flow
cytometric analysis (FACSCaliber, Becton Dickenson, Germany) with antibodies directly
labeled with fluorochromes PE for CD 14 and FITC for CD 11. Data is displayed as the % of total
cells staining positive for the antigens CD14 and CD11b as analyzed by flow cytometry. Arrows
pointing to the right indicates representative cells from each treatment group. Cells were stained
with Wright -Giemsa and magnified 40X for visualization using a standard light microscope.
Abbreviations: CD-Cluster of Differentiation, FITC, fluoresceine isothiocyanate, PE
phycoerythrin.
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Effect of pharmacological inhibition.

To confirm the increased SMS activity observed in Bcr-abl positive cell
lines, SMS activity was also measured in Bcr-abl positive/CD34+ progenitor cells
isolated from CML patients in blast crisis as compared to CD34( -) cells. Increased
SMS activity in CD34( +) cells closely reflected the data obtained from Bcr-ablpositive cell line (Figure 14). In addition, SMSl expression levels from Bcr-abl
positive/CD34( +) cells were analyzed by QRT- peR, and it was found that there

was a substantial increase of SMSl expression in CD34( +) cells as compared to
CD34( -) cells (Figure 15).
Finally, the effect of addition of various dosages of D609 (50ug/ml and
75ug/mJ) on cellular proliferation of CD34( +) cells was determined showing both a
time and dose dependant decrease of CD34(+) cell proliferation (Figure 16). All
together these data corroborate the observations collected from ber-abl-positive
cell lines.
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Figure 14. SMS1 activity is elevated in CD34+ cells isolated/rom CML
patient in blast crisis

04---CD34 negative CD34 positive

Figure 14. SMSI activity is elevated in CD34+ cells isolated from CML patient in blast
crisis. SMS activity was measured as described in "Materials and Method" section from CD34
negative and positive cells.Abbreviations: CD, Cluster of Differentation, ug, microgram.
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Figure 15. SMSI expression is elevated in CD34+ cells from CML patient
in blast crisis

CD34 negative CD34 positive

Figure 15. SMSI expression is elevated in CD34+ cells from CML patient in blast crisis.
mRNA gene expression was determined from CD34 positive and negative cells. All mRNA
Abbreviations:MNE, Mean Normalized
levels were normalized to B-actin expression.
Expression, CD, Cluster of Differentiation.
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Figure 16. Pharmacological inhibition of SMS results in decreased
CD34+ cellular proliferation
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Figure 16. Pharmacological inhibition of SMS results in decreased CD34+ cellular
proliferation. CD34+ cells were treated with the above indicate ugs of D609 for 24 and 72
hours. Cellular proliferation was measured by trypan blue exclusion. Data represents cell
number X 10-4. Abbreviations:CD, Cluster of differentiation
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Chapter 2. Establish SMSI transcriptional activation upon
Bcr-abl expression.

Manuscript 2:

"Transcriptional regulation of SMSl by the Bcr-abl oncogene"

Tara Ann Burns 1 and Chiara Luberto1,2.
Department of tBiochemistry and Molecular Biology, Medical University of South
Carolina, Charleston, South Carolina, USA and 2 Department of Physiology and
Biophysics, Stony Brook University, Stony Brook, New York, USA.

INTRODUCTION
Sphingomyelin synthase (SMS) is a class of enzymes responsible for
the production of sphingomyelin in mammalian cells.
phosphatidylcholine

and

ceramide

as

its

This enzyme uses

precursors

sphingomyelin (SM) and diacylglycerol (DAG).

and

produces

In particular, SMS

transfers the phosphorylcholine moiety from phosphatidylcholine onto
ceramide thereby producing SM and as a byproduct, DAG (1-5,7).
Interestingly, both ceramide and DAG are widely known as bioactive
sphingolipids with opposing functions. Namely ceramide has been widely
studied during cellular stress response such as cell death and differentiation
(5,11,13-18,26,28,33-37). On the other hand, DAG cellular responses are
mainly

studied

In

cellular

processes

such

as

proliferation

and

transformation(8). The ability of this enzyme to modulate the levels of these
two different bioactive sphingolipids makes this enzyme an interesting target
for further investigation. In previous studies conducted by our lab (Burns
and Luberto, manuscript accepted with minor revisions), we have shown that
SMS activity is increased in the K562 celL K562 cells are derived from the
pleural effusion of a patient with chronic myelogenous leukemia (CML).
CML is a hematopoietic stem cell disorder and occurs in 1 to 1.5 out of
100,000 and accounts for 15-20% of all adult leukemias.

The initiating

event of CML is the reciprocal translocation of Chromosomes 9 and 11 and
this event results in a chromosomal fusion between the breakpoint cluster
region (BCR) and the Abelson kinase (ABL) genes resulting in a shortened
chromosome termed "Philadelphia chromosome." (275-278). The shortened
Philadelphia chromosome chimera carries a constitutively active tyrosine
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kinase, Bcr-abl (273,274). Increased SMS activity was due to increased
expression of the SMSl isoform and increased SMS 1 was critical for
sustaining the cell proliferation of BCR-ABL positive cells (Bums et aI,
manuscript accepted with minor revisions). Still unknown is the mechanism
by which Bcr-abl stimulates SMSl expression.

Recently, the SMSl locus has been somewhat characterized.

The

putative structure of SMSl mRNA consists of 3734 nucleotides with 11
exons and a hypothetical coding region of 1239 nucleotides flanked by an
extended 5'-and 3'-UTRs (Figure 17A). The 5'-UTR is 954 nucleotideslong and it comprises exons 1-6 and a portion of exon 7. Upstream open
reading frames (uORFs) are located within exons 1, 5 and 6 corresponding
to ATGs located at nucleotide positions 13-15, 523-525, and 646-648. The
coding region is predicted to start at the weak A TG codon at 955- 957
nucleotide positions and to stop with the T AA codon at positions 2194-2196
and encodes a transmembrane protein of 413 amino acids (327).

The 3'-

UTR of the transcript is 1538 nucleotides long (328).
In this paper we provide evidence of transcriptional regulation of

SMSI by Bcr-abl and we characterize the SMSl promoter under the control
of Bcr-abl. We show that although Bcr-abl upregulates different SMSl
transcripts, the transcription of SMSl is maximally upregulated at sites
located downstream of intron 6. Thus we propose that Bcr-abl expression
results in the use of an alternative transcription start site (TSS) within exon 7
of SMSl and we characterize the first validated promoter (Promoter C) for

SMS1. We also demonstrate that the identified Promoter C is under the
control of Bcr-abl. Finally, we produced a series of 5' promoter C deletions
and we demonstrated that the essential cis-element(s) necessary for Bcr-abl-
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mediated upregulation of this promoter is located between -113 and -110
from the TSS C.

MATERIALS AND METHODS
Materials

RPMI media, fetal bovine serum (FBS) and penicillin/streptomycin
were from Gibco/Invitrogen Corp., Carlsbad, CA.

Methods
Cell culture
K562 and HL-60 cell lines were purchased from the American Type
Culture Collection (Rockville, MD). Human acute myeloid leukemia, HL-60
cells stably expressing p185 Bcr-abl (HI-60IBcr-abl) and HL-60 stably
expressIng the empty vector control (HL-60ICt) were generated as
previously described (292). All cell lines were grown in RPMI-1640
supplemented with 10% fetal bovine serum, 100 U/ml penicillin and
lOOug/ml streptomycin, and were maintained at 37°C at 5% CO 2 •

RNA isolation and reverse transcription for real time peR

RNA isolation and first strand eDNA synthesis were performed as
described previously (165). Primers were designed to specifically amplify
SMSl heteronuclear RNA (the first transcribed RNA; hnRNA) at various

regions within SMS1.

Amplification of genomic DNA was prevented by

treating all RNA samples with DNAse using both on and off-column
digestion (Qiagen, Valencia, CA) and Ambion Turbo DNAse (Invitrogen,
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Carlsbad, CA).

Furthennore., controls were added consisting of RNA

purified from each cell line and not treated with superscript reverse
transcriptase.
transcriptase

Both RNA treated with and without superscript reverse
were

amplified

using

Quantitati ve

Real-Time

reverse

Polymerase Chain Reaction (QRT-PCR) using primers described below.
RNA control samples did not amplify during QRT-PCR thus demonstrating

the absence of genomic DNA.

All primer sequences and their specific

annealing temperatures used during QRT-PCR are provided in Table 1.
QRT-PCR was performed using the Bio-Rad icycler (Bio-Rad, Hercules,
CA) and syber green mixture according to the suggested protocol (Bio-Rad,
Hercules., CA). Bio-Rad icycler parameters are as follows, one cycle of 3min
at 95°C, 40 cycles of lOs at 95°C and 45s at the appropriate annealing
temperatures for each primer set (as indicated in Supplementary Table 6),
one cycle of lmin at 95°C, one cycle of Imin at the appropriate annealing
temperature and 78 cycles., with each cycle increasing by O.soC for 10 s
starting from each primer set's appropriate annealing temperature.

For

QRT-PCR experiments to measure mRNA expression, primers were
designed to span exonJexon junctions thus preventing amplification of
genomic DNA and/or hnRNA with the following exception, Exon7FIR.
Results were normalized to an internal control gene., f3-actin (165) and
amplification efficiency. QRT -peR results were analyzed using Q-Gene®
software, a software that expresses data as means of normalized expression
(329).

120

SMSI mRNA message stability
K562 cells, HL-60/ct, and HL-60/Bcr-abl cells were fe-suspended in
5ml of complete medium (RPMI containing 10% FBS and 1% PIS) at a
concentration of 0.3xl06 cells Iml with either the addition of sterile double
distilled water (ddH 20) or 5 ug/ ml of actinomycin D. Cells were treated for
30 minutes, l, 2, and 4 hrs and collected by centrifugation at 900 RPM for 5
minutes and fe-suspended in RTL buffer containing

f3 mercaptoethanol.

One

ug of RNA was extracted as indicated above (Qiagen Valencia CA) and
eDNA was prepared as indicated above (Invitrogen, Carlsbad, CA). eDNA
was diluted lIla and was used for RT-qPCR. RT-qPCR cycling conditions
were as follows: 95°C for 3min, and 40 cycles of 95°C for lOs, 61°C for
45s, 95°C for lmin and a melt curve analysis was performed by 78 cycles
each increasing by O.5°C from 61 DC. RT-qPCR results were normalized to
B-actin and analyzed using Q-Gene® software (329).

5' RACE

RNA Ligase Mediated Rapid Amplification of cDNA ends (RLMRACE) was used to identify the transcriptional start site of SMSl in the Bcrabl positive K562 cells according to the manufacturer's specified protocol
for Ambion FirstChoice RLM-RACE (Invitrogen, Carlsbad, CA).

In

summary, lug of RNA was purified from K562 cells using the Qiagen
RNAeasy total RNA kit (Qiagen, Valencia, CA) as previously described
(165)

and

phosphatase

was

subsequently

(CIP)

at

37°C

de-phosphorylated
for

lhr,

control

simultaneously but without the addition of CIP.
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with
mRNA

calf intestine
was

treated

For all the following

enzymatic

reactions,

enzymes

were

inactive

by

the

addition

of

phenol/chloroform and RNA was subsequently extracted as suggested by
manufacturer.

Seven microliters of either elP treated versus non-treated

RNA were incubated with tobacco acid pyrophosphatase (TAP), to remove
the mRNA Cap structure, at 37°C for 1 hour.

Seven microliters of CIP

treated mRNA was also added to a reaction without TAP as an additional
control. Both eIP (-) and TAP (-) control reactions were used in all
subsequent RLM-RACE steps using the same amount of uls as for each noncontrol reactions. Six microliters of the dephosphorylated, decapped mRNA
was added to the GeneRacer RNA oligo and incubated with T4 RNA ligase
at 37°C for Ihr. The deeapped, full-length mRNA ligated to the GeneRacer
RNA oligo was used for reverse transcription of mRNA into eDNA using
Superscript III reverse transcriptase and random primers following the
standard protocol (Invitrogen, Carlsbad, CA).

One microliter of this

prepared cDNA was used as a template for an initial outer peR to amplify
cDNA ends. The outer peR was performend using 0.25U of platinum high
fidelity Taq polymerase and all primers were used at O.4uM for a standard
50~L

peR reaction as suggested by the manufacturer (Invitrogen, Carlsbad,

CA). The primers used for the outer peR included the GeneRacer 5' primer
(kit component) and the following gene specific primer (GSP2R), 5'CAA
GAA CGG CCA TGC CAA TGG-3'. The following negative controls were
added: peR reaction without template eDNA, peR reaction without GSP2,
and a peR reaction without the GeneRacer 5' primer.
ensure fidelity of the kit and all its enzymes,

l~L

Additionally to

of HeLa eDNA was used

as template with the GeneRacer 5'primer and control primer B.l provided
with the kit. Two additional peR reactions were used as positive controls
for verification of the presence of the target RNA and for testing RLM122

RACE procedure. These PCR reactions utilized prImers synthesized
upstream to GSP2 and far enough downstream to produce a resolvable peR
product as visualized by agarose gel electrophoresis. The combination of
primers used for these positive control reactions are as follows, GSP/outerlF
(5'-TOC CAA ACA AGT CTC TOe TC-3') with GSPR, or GSP/outerlF
with GSP3R (5'-AAG Tee TOG CCT GTG AAA TG-3').

peR

amplification conditions followed for the outer PCR were as follows: 94°C
for 3min and 35 cycles of 94°C for 30s, 60°C for 30s, 72°C for 30s,
followed by an extension at 72°C for 7min. One microliter of the outer PCR
was used as template for the inner 5' RLM-RACE peR with the following
primers, GSP3R and 5'RACE inner primer provided with kit.

Negative

controls were added as above for inner peR and peR application was
performed using the same peR amplification conditions as above.
Following both outer and inner peR reactions, IOJ-lL of the reactions and all
above mentioned controls were added to a 2% agarose gel containing 100
ug/mL ethidium bromide for visualization of peR products. PCR products
were excised from gel, and purified under standard conditions (Qiagen,
Valencia CA). Four microliters were used for ligation with the pCR-2.1TOPO cloning vector, transformed into DH5a cells according to standard
protocol (Invitrogen, Carlsbad CA) and grown overnight on LB plates
containing 100 ug/ml ampicillin for selection.

Bacterial colonies were

selected and DNA was purified from these colonies according to
manufacturer recommended protocol (Qiagen, Valencia CA).

Two

micrograms of purified DNA were used for sequencing with both M13F and

M13R primers and sequencing results were analyzed with jellyfish software.
The entire 5' RLM RACE protocol was repeated twice.
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Genomatix Analysis

Computational analysis of the SMSl gene (SGMSl) with the
Genomatix Software (www.genomatix.de) predicted a proximal promoter
within intron 6 and 1068 bp upstream from exon 7 which we named
Promoter C. The analyzed sequence included human genomic sequences
from chromosome 10 approximately 18 Kb upstream to SMSl and
overlapping with 31 Kb of SMSl genomic sequence.

Genomic DNA preparation
Genomic DNA was obtained from 15 X 106 exponentially growing
K562 cells. Cells were centrifuged at 3000 RPM for 5 minutes at 4°C and
resuspended in 500 ul of freshly prepared lysis buffer containing 50 mM
EDTA pH 8, 1% SDS, 50 mM Tris pH 7.4, 100 mM NaCl 2 and 750 ug/rnl
Proteinase K (Roche Molecular Biochemical, Indianapolis, Indiana). K562
cell lysate was then incubated for 1 hour at 60°C, vortexed briefly, and then
incubated at 60°C overnight. Following overnight incubation, 200 ul of icecold 5M KOAc was added, the lysate was vortexed for 30s and incubated on
ice for 11/2 hours, centrifuged at 12,000 RPM for 15 minutes and 500 ul of
the supernatant was removed. To precipitate DNA, 1 rnl of ice cold EtOH
was added to the top of supernatant and the mixture was gently rocked a few
times at 90°C.

DNA was spooled from the interface of the supernatant,

washed first with 70% EtOH and then with 100% EtOH. DNA precipitate
was air-dried for 10 minutes and resuspended in 100ul of sterile ddH 20.
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peR amplification of Promoter C

Promoter C was amplified from K562 genomIc DNA by peR
amplification using primers as indicated in Supplementary Table 7, in a
100 ul volume reaction containing approximately 40 ng of DNA and the
following peR conditions: 0.2 mM dNTP, 1.5 mM MgCI 2 , 0.75 uM of
primers, and 2.5U Tag DNA polymerase (Invitrogen Life Technologies,
Carlsbad CA). peR amplification conditions for Promoter C isolation were
as follows: 95°C for 5 min and 35 cycles of 95°C for 50 s, S2°e for 50 s, and
72°C for 2 min, followed by an extension at 72°C for 10 min.

Generation of luciferase reporter plasm ids

Full length promoter C and all deletion constructs were obtained using
the same reverse primer, Promoter CR-5'-AAG Tee TGG CCT GTG AAA
TG-3'

by standard PCR (as above) and TaKaRA LS Taq hot-start DNA

polymerase (Clontech Laboratories, Mountain View, CA) with the forward
primers listed in Supplementary Table 7. Promoter C peR amplicons were
cloned into the pCR 2.1

TOPO~ T A

sub cloning vector and transformed into

DHA5a bacterial cells using standard conditions (Invitrogen, Carlsbad, CA).
The plasmids were extracted from ampicillin resistant bacterial colonies, and
inserts were excised from the peR 2.1 TOPO-T A vector using Kpnl and
ZhoI (Invitrogen Life Technologies, Carlsbad, CA) and cloned into the final
pGL3-basic vector (Promega, Madison, WI, USA).

All sequences were

verified by sequencing (Genewiz, Southplainfield, NJ) with either the
Promoter CR primer and/or the gene specific Promoter CR primer,
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ProCRs-5'

(Supplementary Table 7). Sequence analysis and verification

was carried out using the Jellyfish software.

DNA was prepared for

transfections using the Endofree Plasmid Maxi Kit (Qiagen, Valencia, CA).

Transient transfection and luciferase assay

K562 cells and/or HL-60/Ct cells transfections were performed by
electroporation in a 12 well plate with either Ixl0 6 K562 cells or 2xl06 HL60 cells per well using the Nucleofector 2b solution, according to the
protocol, including electroporation settings, as recommended by the
manufacturer (Amaxa, Allendale, NJ). Cells were electroporated with 2.5ug
of pGL3-basic vector or pGL3-basic/human promoter C constructs and
2.5ug of pCMV -~-galactosidase reporter gene.

Cells were harvested 24

hours after transfection, washed once in ice cold PBS, lysed with IX
reporter lysis buffer (RLB), and luciferase activity was measured using a
Promega kit (Promega, Madison, WI).

For the luciferase activity assay,

either 5ul of K562 cell lysate plus 15ul of IX RLB or 20ul of HL-60 cell
lysate were used. Luciferase activity assay reagent (Promega, Madison, WI)
was mixed briefly with the appropriate amount of cell lysate (as above) and
luciferase activity was measured using a Sirius Luminometer (Bethold
Technologies, GMBh & Co. KG, Germany) programmed with a 2-second
measurement delay followed by a

IO-second measurement read.

13-

Galactosidase activity was used to normalize for cell transfection efficiency
determined by using a colorimetic method as suggested by the manufacturer
(Promega, Madison, WI). Specifically, 20 uls of K562 cell lysate plus 130ul
of RLB or 150ul of HL-60 cell lysate was briefly mixed with 150ul of 2X

13-

galactosidase assay buffer, incubated at 37° C for 1 hour and read at 420 nrn.
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Promoter activity from K562 or HL-60 lysates was calculated after
normalization with the amount of cell lysate used for the luciferase activity
assay, to the B-Galactosidase activity of each sample and by subtraction of
background values (as determined from pGL3 vector only controls). Data
were expressed as average + SO or for experiments measuring promoter
activity and data from deletion constructs the data was expressed as fold
change of luciferase activity to full-length promoter C. All data were from a
minimum of three independent experiments.

Imatinib treatment of K562 cells and luciferase activity

K562 cells were treated with Imatinib mesylate (STI-571) using 0.2,
0.4, 1.0 uM or vehicle (H 2 0) only control for 30 hours in complete medium
and electroporated following the same conditions as above with either 2.5ug
of pCMV -~-galactosidase, 2.5ug of pGL3/promoter C or 2.5ug of pGL3basic vector only control.

K562 cells were treated for 30 hours with STI -

571 according to previously optimized experiments demonstrating no
appreciable effect on cell proliferation (Bums and Luberto, manuscript
accepted with minor revisions).

K562 cells treated with STI-571 were

harvested, lysed and luciferase activity assays along with the p-galactosidase
colorimetric assays were carried out as described above. Data represents a
minimum of 3 independent experiments normalized as above + SD.

RESULTS
Bcr-abl positive cells have increased SMS1 gene expression

In our previous studies, (Bums and Luberto, manuscript accepted with
minor revisions) we have demonstrated increased SMS activity in Bcr-abl
positive, K562 and HL60/Bcr-abl cells compared to Bcr-abl negative, HL60/ct and U937 cells.

In particular, a significant increase of SMSl

expression was observed in Bcr-abl positive (K562 and HL-60/Bcr-abl)
versus negative cells (HL-60/ct and U937) when primers complementary
exon-exon junction of ex on 10/11 to part of exon 11 were used (Figure
17A).

Figure 17A +B. Bcr-abl mediated up-regulation of SMS1
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Figure 17. Bcr-abl mediated up-regulation of SMSI. (A) Schematic representing the
putative exon structure of human SMS1 mRNA. Light gray boxes represent the 5' UTR;
translated SMSl is indicated on the schematic as dark gray boxes; white boxes represent
the 3' UTR region. (B) BCR-ABL positive cells (HL-60IBcr-abl and K562) have an
approximate 35-fold increase of SMS1 expression compared to BCR-ABL negative cells
(HL-60/ct and U937). Expression of SMSl was determined by QRT -peR as indicated in
the "Materials and Methods" section and normalized against fj-actin. Data represents a
minimum of 3 independent experiments + SD. * indicates significance to H-L60/ct (p<
0.05). Where error bars are not visible, the error bars are too small compared to the scale
the y-axis. MNE: Mean of Normalized Expression.

Ber-abi transcriptionally regulates expression of SMSI

In order to further elucidate the mechanism by which Bcr-abl causes
increased SMSl expression, the effects of Bcr-abl expression on SMSI
transcription was determined by measuring the amount of heteronuclear
RNA (hnRNA) by QRT- peR.

Since hnRNA is the very first RNA

transcribed from DNA, its expression is indicative of gene transcription.
Conversely, mRNA expression is indicative of both gene transcription as
well as RNA processing. Total RNA was extracted from K562, HL-60/Bcrabl, HL-60/ct and U937 cells and treated with DNase.

SMSl hnRNA

transcription from both Bcr-abl positive and negative eells was measured by
QRT-PCR using primer pairs designed to target a region between intron 7
and exon 8 (Figure 18A).

As shown in (Figure 18A), SMSl hnRNA

transcription was 35-70-fold higher in Bcr-abl positive, HL-60/Bcr-abl and
K562 compared to Bcr-abl negative HL-60/ct and U937 cells. Importantly,
SMS 1 hnRNA was undetectable from control eDNA.

Control cDNA was

synthesized from total RNA without the addition of reverse transcriptase,
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therefore lack of SMS 1 hnRNA in these samples ensured that all DNase
treated samples were not contaminated with genomic DNA.

Figure 18. Ber-abl transcriptionally regulates expression of SMSI
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Figure 18. Bcr-abl transcriptionally regulates expression of SMSI. (A) BCR-ABL
positive cells (HL-60/Bcr-abl and K562) have increased SMSl hnRNA gene expression
compared to BCR-ABL negative cells (HL-60/ct and U937). Lack of SMSl expression
from hnRNA obtained from cDNAs synthesized without reverse transcriptase
demonstrates lack of genomic contamination. (B) MNE expression of SMSl in Bcr-abl
negative HL-60/ct cells and Bcr-abl positive cells, HL-60/Bcr-abl K562 upon treatment
with 5 ug/ml of actinomycin D for 30 min, Ihr, and 2 hrs. Data points represent the
percent of remaining mRNA at each indicated time point. Expression of SMSl was
determined by QRT -peR as indicated in the "Materials and Methods'" section and
nonnalized against p-actin. These results are representative of two separate experiments.
MNE: Mean of Normalized Expression.
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Increased mRNA stability represents an additional mechanism that
could potentially contribute to enhanced SMSl expression as observed in
Bcr-abl positive versus negative cells (Figure 17B).

To investigate this

potential mechanism, we measured the half life of SMS 1 in Bcr-abl positive
or negative cells. Data were calculated by normalizing all SMSl mRNA
expression levels to f3-actin from K562, HL-60/Bcr-abl and HL-60/ct

(Figure 18B). Each time point was used to calculate linear regression and
data were displayed as percent of remaining mRNA. This analysis indicated
no significant differences in mRNA stability in Bcr-abl positive versus
negative cells.

Bcr-abl promotes SMSI transcription at specific transcription start
sites
To further examine the effect of Bcr-abl on SMSl transcription,
different primer pairs located closer to either the 5' or the 3' ends of SMSl
were designed and QRT-PCR was performed to quantify relative levels of
SMSl hnRNA (Figure 19A) or mRNA (Figure 19D) normalized to

~-actin.

SMSI normalized hnRNA data are shown in Figures 19B and 19C and

SMSl normalized mRNA data are shown in Figures 19E and 19F. These

results revealed that SMSl mRNA is approximately 5-fold higher in Bcr-abl
positive compared to negative cells when measured at exon 5/exon 6

(Figure 19E) and similarly, SMSl gene transcription is approximately 5-fold
higher when measured at intron 5/exon 6 (Figure 19B).
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Figure 19A-F. Bcr-abl promotes SMSI transcription at different
transcription start sites
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Figure 19A-F. Bcr-abl promotes SMSI transcription at different transcription start
sites. (A) Schematic representing the putative genomic organization of SMS1. Black,
solid line numbered with Roman numerals indicate intron regions, white numbered boxes
indicate transcribed/untranslated exons, and black numbered boxes indicate
transcribed/translated exons. Bcr-abl positive, HL-60/Bcr-abl and K562 cells, have an
approximate 5-fold increase of SMSl hnRNA expression as compared to Bcr-abl
negative, HL 60/ct and U937 cells when measured at intron5/exon6 (B) versus a 35-70fold increase of SMSI hnRNA expression when hnRNA is measured at intron7/exon8
(C). (D) Schematic representing the putative mature gene organization of SMSl, colors
representation same as in (A). (E) SMSl mRNA expression is 5-fold higher in Bcr-abl
positive HL 60lBcr-abl and K562 cells versus Bcr-abl negative HL 60/ct and U937 cells
when measured at exon 5/exon6 versus an approximate 35-fold higher SMSI expression
level when measured at exon 10lexon 11 (F). Arrows indicate primer placement; primer
sequence infonnation as in "Methods and Materials" section. Expression of SMSl was
determined by QRT-PCR as indicated in the "Materials and Methods" section,
nonnalized to f3-actin expression and expressed as fold change over HL-60/ct. Figures
(B) and (C) are representative of two separate experiments. Figures (E) and (F) represent
the average of 3 independent experiments + SD. * indicates significance to HL-60/ct (p<
0.05). hnRNA: heteronuclear RNA.

By contrast, QRT-PCR analyzing SMSl expression/transcription
closer to the 3' ends demonstrated that SMSl normalized transcription is
approximately 35 fold higher in Bcr-abl positive compared to negative cells
when measured at intron 7/exon 8 (Figure 19C) and SMSl mRNA is

approximately 40-75-fold higher when measured at exon 10/exon 11

(Figure 19F). Collectively, these results indicate that Bcr-abl mediates
upregulation of both SMSl expression and transcription and that Bcr-abl
preferentially promotes transcription downstream of exon 6 (Figure 20).
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Figure 20. Proposed Bcr-abl-mediated regulation of SMSI
transcription
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Figure 20. Proposed Bcr-abl-mediated regulation of SMSI transcription. SMS1.
Exons are indicated by numbered squares and introns are numbered with Roman
numerals. 5' and 3' UTRs are indicated by light gray colored squares. Data from in silico
analysis and from QRT -peR data (Figure 19) suggest that Bcr-abl regulates transcription
of SMS 1 at both the 5' and 3' end but to the highest extent downstream from exon 6.
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Identification of SMSI transcription start sites in Ber-abl positive
cells
To identify the Bcr-abl dependent 5' end transcription start sites of

SMSl we performed RLM-RACE in Bcr-abl positive, K562 cells, using
reverse primers in exon 7 (GSP-exon 7) or exon 5/6 (GSP-exon 5/6) (Figure
21). RLM-RACE revealed 5 different transcript products identified as SMSI
5' RACE products (Figure 21A). Sequence alignment of the SMSl locus
(ensemble-ENSG0000019864) with transcript products obtained by RLMRACE revealed 4 different TSS named (A, B, C, and D). Importantly, TSS
C and TSS D were both downstream of exon 6 and thus these TSSs were the
once most likely to be utilized in Bcr-abl positive cells. Importantly
bioinformatic analysis of human genomic sequences from chromosome 10
approximately 18 Kb upstream to SMSl and overlapping with 31 Kb of

SMSl genomic sequence predicted the presence of 3 different promoters,
one of 540bp at -480bp from exon 1 (promoter 1), a second one of 228bp
that started within exon 2 (promoter 2) and a third of 1068 bp starting in
intron 6, 735 bp upstream to exon VII and expanding into exon VII
(promoter 3). The predicted promoter 3 being downstream of exon 6 and
upstream of the coding region, matched our prediction based on the TSS
analysis. The transcript upregulated in Bcr-abl cells, as identified by RLMRACE, has its TSS (TSS C) on intron 6, specifically 97 bps upsteam from
exon 7 (Figure 21A). The putative promoter upstream to this TSS was
named Promoter C (Figure 2IB).

Other identified transcripts and their

putative promoters were named Promoter A, Promoter B, and Promoter D
and are shown in (Figure 21A and Table 3).
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Relative abundance of the differellt predicted mature messages of
SMSI in Bcr-abl positive cells

To determine the relative abundance of the different SMSl mRNAs in
Bcr-abl positive versus negative cells, and to confirm that the mRNA
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Figure 21 A +B. Identification of transcription start sites of SMS1
in Bcr-abl positive cells
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Figure 21A+B. Identification of transcription start sites of SMSI in Bcr-abl positive
cells. (A) Schematic of the 5' RLM-RACE products in K562 cells identified by aligning
RACE products with human SMSl (SGMSl) using basic local alignment search tool
(BLAST). As a note, transcripts previously described as introns in other cell lines and
tissues (328,330) are illustrated using large, dashed lines and numbered with Roman
numerals and exons are illustrated with numbered boxes. (B) Schematic of predicted
common hnRNA transcript and putative promoter based on SMSl 5' RLM-RACE
products. TSS: Transcription Start Site. RLM-RACE: RNA ligase Mediated Rapid
Amplification of cDNA ends.
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originated from TSS C is predominant, QRT -peR was performed by
designing primers to detect SMSI mRNA originating from the following
putative TSSs: A, A+B, A+B+C+D, or D. (Figure 22).

All results were

normalized to J3-actin expression. SMSl expression from TSSs A and D
were each calculated each independently. Expression of SMSl mRNA from
TSSs B or C could not be analyzed in isolation due to their locations within
SMSI. Therefore, mRNA from TSS B's contribution to SMSl's overall

expression was determined by comparing mRNA from TSS B to the
combination of A+B. Likewise, mRNA from TSS C's contribution to
SMSI's overall expression was calculated by comparing A+B+C+D to
mRNA from A, A+B, and D. Mature SMSl from TSS C had an approximate
33-fold relative expression compared to HL-60/ct mRNA. In contrast, there
was only an approximate 5-fold increase of SMSI expression from TSS B
and less than I-fold increase of mRNA from TSS D compared to HL-60/ct
mRNA. Message RNA from TSS A was undetectable in HL-60/ct cells and
its mean normalized expression in Bcr-abl positive cells was less than 0.003
on average.
These results confirmed that the mRNA originated from TSSC is the
most abundant in Bcr-abl positive cells.

Identification of core promoter C

Since in Bcr-abl positive cells, the mRNA from TSS C was the most
represented, it is speculated that a putative promoter region upstream of TSS
C (named Promoter C) was activated in these cells as compared to Bcr-abl
negative cells.

The predicted promoter 3 from the Genomatix analysis

matched this predicted promoter C upstream of TSSC. Thus, we cloned the
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Figure 22A +B. Relative abundance of the different mature
messages of SMSI in Bcr-abl positive cells
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Figure 22. Relative abundance of the different mature messages of SMSI in Bcr-abl
positive cells (A) SMSl expression was measured by QRT -PCR as described in the
"Materials and Methods" section from both Bcr-abl positive, HL 60lBcr-abl and K562
cells and Bcr-abl negative, HL 60/ct cells. Specifically, SMSl gene expression from each
TSS was measured by designing primers based on the identified RLM-RACE
transcription product (for specific primer sequence information see "Materials and
Methods"). To analyze the contribution of each putative promoter to overall SMSl gene
expression in Bcr-abl positive cells, SMSl gene expression from Bcr-abl positive cells
was compared to their negative counterparts from all putative promoters (A+B+C+D)
versus SMSl gene expression originating from either putative promoters A, D, or from
the combination of A+B thus revealing that the mass majority of SMSl gene expression
in Bcr-abl positive cells results from putative Promoter C. (B) Genomic organization of
SMS1. See legend box for full description of schematic. TSSs identified by RLM-RACE
are indicated on the schematic using both arrows and corresponding letters. Data
represent the mean of a minimum of 3 independent experiments + SD normalized to ~
actin expression. TSS: Transcription Start Site; int: Intron; ex: exon; RLM-RACE: RNA
Ligase Mediated Rapid Amplification of cDNA ends.
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Genomatix predicted core promoter of 1068 bp starting on intron 6
and overlapping exon 7. This core promoter was cloned in the pGL3-basic
luciferase reporter vector (pGL3-ProC). In all luciferase experiments, the
resulting PGL3-basic luciferase construct was co-transfected with the
pCMV -p-galactosidase plasmid and for each set of experiments, empty
pGL3-vector was transfected separately. Results were normalized to

p-

galactosidase activity to account for differences in transfection efficiency
and the pGL3-vector only control was used to normalize for any background
luciferase activity signal. The plasmid pGL3-ProC was transfected into Bcrabl negative, HL-60/ct cells and Bcr-abl positive, HL-60/Bcr-abl and K562
cells.

Results from this experiment are shown in Figure 23A.

Bcr-abl

positive HL-60/Bcr-abl and K562 cells have an approximate 40 fold increase
of luciferase activity compared to Bcr-abl negative, HL-60/ct cells.
To ensure that increased luciferase activity from pGL3-Pro C
transfections were mediated by Bcr-abl, K562 cells were treated with the
Bcr-abl inhibitor, Imatinib (also STI-571) (Figure 23B). Specifically, K562
cells were transfected with pGL3/Pro C and with 0.2, 0.4, or 1.0 uM of STI571

or vehicle

control.

Luciferase

activity

was

decreased in

all

concentrations approximately 2-fold supporting the dependence of Promoter
C activity on Bcr-abl.
In order to locate the core promoter sequence of promoter C, 6
progressive 5 deletion constructs were generated (Figure 23C).
f

The

original Promoter C cloned into the pGL3-basic vector is termed "Promoter
C-full-length". The remaining deletion constructs were numbered according
to their location in regards to the TSS C identified by RLM-RACE. These
constructs were transfected into HL-60 and K562 cells as described in
"Materials and Methods." Relative luciferase activity of deletion constructs
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Figure 23A-C. Identification of the core Promoter C
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Figure 23. Identification of the core Promoter C. Luciferase activity from celllysates
measured after electroporation with 2.5ug of Promoter C cloned with the pGL3-basic
luciferase reporter vector (pGL3-Promoter C) and 2.5ug of pCMV -B-galactosidase
reporter vector measured from Bcr-abl negative cells, HL-60 and Bcr-abl positive cells,
HL-60IBcr-abl and K562 cells collected 24 hours after electroporation (A), from K562
cells treated with 0.2, 0.4, or 1.0 uM of STI-571 for 30 hours of treatment (B), and from
K562 or HL-60/ct cells lysed 24 hours after electroporation with either full-length or 5'
progressive deletions of full length pGL3-Promoter C (C). Numbers associated with
each deletion construct refers to the distance of the first 5' base pair of the deletion
fragment to the Transcription Start Site (TSS). Data in (C) are expressed as fold-change
compared to full-length pGL3-Promoter C.
Data represents luciferase activity
normalized to pCMV -B-galactosidase activity and pGL3-vector only control. All
experiments represent the mean ± SD of at least 3 independent experiments. STI -571:
Imatinib mesylate. RLU: Relative Light Units. B-gal: B-galactosidase.
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in both cell lines were compared to that of pGL3/ProC and expressed as fold
change over Promoter C. As seen in Figure 23C, transfections in Bcr-abl
positive K562 cells with the deletion construct -110 resulted in a near
complete abolishment of luciferase activity, while the -113 deletion
construct maintained luciferase activity.

These results indicate that the

fragment between -113 and -110 contains cis-elements that are essential to
drive high-level transcription of the SMS 1 gene. These experiments were the
result of a minimum of 3 independent experiments performed on different
days. Smaller deviations could be obtained by doing all the deletions on the
same day in triplicate since the effect of transfection with each deletion
construct varies to some degree from day-ta-day, possibly from differences
in growth state, health and transfection efficiency of cells. But experiments
were chosen based on independent experiments even though larger standard
deviations are obtained. In contrast, transfection in HL-60 cells (Bcr-abl
negative), with the -110 deletion constructs resulted in no appreciable
change of luciferase activity_ In fact, there was no loss of luciferase activity
after transfection in HL-60 cells with any of the Promoter C deletion
constructs.
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DISCUSSION
This study investigated the mechanism responsible for the effect of
Bcr-abl on SMSI transcription. We provide evidence of a unique Bcr-abl
dependent mechanism of SMSl transcriptional regulation via the use of an
alternative transcriptional start site within SMSI. Multiple transcription start
sites and their putative promoters within SMSl are identified. This includes
TSS C and Promoter C., both most likely regulated specifically through BcrabI.

Finally, the region of Promoter C, regulated by Bcr-abl., has been

identified. This region is predicted to contain the cis-elements necessary for
Ber-abl regulation.
Previously, we have demonstrated that Bcr-abl induces increased
SMSl expression (Burns and Luberto., manuscript accepted with minor
revisions) but the mechanism of the increased expression has as yet, been
undescribed. Therefore in order to analyze SMSl transcription we measured
hnRNA by QRT -peR. To analyze hnRNA, primers were designed to have
at least one primer, either forward or reverse, inside introns. By this method,
primers would preferentially amplify precursor transcripts, and not mature
mRNA or excised introns. Precursor transcript levels reflect transcription.
This is a more accurate method to analyze gene transcription then by
measuring mRNA transcript levels, since precursor transcripts are more
rapidly and consistently processed by pre-mRNA splicing. Changes in
precursor transcript levels are reflective of changes in transcription rather
than changes in RNA stability (331-334). In opposition, measuring mRNA
overall gene expression is an indicator of gene expression after post143

transcriptional processIng.

U sing this approach, evidence is provided

showing a 35-70 fold increase of normalized SMSl hnRNA transcription in
the presence of Bcr-abl.

This data therefore suggest that elevated SMSl

expression seen in Bcr-abl positive cells as compared to their negative
counterparts is due to increased SMSl transcription.
An additional mechanism that could contribute to elevated SMSl
expression is increased mRNA stability.

The 3' end of SMSl has been

analysed by Vladychenskaya, et a1. in 2004 (330). This study investigated
SMS1's 3' UTR by in silico analysis and concluded that SMSl had 3' UTRs

approximately lh as long as the estimated average 1027 nucleotides found in
humans (330,335). In addition, SMS1's 3' UTR is comprised 0[70% polyA and poly-T tracts versus the general composition of UTRs with an average
of 55% (330,335). Furthermore, SMSl has six ATTTA motifs found within
the 3'-UTR. These motifs possibly correspond to the functional domains of
adenylate/uridylate-rich elements (AREs).

Importantly, ARE motifs are

known determinants of mRNA instability_ These motifs are normally found
within a number of labile, short-lived mRNAs which encode for regulatory
proteins, such as growth factors and their receptors, proto-oncoprotein's,
inflammatory mediators and cytokines (336,337). Considering the increased
SMSl gene expression observed in Bcr-abl positive compared to negative

cells and in light of SMS]'s complex 3' UTR, mRNA stability/instability as a
post-transcriptional mechanism was explored. These studies were based on
the use of actinomycin D, a strong inhibitor of transcription and they
revealed no difference in mRNA stability in Bcr-abl positive compared to
negative cells.

Overall, transcriptional analysis combined with mRNA

stability studies strongly suggests that increased SMSl expression in Bc-abl
positive cells is due to increased SMSl transcription.
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In the process of determining the effect of Bcr-abl on SMSl
transcription, different primer pairs closer to either the 5' or the 3' ends were
used for QRT-PCR analysis.

Interestingly, using primers probing either

hnRNA or mRNA downstream to exon 6, we found a much larger fold
increase of either SMSl expression or transcription (Figures 19C and F)
than when probing SMSl upstream to intron 6 (Figures 19B and E). These
results suggested to us that perhaps Bcr-abl was promoting SMSl
transcription at least at two different TSSs and that the TSS proximal to exon
7 was stronger (Figure 20).

This hypothesis was in agreement with

promoter analysis of the SMSl locus performed using the Genomatix
software.

Genomatix analysis revealed the presence of 3 predicted

promoters, two at the 5' end of SMSl and one overlapping intron 6 and exon
7. Therefore according to the prediction that SMSI may have multiple TSSs,
we concluded that it was essential to identify the correct TSSs and
appropriate promoter in order to further analyze Bcr-abl regulation on SMS1
expressIon.
Identifying the correct TSS is essential in order to ensure that the
region under investigation is appropriate. To this aim, we used RLM-RACE
to first identify the Bcr-abl dependent TSS of SMS1.

This method is

advantageous to other types of methods seeking to identify the TSS of genes
because RLM-RACE is designed to only detect transcripts containing a 7methylguanylate cap structure at the S' end. Since the structure is only found
in authentic Sf ends of RNA polymerase II, artificial 5' end resulting from
RNA degradation or reverse transcriptase pausing are not detected
(338,339). In addition, degraded mRNAs are not detected as a result of the
initial phosphatase treatment of the RNA sample. Controls were added to
the RLM-RACE procedure without the addition of phosphatase to ensure
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that phosphatase treatment on RLM-RACE products was successful,
therefore confirming that degraded mRNAs were not analyzed.

This

technique was specifically selected instead of other methods used to detect
TSS such as primer extension, RNase protection and S 1 nuclease since the
structure of SMSl is known to be complex. This complexity is demonstrated
by a previous study analyzing SMSl transcripts from cerebellum. This study
predicted two TSS by primer extension, one at 700bps and another at 350bp
upstream from the employed primer located within exon 6

(330).

Unfortunately, primer extension analysis cannot easily reveal actual
sequence information on complex genes with multiple TSS, but instead since
the size of the eDNA corresponds to the distance from the 5' end of the
primer, predictions of the TSS can be made from calculating distance of base
pairs from the reverse primer. Likewise, RNase protection and Sl nuclease
methods reveal the size of a probe fragment resistant to cleavage by RNase
or S 1. This size corresponds to the distance from the 5' end of the labeled
probe to the 5' end of mRNA, if the probe hybridizes to the sequence within
the first exon. Yet, if the probe hybridizes to sequences within the second
exon or intron for example, resistant products will not correspond to the
desired distance (340).

These complications are eliminated by choosing

RLM-RACE for the reasons mentioned above and because products of
RLM-RACE can be sequenced and compared to genomic information
available on public websites, such as NCBI and EnsembL
This technique revealed four different TSSs. Importantly, a TSS was
identified within exon 7 upstream to the ATG (TSS C). The position of TSS
C is also in agreement with the QRT -peR data on SMSl gene transcription
and expression that predicted an alternative TSS driven by Bcr-abl,
downstream of exon 6 and proximal to exon 7 (Figure 19), as well as the
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Genomatix predicted putative promoter starting in introD 6 and spannIng
exon 7. Since more than one TSSs was identified in Bcr-abl positive cells,
the relative abundance of the different mature messages of SMSl was
determined by QRT -peR. This analysis revealed quantitative information
of each of the identified putative transcripts and suggested that Bcr-abl is
preferentially regulating TSS C and its corresponding Promoter C as
compared to all other identified transcripts and putative promoters (Figures

22A and B).
The proper identity of TSS C and its putative promoter C was
confirmed by luciferase reporter analysis in Bcr-abl positive cells as well as
by the changes of hnRNA and mRNA (Figures 22 and 23A).

Transient

transfectians in Bcr-abl positive compared to negative cells revealed a
similar pattern of promoter C transcriptional activity (40-fold increase in
Bcr-abl positive cells) (Figure 23A).
Experiments were also conducted to identify the region of promoter C
containing the minimal base pairs needed for Bcr-abl dependent SMSl
transcription. When base pairs were deleted between -113 and -110 from
TSS C, promoter C driven luciferase activity was reduced to mere
background (Figure 23C).

These results suggest that the important cis-

elements in Promoter C are likely to exist between -110 and -113. Other
deletions showed somewhat reduced luciferase activity (i.e. -119 and -113,

Figure 23C) but the differences between these deletions and the full length
Promoter C activity are minimal when standard deviations are considered.
Importantly, the dependence of SMSl transcription from Bcr-abl was
validated by both experiments demonstrating the lack of any significant
difference in luciferase activity with any of the deletion constructs in the
Bcr-abl negative HL-60 cells (Figure 23C) and by the inhibitory effect of
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Imatinib on the transcription activity of Promoter C in Bcr-abl positive cells

(Figure 23B).
For the first time, these results provide evidence that a known
oncogene, Bc-abl regulates SMSl transcription through a unique mechanism.
Specifically, Bcr-abl is capable of directing SMSI transcription via the use
of TSS C within exon 7 of SMS1.

Future studies will be conducted to

unequivocally identify the potential trans-acting factors within Promoter C
that mediate this Bcr-abl-dependent mechanism.

These studies will

definitively connect this unique mechanism of Bcr-abl regulation to
sphingolipid metabolism,

a

connection to

this

author's

knowledge,

previously unknown. In addition to the identification of the trans-acting
factor, future studies should address the potential benefit in having a much
shorter SMSl transcript in Bcr-abl cells when transcription starts within exon
7 (instead of introD I or II). One possible benefit for Bcr-abl cells in utilizing
Promoter C could be that the resulting mRNA might be more efficiently
post-transcriptionally regulated, perhaps leading to a faster translation.
Interestingly, translational regulation of SMSl has been predicted (330) and
Bcr-abl has been linked to aberrant translation. In particular, Bcr-abl
expression is involved in altered expression of RNA binding proteins (such
as La and hnRNP K) which in tum ultimately enhance translation of proproliferative and pro-survival proteins [for a review (303)].
In summary, this paper has shown for the first time a unique
mechanism utilized by Bcr-abl in regulating SMSl transcription.

This

mechanism is unique to Bcr-abl positive cells, and results from this paper
constitute evidence of a Bcr-abl-regulated mechanism that alters the TSS
and promoter activity of SMS1.
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APPENDIX B: Identification of the transcription
responsible for Bcr-abl-mediated upregulation of
transcription.

(actor
SMSl

The following results are included as part of Specific Aim 2, but
currently they are not included in the manuscript "Transcriptional regulation
of SMSl by the Ber-abl oncogene", because they are very preliminary and
they require further validation.

Materials and methods

Materials
RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and
Trypan Blue dye solution were from Gibeo/Invitrogen Corp., (Carlsbad,
CA).

Cell culture
K562 cells were originally purchased from the American Type
Culture Collection (Rockville, MD). All cell lines were grown in RPMI1640 supplemented with 10% FBS, 100 D/ml penicillin and 100 Jlg/ml
streptomycin, and were maintained at 37°C at 5% CO 2 •

Downregulation of STATS
The siRNA used to knockdown human STAT5 was from a pool of 3
target-specific 20-25 nucleotides (Santa Cruz Biotechnologies, Santa Cruz,
CA).

The Allstar Negative Control was used in experiments as baseline.

K562 cells were transfected with siRNA by electroporation using the Amaxa
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Nucleofector device (Amaxa) according to the manufacturer's instructions.
The protocol was optimized regarding the concentration of STAT5 siRNA,
transfection and post-transfection conditions in preliminary dose-response
experiments (1-10 J.lg STAT5 siRNA). Consequently, the following optimal
conditions were employed. Cells (lxl06 K562 cells) were transfected with

2.2

~gof

siRNA. After 30 minutes of incubation at 37°C, 5% CO 2 in 500 J.lI

of complete growth medium, cells were seeded at O.5xl06 cells/ml in 2 mls
of complete media.

Twenty-four hours after transfection, cells were

harvested for mRNA extraction. Successful downregulation of STAT5 was
confirmed by peR analysis (data not shown) using standard peR conditions
with primers provided with the siRNA kit (Santa Cruz, CA) as suggested by
the manufacturer (Invitrogen, CA).

Downregulation of YYl

For the knockdown of endogenous YY1, Mission shRNA
pLKO.l-puro shRNA vector plasmid was used targeting endogenous YYl
sequence-5'-CCG GCe TeC TGA TTA TTC AGA ATA TCT CGA GAT
ATT CTG AAT AAT CAG GAG OTT TTT-3'(341) (Sigma-Aldrich, MO).
YYl shRNA was provided as a bacterial stab, bacterial cells were grown on

an LB plate containing 100 ug/ml of carbenicillin for selection. One isolated
clone was selected from the LB plate and grown in Terrific broth (SigmaAldrich, MO) with 100 ug/ml of carbenicillin (Sigma-aldrich, MO)
overnight. Overnight cultures (1700 mls) were used for DNA extraction of

YYJ-shRNA plasmids using the GenElute HP Endotoxin-Free Maxiprep Kit
(Sigma-Aldrich, MO). ShRNAVector backbone pLKO.l was used as a
negative control for knock-down validation (342). Transfections with YYJ150

shRNA were optimized regarding the concentration of YYJ-shRNA plasmid,
transfection and post-transfection conditions in preliminary dose-response
experiments (1-15 Jlg YYJ-shRNA plasmid). Consequently, the following
optimal conditions were employed.

Cells

(lxl06 K562 cells) were

transfected with 15 J..lg of YYJ-shRNA plasmid. After 30 minutes of
incubation at 37°C, 5% CO 2 in 500 J.lI of complete growth medium, cells
were seeded at O.5x10 6 cells/ml in 2 mls of complete media.

Cells were

collected at 24, 48, 72 and 96 hours and processed for RNA extraction, see
below.

RNA isolation and reverse transcription for real time peR
To analyze the expression of SMSl in K562 cells after STAT5 siRNA
and YYJ-shRNA transfection, total RNA was first isolated from 1x106 cells
using the RNeasy Mini Kit according to manufacturer's protocol, including
optional DNase digestion (Qiagen, Gmbh, Hilden, Germany). Further DNase
digestion was performed using the Turbo DNA free kit according to
manufacturer's protocol (Applied Biosystems).
synthesis was prepared from 1
according

to

the

~g

The first strand eDNA

of RNA using Superscript III (Invitrogen)

manufacturer's

recommendations.

Real-time

peR

amplification was carried out as described by Villani et al. (165) using the
following primers targeting SMSI hnRNA at intron 7F, 5'-ATT GAG TeA
TTG AAA AAT TAC AG-3' and exon 8R, 5'-GCC AAC TAT GCA GAA
AAA TC-3'.

Nuclear Extraction
6

For nuclear extraction, 4xl0 K562, HL-60/Bcr-abl and HL-60/ct cells
were harvested during the log phase of growth.

Cells were centrifuged at

3000rpm at 4°C for 5 minutes and after the medium was removed, cell
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pellets were subsequently washed with ice cold PBS, and centrifuged as
above. Pellets were re-suspended in 400ul of

ice~cold

lysis buffer [10 mM

HEPES, pH 7.9, 10 mM KC1, 100 mM EGTA, 100 mM EDTA, ImM
dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF)], and
incubated 10 minutes on ice. Just before centrifugation, 5ul of 10% Nonidet
40 was added, the cell suspension was pipetted gently 4-5 times, and nuclei
were pelleted by centrifugation for 10 minutes at 1300 g at 4 cC.
Supernatants were removed, and nuclei were resuspended in 40ul of ice-cold
extraction buffer [20 mM HEPES pH 7.9, 400 rnM NaCI, 25% (v/v)
glycerol, 1 mM EDTA, 1mM EGTA, ImM DTT, 0.5 mM PMSF].

The

suspension was rotated gently for 30 minutes at 4°C and centrifuged at
18,000 g for 15 minutes at 4°C.
stored at -80 c C.

The supernatants were flash-frozen and

Protein concentration was determined using the Bio-fad

protein assay (Biorad, Hercules, CA).

Electrophoretic Mobility Shift Assay (EMSA)

Assays were performed as previously described (343) with
minor modifications. Assays were performed in a final volume of 20ul using
18ug of protein nuclear extracts and incubated in HDKE buffer [20 mm
Hepes, pH 7.9,50 mm KCI, 5% (v/v) glycerol, 1 mm EDTA, 5 mm DTT]
containing 1flg poly( dI -de), 1

~g

poly( dN 6), and 10 f-lg of bovine serum

albumin. One JlI of radiolabeled oligonucleotide probe (60,000-100,000
cpm) was added to each reaction and incubated at room temperature for 20
min before the addition of the loading buffer.
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Oligonucleotides

The following oligonucleotide was used corresponding to
sequences within Promoter C spanning -133 to -96 as numbered from the
identified TSS C: 5'-AAG TAC AGe ATe TTG ATA TTT TCT CTT GeT
TTC ACA G-3'. This oligonucleotide was end-labeled using polynucleotide

T4

kinase

(Promega,

Wi)

and

[y- 32 p ]ATP (American Radiolabeled

Chemicals, MO) and purified on a microspin G25 column (Amersham, PA).

Evi-l
The oligonucleotide containing the core Promoter C (initially
identified between -133 and -97 nucleotides) was predicted to carry a
putative consensus sequence for Evi -1. Thus, in order to determine if Evi-l
is responsible for activation of Promoter C in Bcr-abl positive cells, we
produced an Evi-I mutated Promoter C and tested it for luciferase reporter
activity in K562 cells. With the support of the Genomatix software,
nucleotides substitutions were made to mutate the Evi-l consensus sequence
(Promoter C/Evi -1-M) without generating or deleting any other potential
transcription factor binding site. Therefore, the following oligonucleotides
were generated for site directed mutagenesis, EVIIF, 5'-TAA TTT GGA
AGT ACA GCA TCT TGA Tee TTT eTC TTG CTT TCA CAG AAG

GAA G-3', and EVIIR-, 5'-CTT CCT TCT GTG AAA GCA AGA GAA
AGO ATC AAG ATG CTG TAC TTC CAA ATT A-3'.

Site directed

mutagenesis was performed using the above primers according to the
standard protocol, as suggested by the manufacturer (Stratagene, TX) and
using the full length Promoter C cloned in the PGL3-basic vector as a
template.

All

sequences

were

verified by
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sequencing

(Genewiz,

Southplainfield, NJ) with either the Promoter CR primer and/or the gene
specific Promoter CR primer, ProCRs-5' (Supplementary Table 7).
Sequence analysis and verification of Evi-l mutation was carried out using
the Jellyfish software. Plasmid DNA was prepared for transfections using
the Endofree Plasmid Maxi Kit (Qiagen, Valencia, CA).

Transfection of

Promoter C and Promoter C/Evi-l-M and luciferase activity were performed
as described in the "Materials and Methods" section of Chapter 2.
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Results

Identification of the trans-acting factor regulated by Bcr-abl

Based upon initial results with the luciferase reporter system
obtained by deleting portions of Promoter C cloned into the PGL3 -basic
vector as described in Chapter 2 (Figure 23C), the region between -110 and
-127 from TSS C was predicted to contain the necessary cis-elements needed
for Bcr-abl mediated upregulation of SMS1.
Thus to confirm the existence of a DNA binding factor present in Bcrabl positive cells and absent in Bcr-abl negative cells, we performed binding
assays with nuclear extracts using an oligonucleotide corresponding to the
putative core Promoter C (-110/-127) and spanning few extra nucleotides on
each side (-133/-97). The radiolabeled oligonucleotide probe was incubated
with Bcr-abl positive K562 and HL-60IBcr-abl and Bcr-abl negative HL60/ct nuclear cell extracts (Figure 24). This analysis revealed 3 separate
bands unique to Bcr-abl positive cells, providing an indication of the
existence of different binding factors.
Computational analysis of the core Promoter C using MatInspector
(Genomatix) and TRANSFAC were used to identify matches in DNA
consensus sequences within the -110 and -127 region. Based on this
analysis, 5 candidate transcription factors were identified (Supplementary
Table 9). Importantly, interferon regulatory factor 4 (IRF4) is not expressed
in K562 cells so it can be excluded from further analysis (344,345).
To investigate the potential involvement of YYl in the regulation of

SMSl transcription, YYl was transiently downregulated by shRNA and its
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Figure 24. Binding ofpotential transacting factors to Promoter C

HL-601
Ct

K562

HL-601
Bcr-abl

Figure 24. Binding of potential transacting factors to Promoter C. Electromobility
shift assay of oligonucleotide within Promoter C spanning -133 to -97 as numbered from
the identified TSS C. Equal amounts of nuclear proteins from 6xl06 of HL-60/ct, K562
and HL-60IBcr-abl cells were incubated and prelabeled with the Promoter C
oligonucleotide, and binding was studied using a 5% nondenaturing polyacrylamide gel
as described in the "Materials and Methods" section. Arrows indicate bands unique to
Bcr-abl positive, K562 and HL-60 cells as compared to Bcr-abl negative, HL-60/ct cells.

effect on SMSl hnRNA levels were determined. Cells were harvested 48 and
72 hours post transfection. As shown in Figure 25, significant downregulation of YYl was achieved starting at 24 hours post transfection (Figure
25A) but no significant differences in SMSl transcription was observed at
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any time point (Supplementary Figure 25B). Similar results were obtained
when SMSI transcription was measured after 96 hours of YYl downregulation (data not shown), suggesting that YYl is not involved in the
regulation of SMSl transcription.

Figure 25. YYl down-regulation does not impair SMSI transcription
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Figure 25. YYl down-regulation does not impair SMSI transcription. ShRNA
mediated downregulation of YYl in K562 cells resulted in an ,. . 7-8-fold decrease of YYl
expression at 48 and 72 hours post-transfections (A) yet it did not result in decreased
SMSl transcription (B). QRT-PCR was performed using YYl primers and SMSI
primers targeting intron 7/exon 8 as indicated in the "Materials and Methods" section and
normalized against B-actin.
Abbreviations: AS-Allstar negative scrambled siRNA
(Qiagen, CA).
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To determine if Evi-l is responsible for activation of Promoter C in
Bcr-abl positive cells, we produced a Promoter C with mutated Evi-l
consensus sequence and tested it for luciferase reporter activity in K562 cells
as compared to wild type Promoter C (Supplementary Figure 10). These
results demonstrated no significant difference between transcriptional
activity comparing PGL3-Promoter C and PGL3-Promoter ClEvi-1 thus
suggesting that Evi -1 is not involved in regulating SMS 1 transcription.
Moreover negative results were also obtained when antibodies against Evi-1
were used to cause a supershift of one or more bands evidenced by EMSA
but no supershift could be observed (data not shown).

Figure 26. Transfection of Promoter C harboring the mutated Evil-consensus sequence does not result in decreased SMSI
transcription
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Figure 26. Transfection of Promoter C harboring the mutated Evi-l-consensus
sequence does not result in decreased SMSI transcription. Luciferase activity from
K562 cell lysates measured after transfection with either 2.5ug of Promoter C or
Promoter C with a mutated Evi-l binding site and 2.5ug of pCMV-~-galactosidase
reporter vector. Cells were collected 24 hours after electroporation. Data represents
luciferase activity normalized to pCMV -f3-galactosidase activity and pGL3-vector only
control. RLU: Relative Light Units. B-gal: ~-galactosidase.

Finally, the involvement of STAT5 in the regulation of SMSl
transcription was considered. STAT5 was transiently downregulated in K562
cells with siRNA and cells were harvested 168 hours post transfection
(Figure 27). QRT-PCR analysis for SMSI transcription was performed as
described in the "Materials and Methods" section. Indeed, an approximate
4-5 fold reduction of SMSl transcription upon STAT5 down-regulation was
observed, thus suggesting that this transcription factor might be in part
involved in Bcr-abl-mediated regulation of SMSl transcription.
Importantly an indirect confirmation of the possible involvement of
STAT5 and exclusion of the other transcription factors for the regulation of

SMSl comes from results obtained with the final deletion constructs of
Promoter C: -119 and -113 (Figure 23). In fact deleting nucleotides of
Promoter C

up to -113

does

not significantly affect Promoter C

transcriptional activity. Given the fact that STAT5 consensus sequence sits
at nucleotides -108/-90 f Promoter C, makes STAT5 the most likely
candidate.
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Figure 27. STATS inhibition may inhibit SMSI transcription
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Figure 27. STAT5 inhibition may inhibit SMSI transcription. STAT5 inhibition in
K562 cells resulted in an approximate 4-fold decrease of SMSI transcription. SMSl
transcription was determined by QRT-PCR 168 hours post siRNA transfection. QT-PCR
was perfonned as indicated in the "Materials and Methods" section and normalized
against B-actin. Abbreviations: AS-Allstar negative scrambled siRNA (Qiagen, CA).
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Figure 28A +B. Roles of different SLs and SL metabolizing enzymes
in CML cells
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Figure 25. Roles of different SLs and SL metabolizing enzymes in CML cells. A.
Bcr-abl increases the expression of SKI and SMSI causing an increase of the proproliferative lipids SIP and DAG and the decrease of ceramide levels. The particular SL
profile contributes to the proliferative advantage and pro-survival characteristics of CML
cells. B. Pharmacological inhibition of Bcr-abl by Imatinib activates CerS 1 and inhibits
SKI and SMSI with consequent accumulation of C l8 _ceramide levels and decrease of
DAG and SIP levels. This particular profile contributes to the cytotoxic effect of this
drug in CML cells (See text for details).
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Supplementary Tables
Supplementary Table 6

Supplementary Table 6. Primer sets sequences used for QRT-PCR analysis and their
respecti ve annealing temperatures.

Anneal

Primer set
Intron 5/exon 6

Primer
Intron5F

Sequence
5' -TGACTGGACTITTCTATGTCTTGTG -3'

Intron 5/exon 6

Exon6R

5' -GeT ACCAGCTTCTCCCATTG·3'

58

Intron7/exon 8

Intron7F

5'-ATTGAGTCATTGAAAAATIACAG-3'

58

Intron7/exon 8

Exon8R

5' -GCCAACT ATGCAGAAAAATC-3'

58

Exon7F/R

Exon7F

5' ·GCCAGGACTTGATCAACCTAACC-3'

58

Exon 7F/R

Exon 7R

5'CAAGAACGGCCATGCCAATGG-3'

58

Exon 5/exon 6

Exon 5F

5'·AAGACGAGAACCTGCCTCAGC -3'

58

Exon 5/exon 6

Exon 5/6R

5' ~GCTGTTGCAGGTGATGGAACT -3'

58
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58

Supplementary Table 6-continued

Exon 10/exon 11

exon 10/11 F

5' -GCCAATCAGCAAGTGCTAAAG-3'

58

Exon 10/exon 11

exon 11 R

5' -AGG CCAATGGTAAGATCGAG-3

58

Promoter A

ProAF

5' -GTGCCCTAGTCCAGCT AACG-3'

62

Promoter A

ProAR

5' -AGGATTCTTCCTTCTTTCAAA TG-3'

62

Promoter B

Exon5F

5' -GCTGTTG CAG GTGATGGAACT -3'

58

Promoter B

Exon 5/6R

5'-GCTGTTGCAGGTGATGGAACT-3'

58

Promoter C

Exon7F

5'-GCCAGGACTTGATCAACCTAA CC-3'

58

Promoter C

Exon 7R

5'CAAGAACGGCCATGCCAATGG-3'

58

Promoter 0

ProOF

5' -CGAGAGACCAAGGAAGAATCC-3'

64

Promoter 0

PraDR

5'-CTCTCTCTTGGCAGGTCAGC-3'

64

Promoter C Luc.

PraCLF

5'-TCTGTGAGTTGCTGT ATGTTA-3'

52

Promoter C Luc

ProCLR

5'-AAGTCCTGGCCTGTGAAA TG-3'

52
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Supplementary Table 7
Supplementary Table 7. Deletion constructs cloned into the PGL3-basic vector. All
constructs were amplified using the reverse primer ProeR indicated in the table below
using standard peR conditions as described in the "Materials and Methods" section.
Constructs are named according to their position relative to TSS C.

Promoter C Construct

Primer sequence

Promoter C full length

5' -TCTGTGAGTTGCTGT ATGTTATG -3'

-158

5' -TGCGTTTTGAGAGGGGT AAT -3'

-127

5' -AGCATCTTGAT ATTTTCTCTTGCTTTC-3 '

-119

5' -GAT ATTTTCTCTTGCTTTCACAGAA-3'

-113

5' -TTCTCTTGCTTTCACAGAAGG-3'

-110

5' -TCTTG CTTTCACAGAAGGAAGAATC-3'

-87

5'TCCTGCTCAAAAATGAGGTG'

ProCRs

5' -AAGTCCTGGCCTGTGAAATG-3'
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Supplementary Table 8
Supplementary table 8. Identification of the 5'RLM RACE products by alignment of
RACE products with human SMSl (SGMSl) using BLAST software. Closest proximal
downstream exons are identified with the # of bps from the nearest proximal downstream
exon.

SMS1 5' RLM-RACE
products

Putative
Promoter

Proximal downstream
exon

# of bps from
proximal
downstream exon

Int 1/exon 2/exon 7

Promoter A

exon 1

-1429

Int 2/ex 3/ex 4/ex 5/ ex 6

Promoter B

exon 6

-35477

Int 2/exon 7

Promoter B

exon7

-211065

Exon 7

Promoter C

exon 7

-97

Int 6/exon 7

Promoter 0

exon 7

-73741
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Supplementary Table 9

Supplementary table 9. Predicted transcription factors and the site of their binding to
Promoter C as obtained from Matlnspector and TRANSFAC.

Predicted Transcription Factor

Predicted Binding site

STAT5

-108/-90

EVIl

-122/-106

DEF

-120/-113

YY1

-116/-112

IRF4

-120/-100
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Chapter 3. Concluding discussion

DISCUSSION
Summary

This dissertation was designed to explore Bcr-abl's role as a potential
regulator of SMS. In a foundational study, we screened cell lines from a
variety of leukemia and lymphoma and tested the activity of SMS. This
study revealed that K562 cells, derived from the pleural effusion of a patient
with CML in blast crisis, had increased SMS activity compared to all other
cell lines tested (Figure 6). In particular, expression of the SMSI gene was
enhanced and inhibition of SMS1 impaired cell proliferation of Bcr-abl
positive cells. Thus, our overall hypothesis was that enhanced transcription
of SMSl contributes to the undifferentiated, pro-proliferative phenotype of
Bcr-abl positive cells.
Initial characterization of SMS described SMS as an important
housekeeping enzyme for the synthesis of SM, an abundant phospholipid
with an important structural role for the integrity of the plasma membrane.
Its enzymatic activity was described as a transferase, in that it transfers the
phosphorylcholine moiety from PC onto ceramide, therefore creating SM
and DAG (307-313). But in addition to SMS's role in the synthesis ofSM,
SMS modulates the bioactive lipids, ceramide and DAG (Figure 1). These
lipids have opposing functions on cellular processes: ceramide is known to
regulate processes such as senescence and cell death while DAG regulates
processes such as proliferation and transformation (8,307-313).

The

hypothesized role of Bcr-abl in mediating SMS upregulation was therefore
based upon SMS' ability to modulate ceramide and DAG, as well as the
observation that Bcr-abl positive cells had increased SMS activity.
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Further evidence had been provided supporting the possibility of SMS
as a regulated entity by the following important studies. In general, increased
SMS activity correlates with increased proliferation (as in the case of
regenerating rat liver (192) and in quiescent primary astrocytes stimulated
with basic fibroblast growth factor (193)) and some transformed phenotypes,
such as hepatocellular carcinoma. On the other hand, decreased SMS
activity has been observed prior to the onset of apoptosis (194). Importantly,
the loss of SMS activity was found to be a caspase-dependent event thus
suggesting that inhibition of SMS could be a regulated process required for
the full development of the apoptotic program.
Bcr-abl's role as an upstream regulator of SMS was the focus of Aim

1. These results are the subject of Chapter 1 and provided the data for the
manuscript, "Sphingomyelin synthase 1 activity is regulated by the BCR-

ABL oncogene"'.
Aim 1 focused on the evidence of a link between Bcr-abl expression
and elevated SMS activity.

These studies demonstrated that SMSl, as

opposed to SMS2 was the isoform responsible for increased SMS activity
and responsible for maintain cellular proliferation of Bcr-abl positive cells

(Figure 12).

In addition, evidence was provided demonstrating that

inhibition of Bcr-abl, of SMS activity or of SMSl expression resulted in an
alteration of the ratio of bioactive lipids, ceramide and DAG in favor of
ceramide (Figures 9 and 11).

Importantly, SMS inhibition significantly

affected cellular proliferation of Bcr-abl positive cells (Figure 12)
consistently with the shift of the ceramide to DAG ratio in favor of
ceramide. Increased SMSl expression and SMS activity were also observed
in progenitor cells isolated from patients with CML in blast crisis and
pharmacological inhibition of SMS caused a decrease of their proliferation.
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Aim 2 focused on establishing the mechanism by which Bcr-abl
regulates SMSl, and in particular how it enhances SMSl expression. These
studies provided evidence that Bcr-abl transcriptionally upregulates SMSl
and it does so by activation of specific transcription start sites. We
demonstrated that Bcr-abl upregulated SMSl, to the most extent, from TSS
C and its upstream Promoter C. Finally, we showed that the cis-elements
necessary for Bcr-abl-mediated SMSl

upregulation,

resides between

nucleaotides -113 and -110 upstream to TSS C.

Implications and Significance
These studies provide the very first molecular connection between an
oncogene, Bcr-abl and SMS. This connection is novel and significant at
multiple levels.

First, treatment or containment of CML blast phase still

represents a significant clinical challenge. By providing a molecular link
between Bcr-abl and SMS 1, these studies have thus provided the first steps
on understanding

the

role

of SMS 1 tn

the

maintenance

of the

undifferentiated phenotype of CML blasts cells, which is ultimately
responsible for their aggressiveness and resistance to chemotherapy. These
types of studies are of utmost importance since, in spite of the success
obtained in controlling the chronic phase of CML, BCR-ABLI inhibitors
have limitations since CML patients develop mutations over time resulting
in poor clinical outcome.

In addition, BCR-ABLI inhibitors are not

successful in the blast stage of CML. Interestingly, even if K562 cells are
blast phase CML, and therefore characterized by a block of differentiation
potentially due to the accumulation of mutations in addition to the formation
of the Bcr-abl chimaera, SMS 1 activity is still under the control of the Bcr171

abl tyrosine kinase activity. Therefore it is unlikely that SMS 1 may represent
a "druggable" target to contain newly diagnosed blast phase CML. On the
other hand, in spite of the success obtained in controlling the chronic phase
of CML, the increase in resistance to Bcr-abl inhibitors is starting to
represent a significant medical challenge. Thus, establishing SMS 1 as an
important down-stream regulator of Bcr-abl may provide the basis for future
work set to test SMS 1 as a potential novel pharmacological target for CML,
in particular for those cases that arise from resistance to Bcr-abl inhibitors.
The characterization of the molecular mechanism that links Bcr-abl
and SMS 1 is also critical since it will reveal the transcription factor
responsible for Bcr-abl-mediated regulation of SMSI. It could then be
hypothesized that in conditions in which the expression or activity of this
newly identified transcription factor are altered (i.e. specific pathologies),

then also SMSl expression might be affected with potential significant
biological consequences.
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FUTURE DIRECTIONS AND CONCLUDING REMARKS

There are a number of interesting and unanswered questions that branch
from this project and that represent the next challenges for the full understanding
of the Bcr-abl/SMS connection and even for the biology of SMS in general.

How does SMSI regulate proliferation and/or differentiation?

This dissertation has focused on establishing Bcr-abl as an upstream
activator of SMSI via SMSl transcription of Promoter/TSS C. Future studies need
to be conducted to understand the downstream mechanisms through which SMS 1
regulates proliferation upon Bcr-abl expression.

Bcr-abl and sphingolipids

In general, the role of SLs in Bcr-Abl mediated signaling is unclear. In
particular, whereas bcr-abl expression was shown to impart total or partial
resistance to treatment with exogenous short chain ceramide analogues (C2 or C6ceramide), bcr-abl was also found to accelerate ceramide-mediated apoptosis by
these same analogues (292-294). Recently, accumulation of endogenous ceramide
and decrease of the anti-apoptotic sphingolipid, SIP was shown to be in part
responsible for the cytotoxic effect exerted by imatinib treatment in CML derived
cell lines. Moreover, it was also shown that a shift of the balance between
endogenous ceramide and SIP in favor of SIP may be of critical relevance for
imparting imatinib resistance to CML cells (298,299). Thus it is possible that
increased SMSl expression in Bcr-abl positive cells leads to less ceramide
accumulation which brings a proliferative advantage (Figure 28A).
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Interestingly, a link between ceramide and bcr-abl may involve the protein
phosphatase 2A (PP2A). In particular, inhibition of the tumor suppressor PP2A has
been proposed as a mechanism through which Bcr-abl promotes its tumorigenic
effects. Indeed expression of Bcr-abl was shown to lower PP2A activity by
increasing the level of its inhibitor IPP2A (346,347).

In fact, Perrotti et al.

demonstrated that the cytotoxic effect of the immunomodulator FTY720 to CML
cells occurs through activation of PP2A (303). Interestingly, it was recently shown
that FTY720 treatment induces accumulation of ceramide (304) and ceramide is
known to activate PP2A by binding to SET and dissociating it from PP2A (115).
Therefore a novel link between FTY720/ceramide accumulation/activation of
PP2A and inhibition of bcr-abl may exist. It is tempting to speculate that ceramide
accumulated after down-regulation of SMSl may contribute to blocking cell
proliferation by activation of PP2A.

Bcr-abl and DAG

As already discussed, it is very surprising that the relationship between Bcrabl and DAG has not been documented in the literature. DAG has been indirectly
linked to cell proliferation in bcr-abl positive cells through activation of PLCyl,
classical and novel protein kinases C (PKCs), and mTor. Indirect evidence of the
involvement of DAG as a downstream signaling molecule of Bcr-abl come from
reports showing that activation of phospholipase C (PLC) yl and of the PI3KJAkt
pathway are required for Bcr-abl signaling through mTOR/p70S6-kinase
(305,306). The regulation of mTORlp70S6-kinase by PLCyl seems to occur via
modulation of both calcium signaling (CaMKII) (presumably through formation of
IP3) and classical and novel protein kinase C (likely through production of DAG).
In our system, we observed a very significant drop of DAG levels when either Bcr174

abl or SMS/SMS 1 were inhibited. Being SMS 1 regulated by Bcr-abl, it is possible
that part of the observed drop of DAG levels after inhibition of Bcr-abl is due to
the decrease of SMS/SMS 1 activity, in addition to inhibition of PLCyl and it is
possible that DAG regulated by SMSI maybe involved in the regulation of PKCs and
mTor.

What is the transcription (actor responsible for BeT-abI mediated SMSI
upregulation?

Deletion analysis has demonstrated that the region of Promoter C., -113 to 110 is necessary for Bcr-abl mediated upregulation of SMS1. Although this region
contains only 3 base pairs, an oligonucleotide labeled probe may need at least 5-10
bases on each side of the functional control element. For most proteins contained
within crude extracts, probes are made with 20-30 base pairs in order to yield
consistent and high quality results. The length of these oligonucleotides may be
necessary, since the adjacent sequences, although not necessarily required for
recognition of the protein, may be needed for a stable protein-DNA interaction
(340). For example, EMSA experiments to detect NF-KB complexes are usually
performed with 19-bp oligonucleotide probes (348). Therefore, it is possible that
the stretch of -110 to -113 nucleotides on Promoter C is the one necessary for
stable protein-DNA interaction and that the real consensus sequence for the
binding of the transcription factor is slightly closer to the TSS C. This scenario
supports the involvement of STAT5 as the transcription factor binding to Promoter
C, since the putative consensus sequence for STAT5 on Promoter C is between
nucleotides -108/-90 and mostly excludes the other putative factors.
Studies have shown a pronounced constitutive activation of STAT5 in both
Bcr-abl positive cell lines as well as CML patient samples (349). Importantly,
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down-regulation of STAT5 with siRNA in prImary CML samples inhibited
myeloid colony formation (319) and fetal liver hematopoietic progenitors from
STAT5 knockout mice did not induce leukemia in recipient mice after transduction
with BCR-ABL (350). Activation of STAT5 in bcr-abl positive cells may be a
result of phosphorylation by bcr-abl, the janus kinase 2 or the Src kinases
(349,351-353). Studies have shown that STAT5 activation causes cell growth and
transformation by promoting cell proliferation, interfering with differentiation
programs and inhibiting apoptosis [For a review (354)]. These studies, in
combination with the results shown in Supplementary Figure 11, provide
promIsIng evidence of STATS's involvement in Bcr-abl mediated SMSI
regulation.

In summary, the discovery of the bcr-abl/smsl connection provides the first
molecularly-characterized model for a better understanding of potential modes of
regulation and down-stream functions of the elusive SMSI. The potential
regulation of SMSl transcription by STAT5 and the potential involvement of PP2A
as target for SMS 1 activity in bcr-abl cells would establish novel connections in
the bcr-abl signaling network. Being SMSl a potential target for STAT5,
conditions in which STAT5 is up-regulated may also cause an up-regulation of
SMS1. Furthermore, the same down-stream functions of SMS 1 in Bcr-abl cells

could be also aberrant in other pathological conditions associated with altered smsl
expression (or STAT5) and/or activity. Finally, in spite of the success obtained in
controlling the chronic phase of CML, bcr-abl inhibitors are showing a few
setbacks. Thus, establishing SMS 1 as an important down-stream regulator of bcrabl signaling may provide the basis for future work set to test SMS 1 as a potential
novel pharmacological target for CML.

176

BIBLIOGRAPHY
1.
2.

3.
4.
5.
6.

7.
8.
9.
10.

11.
12.
13.
14.
15.

Bernert, J. T., Jr., and Ullman, M. D. (1981) Biochim Biophys Acta
666,99-109
Hatch, G. M., and Vance, D. E. (1992) J BioI Chern 267, 1244312451
Marggrat, W. D., Anderer, F. A., and Kanter, J. N. (1981) Biochirn
Biophys Acta 664, 61-73
Marggrat, W. D., Zertani, R., Anderer, F. A., and Kanter, J. N. (1982)
Biochim Biophys Acta 710, 314-323
Merrill, A. H., Jr., and Jones, D. D. (1990) Biochim Biophys Acta
1044, 1-12
Ullman, M. D., and Radin, N. S. (1974) JBiolChem249, 1506-1512
Voelker, D. R., and Kennedy, E. P. (1982) Biochemistry 21, 27532759
Luberto, C., and Hannun, Y. A. (1998) J BioI Chern 273, 1455014559
Huitema, K., van den Dikkenberg, J., Brouwers, J. F., and Holthuis, J.
C. (2004) EMBO J 23, 33-44
Itoh, M., Kitano, T., Watanabe, M., Kondo, T., Yabu, T., Taguchi, Y.,
Iwai, K., Tashima, M., Uchiyama, T., and Okazaki, T. (2003) Clin
Cancer Res 9, 415-423
Hannun, Y. A., and Obeid, L. M. (2008) Nat Rev Mol Cell Bio/9, 139150
Thudichum, J. (1884)
Futerman, A. H., and Riezman, H. (2005) Trends Cell BioI 15, 312318
Gulbins, E. (2008) BioI Chern 389, 1347-1348
Maceyka, M., Milstien, S., and Spiegel, S. (2009) J Lipid Res 50

Suppl, 8272-276
16.
17.
18.
19.

Merrill, A. H., Jr. (2002) J BioI Chern 277, 25843-25846
Merrill, A. H., Jr.~ Wang, M. D., Park, M., and Sullards, M. C. (2007)
Trends Biochem Sci 32,457-468
Sabourdy, F., Kedjouar, B., Sarli, S. C., Colie, S., Milhas, D., Salma,
Y., and Levade, T. (2008) Biochim Biophys Acta 1781, 145-183
Burns, T. A., and Luberto, C. Anticancer Agents Med Chern 11, 863881

177

20.
21.

22.
23.
24.
25.

26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.

39.

Kitatani, K., Idkowiak-Baldys, J., and Hannun, Y. A. (2008) Cell
Signal 20, 1010-1018
Maceyka, M., Sankala, H., Hait, N. C., Le Stunff, H., Liu, H., Toman,
R., Collier, C., Zhang, M., Satin, L. S., Merrill, A. H., Jr., Milstien, S.,
and Spiegel, S. (2005) J BioI Chern 280, 37118-37129
Serra, M., and Saba, J. D. Adv Enzyme Regul50, 349-362
EI Bawab, S., Roddy, P., Qian, T., Bielawska, A., Lemasters, J. J.~
and Hannun, Y. A. (2000) J BioI Chern 275,21508-21513
Mao, C., Xu, R., Bielawska, A., and Obeid, L. M. (2000) J BioI Chern
275, 6876-6884
Mao, C., Xu, R., Bielawska, A., Szulc, Z. M., and Obeid, L. M. (2000)
J BioI Chern 275, 31369-31378
Ogretmen, S., and Hannun, Y. A. (2004) Nat Rev Cancer 4, 604-616
Mao, C., and Obeid, L. M. (2008) Biochim Biophys Acta 1781, 424434
Shida, D., Takabe, K., Kapitonov, D., Milstien, S., and Spiegel, S.
(2008) Curf Drug Targets 9, 662-673
Hannun, Y. A., Luberto, C., and Argraves, K. M. (2001) Biochemistry
40, 4893-4903
Okazaki, T., Bell, R. M., and Hannun, Y. A. (1989) J BioI Chern 264,
19076-19080
Okazaki, T., Bielawska, A., Bell, R. M., and Hannun, Y. A. (1990) J
BioI Chern 265, 15823-15831
Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun, Y. A.
(1993) Science 259,1769-1771
Futerman, A. H. (2002) Ceramide Signaling~ Plenum Publishers, New
York
Kolesnick, R. (2002) J Clin Invest 110, 3-8
Lavieu, G., Scarlatti, F., Sala, G., Levade, T., Ghidoni, R., Botti, J.,
and Codogno, P. (2007) Autophagy 3, 45-47
Ryland, L. K., Fox, T. E., Liu, X., Loughran, T. P., and Kester, M.
(2011) Cancer BioI Ther 11, 138-149
Zhang, Y., Li, X., Becker, K. A., and Gulbins, E. (2009) Biochim
Biophys Acta 1788, 178-183
Seumois, G., Fillet, M., Gillet, L., Faccinetto, C., Desmet, C.,
Francois, C., Dewals, B., Oury, C., Vanderplasschen, A., Lekeux, P.,
and Bureau, F. (2007) J Leukoc Bio/81 , 1477-1486
Farrell, A. M., Uchida, Y., Nagiec, M. M., Harris, I. R., Dickson, R. C.,
Elias, P. M., and Holleran, W. M. (1998) J Lipid Res 39,2031-2038
178

40.
41.
42.

43.

44.
45.
46.

47.
48.
49.

50.
51.
52.
53.

54.

55.
56.

57.

Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z.~
and Kolesnick, R. (1995) Cell 82, 405-414
Perry, D. K., Carton, J., Shah, A. K., Meredith, F., Uhlinger, D. J., and
Hannun, Y. A. (2000) J BioI Chern 275, 9078-9084
Senkal, C. E., Ponnusamy, S., Rossi, M. J., Bialewski, J., Sinha, D.,
Jiang, J. C., Jazwinski, S. M., Hannun, Y. A., and Ogretmen, B.
(2007) Mol Cancer Ther 6, 712 .. 722
Shirakabe, K., Yamaguchi, K., Shibuya, H., Irie, K., Matsuda, S.,
Moriguchi, T., Gotoh, Y., Matsumoto, K., and Nishida, E. (1997) J Bioi
Chern 272, 814 1-8144
Jenkins, G. M. (2003) Cell Mol Life Sci 60, 701-710
Karakashian, A. A., Giltiay, N. V., Smith, G. M., and NikolovaKarakashian, M. N. (2004) FASEB J 18,968-970
Jin, J., Hou, Q., Mullen, T. D., Zeidan, Y. H., Bielawski, J., Kraveka, J.
M., Bielawska, A., Obeid, L. M., Hannun, Y. A., and Hsu, Y. T. (2008)
J BioI Chern 283, 26509-26517
Watson, M. L., Coghlan, M., and Hundal, H. S. (2009) Biochem J
417, 791-801
Chavez, J. A., and Summers, S. A. (2003) Arch Biochem Biophys
41 9, 101 -1 09
Lahiri, S., and Futerman, A. H. (2007) Cell Mol Life Sci 64,2270-2284
Ito, Y., Sato, S., Ohashi, T., Nakayama, S., Shimokata, K., and
Kume, H. (2004) Biochem Biophys Res Commun 324, 901-908
Vilela, R. M., Lands, L. C., Meehan, S., and Kubow, S. (2006) Int
Immunopharmacol6, 1651-1664
Summers, S. A. (2006) Prog Lipid Res 45, 42-72
Petrache, I., Natarajan, V., Zhen, L., Medler, T. R., Richter, A. T.,
Cho, C., Hubbard, W. C., Berdyshev, E. V., and Tuder, R. M. (2005)
Nat Med 11, 491-498
Petrache, I., Natarajan, V., Zhen, L., Medler, T. R., Richter, A.,
8erdyshev, E. V., and Tuder, R. M. (2006) Proc Am Thorac Soc 3,
510
Yao, H. S., Norred, W. P., Wang, E., Merrill, A. H., Jr., and Riley, R.
T. (1992) TaxieDI Appl Pharmaco/114, 9-15
Wu, W. I., McDonough, V. M., Nickels, J. T., Jr., Ko, J., Fischl, A. S.,
Vales, T. R., Merrill, A. H., Jr., and Carman, G. M. (1995) J BioI Chern
270,13171-13178
Nilsson, A. (1969) Biochim Biophys Acta 176,339-347

179

58.

59.
60.
61.
62.
63.
64.
65.
66.

67.
68.
69.

70.
71.
72.
73.

74.

75.

Duan, R. D., Bergman, To, Xu, N., Wu, J., Cheng, Yo, Duan J.,
Nelander, S., Palmberg, C., and Nilsson, A. (2003) J Bioi Chern 278,
38528-38536
Wu, Jo, Cheng, Y., Palmberg, Co, Bergman, T., Nilsson, A., and Duan,
Ro D. (2005) Biochim Biophys Acta 1687,94-102
Krut, 0., Wiegmann, K., Kashkar, H., Yazdanpanah, B., and Kronke,
M. (2006) J Bioi Chern 281, 13784-13793
Wu, B. X., Rajagopalan, V., Roddy, P. L., Clarke, C. J., and Hannun,
Y. A. (2010) J Bioi Chern 285,17993-18002
Tomiuk, S., Hofmann, K., Nix, M., Zumbansen, M., and Stoffel, W.
(1998) Proc Natl Acad Sci USA 95, 3638-3643
Hofmann, K., Tomiuk, S., Wolff, G., and Stoffel, W. (2000) Proc Natl
Acad Sci USA 97, 5895-5900
Schuchman, E. H. (2010) FEBS Lett 584, 1895-1900
Sawai, H., Domae, N., Nagan, N., and Hannun, Y. A. (1999) J Bioi
Chern 274,38131-38139
Horinouchi, K., Erlich, S., Perl, D. P., Ferlinz, K., Bisgaier, C. L.,
Sandhoff, K., Desnick, Ro J., Stewart, C. L., and Schuchman, E. H.
(1995) Nat Genet 10, 288-293
Brady, R. 0o, Kanfer, J. N., Mock, M. Bo, and Fredrickson, D. S.
(1966) Proc Natl Acad Sci USA 55, 366-369
Becker, K. Ao, Grassme, H., Zhang, Y., and Gulbins, E. (2010) Cell
Physio/ Biochem 26,57-66
Grassme, Ho, Becker, K. A., Zhang, Yo, and Gulbins, E. (2008) Bioi
Chern 389, 1371-1379
Utermohlen, 0., Herz, J., Schramm, M., and Kronke, M. (2008)
Immunobiology 213, 307-314
Schramm, M., Herz, J., Haas, A., Kronke, M., and Utermohlen, O.
(2008) Cell Microbio/1 0, 1839-1853
Ng, Co G., and Griffin, D. E. (2006) J Viro/80, 10989-10999
Zeidan, Y. H., Wu, B. X., Jenkins, R. Wo, Obeid, L. M., and Hannun,
Y. A. (2008) FASEB J22, 183-193
Santana, Po, Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green,
D., McLoughlin, M., Cordon-Carda, C., Schuchman, E. H., Fuks, Z., .
and Kolesnick, R. (1996) Gel/86, 189-199
Cifone, M. Go, De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M.,
Lanier, L. L., Santoni, A., and Testi, R. (1994) J Exp Med 180, 15471552
1

180

76.

77.

78.

79.
80.
81.
82.
83.

84.

85.

86.

87.

88.
89.
90.

Gulbins, E., Bissonnette, R., Mahboubi, A., Martin, S., Nishioka, W.,
Brunner, T., Baier, G., Baier.. Bitterlich, G., Byrd, C., Lang, F., and et
al. (1995) Immunity 2, 341-351
Grassme, H., Jekle, A., Riehle, A., Schwarz, H., Berger, J., Sandhoff,
K., Kolesnick, R., and Gulbins, E. (2001) J BioI Chern 276, 2058920596
Rosato, R. R., Maggio, S. C., Almenara, J. A., Payne, S. G., Atadja,
P., Spiegel, S., Dent, P., and Grant, S. (2006) Mol Pharmacol 69,
216-225
Segui, B., and Legembre, P. (2010) Recent Pat Anticancer Drug
Discov 5, 22-28
Castillo, S. S., Levy, M., Thaikoottathil, J. V., and Goldkorn, T. (2007)
Exp Cell Res 313, 2680-2686
Grassme, H., Bock, J., Kun, J., and Gulbins, E. (2002) J BioI Chern
277,30289-30299
Huang, Y., Yang, J., Shen, J., Chen, F. F., and Yu, Y. (2005)
Biochem Biophys Res Commun 330, 430-438
Lacour, S., Hammann, A., Grazide, S., Lagadic-Gossmann, D.,
Athias, A., Sergent, 0., Laurent, G., Gambert, P., Salary, E., and
Dimanche-Boitrel, M. T. (2004) Cancer Res 64,3593-3598
Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C.,
Gahr, J., Schwandner, R., Weber, T., Saftig, P., Peters, C., Brunner,
J., Kronke, M., and Schutze, S. (1999) EMBOJ18, 5252-5263
Heinrich, M., Neumeyer, J., Jakob, M., Hallas, C., Tchikov, V.,
Winoto-Marbach, S., Wickel, M., Schneider-Brachert, W., Trauzald,
A., Hethke, A., and Schutze, S. (2004) Cell Death Differ 11, 550-563
Lansmann, S., Schuette, C. G., Bartelsen, 0., Hoernschemeyer, J.,
Linke, T., Weisgerber, J., and Sandhoff, K. (2003) Eur J Biochem
270, 1076-1088
Qiu, H., Edmunds, T., Baker-Malcolm, J., Karey, K. P., Estes, S.,
Schwarz, C., Hughes, H., and Van Patten, S. M. (2003) J BioI Chern
278, 32744-32752
Charruyer, A., Grazide, SI, Bezombes, C., Muller, SI, Laurent, G.,
and Jaffrezou, J. P. (2005) J BioI Chem 280, 19196-19204
Dumitru, C. A., and Gulbins, E. (2006) Oncogene 25,5612-5625
Zeidan, Y. H., Jenkins, R. W., and Hannun, Y. A. (2008) J Cell BioI
181 335-350
Edelmann, B., Bertsch, U., Tchikov, V., Winota-Morbach, S., Perrotta,
C., Jakob, M., Adam-Klages, S., Kabelitz, D., and Schutze, S. (2011)
EMBO J 30, 379-394
1

91.

181

92.

93.
94.
95.

96.
97.
98.
99.

Nikolova-Karakashian, M., and Rozenova, K. (2010) Ceramide in
stress response. in Sphingolipids as signaling and regulatory
molecules, Landes Bioscience, New York
Nikolova-Karakashian, M., Karakashian, A., and Rutkute, K. (2008)
Subcell Biochem 49, 469-486
Clarke, C. J., Wu, B. X., and Hannun, Y. A. (2010) Adv Enzyme
Regul
Marchesini, N., Osta, W., Bielawski, J., Luberto, C., Obeid, L. M., and
Hannun, Y. A. (2004) J BioI Chern 279,25101-25111
Levy, M., Castillo, S. S., and Goldkorn, T. (2006) Biochem Biophys
Res Commun 344, 900-905
Tani, M., and Hannun, Y. A. (2007) J BioI Chem 282, 10047-10056
Marchesini, N., Luberto, C., and Hannun, Y. A. (2003) J BioI Chern
278, 13775-13783
Clarke, C. J., Guthrie, J. M., and Hannun, Y. A. (2008) Mol

Pharrnacol74, 1022-1032
100. Tellier, E., Negre-Salvayre, A., Bocquet, S., Itohara, S., Hannun, Y.
A., Salvayre, R., and Auge, N. (2007) Mol Cell 8io127, 2997-3007
101. Ito, H., Murakami, M., Furuhata, A., Gao, S., Yoshida, K., Sobue, S.,
Hagiwara, K., Takagi, A., Kojima, T., Suzuki, M., Banno, Y., Tanaka,
K., Tamiya-Koizumi, K., Kyogashima, M., Nozawa, Y., and Murate, T.
(2009) Biochim Biophys Acta 1789, 681-690
102. Clarke, C. J., Truong, T. G., and Hannun, Y. A. (2007) J Bioi Chern
282, 1384-1396
103. De Palma, C., Meacci, E., Perrotta, C., Bruni1 P., and Clementi, E.
(2006) Arteriosc/er Thromb Vase BioI 26, 99-105
104. Adam-Klages, S., Adam, D., Wiegmann, K., Struve, S., Kolanus, W.,
Schneider-Mergener, J., and Kronke, M. (1996) Ge1/86, 937-947
105. Philipp, S., Puchert, M., Adam-Klages, SI, Tchikov, V., WinotoMarbach, S., Mathieu, S., Deerberg, A., Kolker, L., Marchesini, N.,
Kabelitz, D., Hannun, Y. A., Schutze, S., and Adam, D. (2010) Proc
Natl Acad Sci USA 107, 1112-1117
106. Bourteele, S., Hausser, A., Doppler, H., Horn-Muller, J., Ropke, C.,
Schwarzmann, G., Pfizenmaier, K., and Muller, G. (1998) J BioI
Chern 273, 31245-31251
107. Dolgachev, V., Farooqui, M. S., Kulaeva, O. I., Tainsky, M. A., Nagy,
B., Hanada, K., and Separovic, D. (2004) J Bioi Chern 279, 2323823249

182

108. Watanabe, M., Kitano, T., Kondo, T., Yabu, T., Taguchi, Y., Tashima,
M., Umehara, H., Domae, N., Uchiyama, T., and Okazaki, T. (2004)
Cancer Res 64, 1000-1007
109. Lafont, E., Milhas, D., Carpentier, S., Garcia, V., Jin, Z. X., Umehara,
H., Okazaki, T., Schulze-Osthoff, K., Levade, T., Benoist, H., and
Segui, B. (2010) Cell Death Differ 17, 642-654
110. Chalfant, C. E., Ogretmen, B., Galadari, S., Kroesen, B. J., Pettus, B.
J., and Hannun, V. A. (2001) J Bioi Chern 276,44848-44855
111. Marchesini, N., Jones, J. A., and Hannun, Y. A. (2007) Biochim
Biophys Acta 1771, 1418-1428
112. Kim, S. W., Kim, H. J., Chun, Y. J., and Kim, M. Y. (2010) J Toxieo/
Environ Health A 73, 1465-1476
113. Zhou, H., Summers, S. A., Birnbaum, M. J., and Pittman, R. N. (1998)
J BioI Chern 273, 16568-16575
114. Chalfant, C. E., Kishikawa, K., Mumby, M. C., Kamibayashi, C.,
Bielawska, A., and Hannun, Y. A. (1999) J Bioi Chern 274, 2031320317
115. Mukhopadhyay, A., Saddoughi, S. A., Song, P., Sultan, I.,
Ponnusamy, S., Senkal, C. E., Snook, C. F., Arnold, H. K., Sears, R.
C., Hannun, Y. A., and Ogretmen, B. (2009) Faseb J23, 751-763
116. Lee, J. Y., Hannun, Y. A., and Obeid, L. M. (1996) J BioI Chern 271,
13169-13174
117. Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and
Pfizenmaier, K. (1995) EMBO J 14, 1961-1969
118. Bourbon, N. A., Sandirasegarane, L., and Kester, M. (2002) J BioI
Chern 277, 3286-3292
119. Zhang, Y., Vao, B., Delikat, S., Bayoumy, S., Lin, X. H., Basu, S.,
McGinley, M., Chan-Hui, P. Y., Lichenstein, H., and Kolesnick, R.
(1997) Gella9, 63-72
120. Lee, M. J., Van Brocklyn, J. R., Thangada~ S., Liu, C. H., Hand, A. R.,
Menzeleev, R., Spiegel, SI, and Hla, T. (1998) Science 279, 15521555
121. Spiegel, S., and Milstien, S. (2003) Nat Rev Mol Cell Bioi 4, 397-407
122. Boujaoude, L. C., Bradshaw-Wilder, C., Mao, C., Cohn, J., Ogretmen,
B., Hannun, Y. A., and Obeid, L. M. (2001) J BioI Chern 276, 3525835264
123. Mitra, P., Oskeritzian, C. A., Payne, S. G., Beaven, M. A., Milstien, S.,
and Spiegel, S. (2006) Proc Nat! Aead Sci USA 103,16394-16399
124. Doll, F., Pfeilschifter, J., and Huwiler, A. (2005) Biochim Biophys Acta
1738, 72-81
183

125. Sukocheva, O. A., Wang, L., Albanese, N., Pitson, S. M., Vadas, M.
A., and Xia, P. (2003) Mol Endocrino/17, 2002-2012
126. Nakade, Y., Sanno, Y., K, T. K., Hagiwara, K., Sobue, S., Koda, M.,
Suzuki, M., Kojima, T., Takagi, A., Asano, H., Nozawa, Y., and
Murate, T. (2003) Biochim Biophys Acta 1635,104-116
127. Huwiler, A., Doll, F., Ren, S., Klawitter, S., Greening, A., Romer, I.,
Bubnova, S., Reinsberg, L., and Pfeilschifter, J. (2006) Biochim
Biophys Acta 1761, 367-376
128. Klawitter, S., Hofmann, L. P., Pfeilschifter, J., and Huwiler, A. (2007)
Br J Pharmaco/150, 271-280
129. Pitson, S. M., Moretti, P. A., Zebol, J. R., Lynn, H. E., Xia, P., Vadas,
M. A., and Wattenberg, B. W. (2003) EMBO J 22, 5491-5500
130. Jarman, K. E., Moretti, P. A., Zebol, J. R., and Pitson, S. M. (2010) J
Bioi Chern 285, 483-492
131. Alvarez, S. E., Harikumar, K. S., Hait, NI C., Allegood, J., Strub, G.
M., Kim, E. Y., Maceyka, M., Jiang, HI, Luo, C., Kordula, T., Milstien,
S., and Spiegel, S. Nature 465,1084-1088
132. Ghosh, T. K., Bian, J., and Gill, D. L. (1994) J BioI Chern 269,2262822635
133. Thompson, CI R., Iyer, S. S., Melrose, N., VanOosten, R., Johnson,
K., Pitson, S. M., Obeid, L. MI, and Kusner, D. JI (2005) J Immunol
174, 3551-3561
134. Venkataraman, KI, Thangada, S., Michaud, J., 00, M. L., Ai, Y., Lee,
Y. M., Wu, MI, Parikh, N. S., Khan, FI, Proia, R. L., and Hla, T. (2006)
Biochem J 397, 461-471
135. Hammad, S. M., Taha, T. A., Nareika, A., Johnson, K. R., LopesVirella, M. F., and Obeid, L. M. (2006) Prostaglandins Other Lipid
Mediat 79, 126-140
136. Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. S.,
Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., and
Spiegel, s. (2009) Science 325, 1254-1257
137. Igarashi, N., Okada, T., Hayashi, S., Fujita, T., Jahangeer, S., and
Nakamura, S. (2003) J BioI Chern 278,46832-46839
138. Liu, H., Toman, R. E., Goparaju, SI K., Maceyka, M., Nava, V. E.,
Sankala, H., Payne, S. G., Bektas, M., Ishii, I., Chun, J., Milstien, S.,
and Spiegel, S. (2003) J Bioi Chern 278,40330-40336
139. Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S.,
and Proia, R. L. (2005) Mol Cell 8io/25, 11113-11121

184

140. Xia, P., Gamble, J. R., Wang, L., Pitson, S. M., Moretti, P. A.,
Wattenberg, B. W., D'Andrea, R. J., and Vadas, M. A. (2000) Curr
BioI 10, 1527-1530
141. Kapitonov, D., Allegood, J. C., Mitchell, C., Hait, N. C., Almenara, J.
A., Adams, J. K., Zipkin, R. E., Dent, P., Kordula, T., Milstien, S., and
Spiegel, S. (2009) Cancer Res 69, 6915-6923
142. Kawamori, T., 08ta, W., Johnson, K. R., Pettus, B. J., Bielawski, J.,
Tanaka, T., Wargovich, M. J., Reddy, B. S., Hannun, Y. A., Obeid, L.
M., and Zhou, D. (2006) FASEB J 20,386-388
143. Kawamori, T., Kaneshiro, T., Okumura, M., Maalouf, S., Uflacker, A.,
Bielawski, J., Hannun, Y. A., and Obeid, L. M. (2009) FASEB J 23,
405-414
144. Facchinetti, M. M., Gandini, N. A., Fermento, M. E., Sterin-Speziale,
N. S., Ji, Y., Patel, V., Gutkind, J. S., Rivadulla, M. G., and Curino, A.
C. Cells Tissues Organs 192,314-324
145. Shirai, K., Kaneshiro, T., Wada, M., Furuya, H., Bielawski, J.,
Hannun, Y. A., Obeid, L. M., Ogretmen, S., and Kawamori, T. (2011)
Cancer Prev Res (Phi/a) 4, 454-462
146. French, K. J., Schrecengost, R. S., Lee, B. D., Zhuang, Y., Smith, S.
N., Eberly, J. L., Yun, J. K., and Smith, C. D. (2003) Cancer Res 63,
5962 .. 5969
147. Johnson, K. R., Johnson, K. Y., Crellin, H. G., Ogretmen, S., Boylan,
A. M., Harley, Ro A., and Obeid, L. M. (2005) J Histochem Cytochem
53,1159-1166
148. SObU9, So, Iwasaki, T., Sugisaki, Co, Nagata, K. Kikuchi, R.,
Murakami, M., Takagi, A., Kojima, T., Banno, Y., Akao, Y., Nozawa,
Yo, Kannagi, R., Suzuki, M., Abe, A., Naoe, T., and Murate, To (2006)
Leukemia 20, 2042-2046
149. Shirai, K., Kaneshiro, T., Wada, M., Furuya, Ho, Bielawski, Jo,
Hannun, Y. A., Obeid, Lo M., Ogretmen, B., and Kawamori, To Cancer
Prev Res (Phi/a) 4, 454-462
150. Doll, F., Pfeilschifter, J., and Huwiler, A. (2007) Endocr Relat Cancer
14,325-335
151. Sarkar, S., Maceyka, Mo, Hait, No C., Paugh, S. W., Sankala, H.,
Milstien, So, and Spiegel, S. (2005) FEBS Lett 579, 5313-5317
152. Liu, Fo, Verin, A. D., Wang, P., Day, R., Wersto, R. P., Chrest, F. J.,
English, D. K., and Garcia, J. Go (2001) Am J Respir Cell Mol BioI 24,
711-719
t

185

153. Annabi, S., Thibeault, S., Lee, Y. T., Bousquet-Gagnon, N.,
Eliopoulos, N., Barrette, S., Galipeau, J., and Beliveau, R. (2003) Exp
Hemato/31 , 640-649
154. Lee, M. J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk,
M., Volpi, M., Sha'afi, R. I., and Hla, T. (1999) CeJ/99, 301-312
155. Argraves, K. M., Wilkerson, B. A., Arg raves , W. S., Fleming, P. A.,
Obeid, L. M., and Drake, C. J. (2004) J Bioi Chern 279,50580-50590
156. Limaye, V., Li, X., Hahn, C., Xia, P., Berndt, M. C., Vadas, M. A., and
Gamble, J. R. (2005) Blood 105, 3169-3177
157. Visentin, S., Vekich, J. A., Sibbald, B. J., Cavalli, A. L., Moreno, K.
M., Matteo, R. G., Garland, W. A., Lu, Y., Yu, S., Hall, H. S., Kundra,
V., Mills, G. S., and Sabbadini, R. A. (2006) Cancer Cell 9, 225-238
158. Futerman, A. H., and Hannun, Y. A. (2004) EMBO Rep 5,777-782
159. Hanada, K., Kumagai, K., Yasuda, S., Miura, Y., Kawano, M.,
Fukasawa, M., and Nishijima, M. (2003) Nature 426, 803-809
160. Simon, C. G., Jr., Holloway, P. W., and Gear, A. R. (1999)
Biochemistry 38, 14676-14682
161. Bai, J., and Pagano, R. E. (1997) Biochemistry 36, 8840-8848
162. van Meer, G., and Holthuis, J. C. (2000) Biochim Biophys Acta 1486,
145-170
163. Stiban, J., Tidhar, R., and Futerman, A. H. (2010) Adv Exp Med BioI
688,60-71
164. Ternes, P., Franke, S., Zahringer, U., Sperling, P., and Heinz, E.
(2002) J Bioi Chern 277,25512-25518
165. Villani, M., Subathra, M., 1m, Y. B., Choi, Y., Signorelli, P., Del Poeta,
M., and Luberto, C. (2008) Biochem J 414,31-41
166. Senkal, C. E., Ponnusamy, S., Bielawski, J., Hannun, Y. A., and
Ogretmen, B. (2010) FASEB J 24, 296-308
167. Kroesen, B. J., Jacobs, S., Pettus, B. J., Sietsma, H., Kok, J. W.,
Hannun, Y. A., and de Leij, L. F. (2003) J Bioi Chern 278, 1472314731
168. White-Gilbertson, S., Mullen, T., Senkal, C., Lu, P., Ogretmen, S.,
Obeid, L., and Voelkel-Johnson, C. (2009) Oncogene 28, 1132-1141
169. Venkataraman, K., Riebeling, C., Bodennec, J., Riezman, H.,
Allegood, J. C., Sullards, M. C., Merrill, A. H., Jr., and Futerman, A.
H. (2002) J BioI Chern 277,35642-35649
170. Griner, E. M., and Kazanietz, M. G. (2007) Nat Rev Cancer 7, 281294
171. Yang, C., and Kazanietz, M. G. (2007) Biochem J 403, 1-12
172. Carrasco, S., and Merida, I. (2007) Trends Biochem Sci 32, 27-36
186

173. Colon-Gonzalez, F., and Kazanietz, M. G. (2006) Biochim Biophys
Acta 1761, 827-837
174. Huitema, K., Van Den Dikkenberg, J., Brouwers, J. F., and Holthuis,
J. C. (2004) Embo J 23, 33-44. Epub 2003 Dec 2018.
175. Yamaoka, S., Miyaji, M., Kitano, T., Umehara, H., and Okazaki, T.
(2004) J BioI Chern 279, 18688-18693
176. Futerman, A. H., Stieger, B., Hubbard, A. L., and Pagano, R~ E.
(1990) J.Biol.Chem. 265, 8650-8657
177. Jeckel, D., Karrenbauer, A., Birk, R., Schmidt, R. R., and Wieland, F.
(1990) FEBS Lett. 261,155-157
178. Kobayashi, T., and Pagano, R. E. (1989) J BioI Chern 264, 59665973
179. Lipsky, N. G., and Pagano, R. E. (1983) Proc Natl Acad Sci USA 80,
2608-2612.
180. Lipsky, N. G., and Pagano, R. E_ (1985) J.Cel/ BioI. 100,27-34
181. Schweizer, A., Clausen, H., Van Meer, G., and Hauri, H.-P. (1994)
J.Biol. Chern. 269, 4035 ..4041
182. Yeang~ C., Varshney, S., Wang, R., Zhang, Y., Ye, D., and Jiang, X.
C. (2008) Biochim Biophys Acta 1781,610-617
183. Tani, M., and Kuge, O. (2009) Biochern Biophys Res Commun 381,
328-332
184. Tafesse, F. G., Huitema, K., Hermansson, M., van der Poel, S., van
den Dikkenberg, J., Uphoff, A., Somerharju, p", and Holthuis, J. C.
(2007) J BioI Chern 282 17537-17547
185. Ding, T., Li, Z., Hailemariam, T., Mukherjee, S., Maxfield, F. R., Wu,
M. P., and Jiang, X. C. (2008) J Lipid Res 49,376-385
186. Jin, Z. X., Huang, C. R., Dong, L., Goda, S., Kawanami, T., Sawaki,
T., Sakai, T., Tong, X. P., Masaki, Y., Fukushima, T., Tanaka, M.,
Mimori, T., Tojo, H., Bloom, E. T., Okazaki, T., and Umehara, H.
(2008) Int Immunol
187. Miyaji, M., Jin, Z. X., Yamaoka, S., Amakawa, R., Fukuhara, S., Sato,
Sa S., Kobayashi, T., Domae, N., Mimori, T., Bloom, E. T., Okazaki,
T., and Umehara, H. (2005) J Exp Med 202, 249-259
188. Hailemariam, T. K., Huan, C., Liu, J., Li, Z., Roman, C., Kalbfeisch,
1

M., Bui, H. H., Peake, D. A., Kuo, M. S., Cao, G., Wadgaonkar, R.,
and Jiang, X. C. (2008) Arteriosc/er Thromb Vase Bio/28, 1519-1526
189. Yano, M., Watanabe, K., Yamamoto, T., Ikeda, K., Senokuchi, T., Lu,
M., Kadomatsu, T., Tsukano, H., Ikawa, M., Okabe, M., Yamaoka, S.,
Okazaki, T., Umehara, H., Gotoh, T., Song, W. J., Node, K., Taguchi,
R., Yamagata, K., and Oike, Y. (2011) J BioI Chern 286,3992-4002
187

190. Mira-Obradars, M. J., Osada, J., Aylagas, H., Sanchez-Vegazo, I.,
and Palacios-Alaiz, E. (1993) Carcinogenesis 14, 941-946
191. Riboni, L., Viani, P., Bassi, R., Giussani, P., and Tettamanti, G.
(2001) J BioI Chern 276, 12797-12804
192. Miro-Obradors, M.-J., Osada, J., Aylagas, H., Sanchez-Vegazo, I.,
and and Palacios-Alaiz, E. (1993) Carcinogenesis 14, 941-946
193. Ribani, L., Viani, P., Bassi, R., Giussani, P., and Tettamanti, G.
(2001) J BioI Chern 276, 12797-12804.
194. Baurteele, S., Hausser, A., Doppler, H., Horn-Muller, J., Ropke, C.,
Schwarzmann, G., Pfizenmaier, K., and Muller, G. (1998) J BioI
Chern 273, 31245-31251.
195. Vardiman, J. W. (2009) Chern BioI Interact 184, 16-20
196. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D.
A., Gralnick, H. R., and Sultan, C. (1976) Br J Haemato/33, 451-458
197. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D.
A., Gralnick, H. R., and Sultan, C. (1980) BrJ Haemato/44, 169-170
198. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D.
A., Gralnick, H. R., and Sultan, C. (1985) Ann Intern Med 103, 460462
199. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D.
A., Gralnick, H. R., and Sultan, C. (1991) BrJ Haemato/78, 325-329
200. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D.
A., Gralnick, H. R., and Sultan, C. (1985) Ann Intern Med 103,620625
201. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink,
H. K., Vardiman, J., Lister, T. A., and Bloomfield, C. D. (2000)
Hematol J 1, 53-66
202. Jabbour, E. J., Faderl, S.~ and Kantarjian, H. M. (2005) Mayo Clin
Proc80, 1517-1527
203. Porth, C., and Mattfin, G. (2011) Hematopoietic Function. in
Essentials of Pathophysiology; Concepts of Altered Health States
(Surrena, H. ed., Lippincott Williams and Wilkins, WoltersKluwer
Health
Jefferson City
204. Cairns, J. (1975) Nature 255, 197-200
205. Morrison, S. J., and Kimble, J. (2006) Nature 441, 1068-1074
206. Watt, F. M., and Hogan, B. L. (2000) Science 287, 1427-1430
207. Thalia Papayannopoulou, and Lemischka, I. (2001) Stem Cell
Biology.
In
The
Molecular
Basis
of
Blood
Disease
188

208.
209.
210.
211.

212.
213.
214.

215.
216.

217.
218.
219.
220.

221.
222.

223.

224.
225.
226.
227.
228.

(Stamatoyannopoulos, G. ed., 3 Ed., W.B. Saunders Company,
Philadelphia
Morrison, S. J., and Weissman, I. L. (1994) Immunity 1, 661-673
Sato, T., Laver, J. H., and Ogawa, M. (1999) Blood 94, 2548-2554
Bonnet, D., and Dick, J. E. (1997) Nat Med3, 730-737
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., CaceresCortes, J., Minden, M., Paterson, B., Caligiuri, M. A., and Dick, J. E.
(1994) Nature 367, 645-648
Dick, J. E., and Lapidot, T. (2005) Int J Hematol82, 389-396
Huntly, B. J., and Gilliland, D. G. (2005) Nat Rev Cancer 5, 311-321
Collins, S. J., Gallo, R. C., and Gallagher, R. E. (1977) Nature 270,
347-349
Kim, M. Y., Linardic, C., Obeid, L., and Hannun, Y. (1991) J BioI
Chern 266,484-489
Dbaibo, G. S., Pushkareva, M. Y., Jayadev, S., Schwarz, J. K.,
Horowitz, J. M., Obeid, L. M., and Hannun, Y. A. (1995) Proc Nat!
Aead Sci USA 92,1347-1351
Wolff, R. A., Dobrowsky, R. T., Bielawska, A., Obeid, L. M., and
Hannun, Y. A. (1994) J BioI Chern 269,19605-19609
Mathias, S., Younes, A., Kan, C. C., Orlow, I., Joseph, C.,. and
Kolesnick, R. N. (1993) Science 259, 519-522
Furuya, S., Mitoma, J., Makino, A., and Hirabayashi, Y. (1998) J
Neurochem 71, 366-377
Ragg, S. J., Kaga, S., Berg, K. A., and Ochi, A. (1998) J Immunol
161, 1390-1398
Hannun, Y. A., and Luberto, C. (2000) Trends Cell Bioi 1 0, 73-80
Hannun, Y. A., and Obeid, L. M. (2002) J BioI Chern 277, 2584725850
Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C.,
Maestre, N., Vermeersch, S., Rousse, A., and Laurent, G. (1996)
EMBO J 15, 2417-2424
Sonneveld, P. (2000) J Intern Med 247,521-534
Bonhoure, E., Pchejetski, D., Aouali, N., Morjani, H., Levade, T.,
Kohama, T., and Cuvillier, O. (2006) Leukemia 20,95-102
Senchenkov, A., Han, T. Y., Wang, H., Frankel, A. E., Kottke, T. J.,
Kaufmann, S. H., and Cabot, M. C. (2001) Blood 98, 1927-1934
Cakir, Z., Saydam, G., Sahin, F., and Baran, Y. (2011) J Cancer Res
Clin Oneol
Advani, A., and Lazarus, H. (2010) Adult Acute Lymphocytic
Leukemia: Biology and Treatment, Springer Verlag
189

229. Biswal, S. S., Datta, K., Acquaah-Mensah, G. K., and Kehrer, J. P.
(2000) Toxicology 154,45-53
230. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin~ K. M. (1997)
EMBO J 16, 6200-6208
231. Zhang, J., Alter, N., Reed, J. C., Borner, C., Obeid, L. M., and
Hannun, Y. A. (1996) Proc Nat! Acad Sci USA 93, 5325-5328
232. Olshefski, R. S., and Ladisch, S. (2001) tntJ Cancer 93, 131-138
233. Gruber, C., Henkel, M., Budach, W., Belka, C., and Jendrossek, V.
(2004) Biochem Pharmacol67, 1859-1872
234. Sillence, D. J., and Allan, D. (1997) Biochem J 324 ( Pt 1), 29-32
235. Watts, J. D., Gu, M., Polverino, A. J., Patterson, S. D., and
Aebersold, R. (1997) Proc Natl Acad Sci USA 94,7292-7296
236. Brenner, B., Ferlinz, K., Grassme, H., Weller, M., Koppenhoefer, U.,
Dichgans, J., Sandhoff, K., Lang, F., and Gulbins, E. (1998) Cell
Death Differ 5, 29-37
237. Cock, J. G., Tepper, A. D., de Vries, E., van Blitterswijk, W. J., and
Borst, J. (1998) J Bioi Chern 273,7560-7565
238. Cuvillier, 0., Rosenthal, D. So, Smulson, M. E., and Spiegel, S. (1998)
J BioI Chern 273,2910-2916
239. Hsu, S. C., Wu, C. C., Luh, T. Y., Chou, C. K., Han, S. H., and Lai, M.
Z. (1998) Blood 91, 2658-2663
240. Rodriguez-Lafrasse, C., Alphonse, G., Broquet, P., Aloy, M. To,
Louisot, P., and Rousson, R. (2001) Biochem J 357, 407-416
241. Caricchio, R., D1Adamio, L., and Cohen, P. Lo (2002) Cell Death Differ
9,574-580
242. Hetz, C. A., Hunn, M., Rojas, P.~ Torres, V., Leyton , L., and Quest, A.
F. (2002) J Cell Sci 115, 4671-4683
243. Grassme, H., Cremesti, A., Kolesnick, R., and Gulbins, E. (2003)
Oncogene 22,5457-5470
244. Rotolo, J. A., Zhang, J., Donepudi, M., Lee, H., Fuks, Z., and
Kolesnick, R. (2005) J BioI Chem 280, 26425-26434
245. Chaigne-Delalande, B., Moreau, J. F., and Legembre, P. (2008) Arch
Immunol Ther Exp (Warsz) 56, 9-14
246. Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z.,
Gulbins, E., and Kolesnick, R. (2001) J BioI Chern 276, 23954-23961
247. Jin, Z. X., Huang, C. R., Dong, L., Gada, S., Kawanami, T., Sawaki,
T., Sakai, T., Tong, X. P., Masaki, Y., Fukushima, T., Tanaka, M.,
Mimori, T., Tojo, H., Bloom, E. To, Okazaki, T., and Umehara, H.
(2008) tnt Immuno/20, 1427-1437
248. Chatterjee, M., and Wu, S. (2001) Mol Cell Biochem 219,21-27
190

249. Matsko, C. Mo, Hunter, 0o Co, Rabinowich, H., Lotze, M. T., and
Amoscato, A. A. (2001) Biochem Biophys Res Commun 287, 11121120
250. Alphonse, G., Aloy, M. T., Broquet, P., Gerard, J. P., Louisat, P.,
Rousson, R., and Rodriguez-Lafrasse, C. (2002) Int J Radiat Bio17S,
821-835
251. Rodriguez-Lafrasse, C., Alphonse, G., Aloy, M. T., Ardail, D., Gerard,
J. P., Louisot, P., and Rousson, R. (2002) Int J Cancer 101, 589-598
252. Herrera, B., Carracedo, A., Diez-Zaera, M., Gomez del Pulgar, T.,
Guzman, M., and Velasco, G. (2006) Exp Cell Res 312, 2121-2131
253. Ion, G., Fajka-Boja, R., Kovacs, F., Szebeni, G., Gombos, I., Czibula,
A., Matko, J., and Monostori, E. (2006) Cell Signa/1S, 1887-1896
254. Ardail, D., Maalouf, M., Boivin, A., Chapet, 0., Bodennec, J.,
Rousson, R., and Rodriguez-Lafrasse, C. (2009) Int J Radiat Oncol
BiolPhys73, 1211-1218
255. Granot, T., Milhas, D., Carpentier, S., Dagan, A., Segui, Bo, Gatt, S.,
and Levade, T. (2006) Leukemia 20,392-399
256. Villena, J., Henriquez, M., Torres, V., Moraga, F., Diaz-Elizondo, J.,
Arredondo, C., Chiong, M., Olea-Azar, C., Stutzin, A., Lavandero, S.,
and Quest, A. F. (2008) Free Radic Bioi Med 44, 1146-1160
257. Furlong, S. J., Ridgway, N. D., and Hoskin, D. W. (2008) Int J Oneol
32,537-544
258. Paugh, S. W., Paugh, B. S., Rahmani, M., Kapitonov, D., Almenara,
J. A., Kordula, T., Milstien, S., Adams, J. K., Zipkin, R. E., Grant, S.,
and Spiegel, S. (2008) Blood 112, 1382-1391
259. Separovic, D., Hanada, K., Maitah, M. V., Nagy, B., Hang, I., Tainsky,
M. A., Kraniak, J. M., and Bielawski, J. (2007) Biochem Biophys Res
Commun 358, 196-202
260. Separovic, D., Semaan, L., Tarca, A. L., Awad Maitah, M. Y.,
Hanada, Ko, Bielawski, J., Villani, M., and Luberto, C. (2008) Exp Cell
Res 314, 1860-1868
261. Lin, C. F., Chen, C. L., Chang, W. T., Jan, M. So, Hsu, L. J., Wu, R.
H., Tang, M. J., Chang, W. C., and Lin, Y. S. (2004) J BioI Chern 279,
40755-40761
262. Chen, C. L., Lin, C. F., Chang, W. T., Huang, W. C., Teng, C. F., and
Lin, Y. S. (2008) Blood 111, 4365-4374
263. Jayadev, S., Liu, S., Sielawska, A. E., Lee, J. Y., Nazaire, F.,
Pushkareva, M., Obeid, L. M., and Hannun, Y. A. (1995) J Bioi Chern
270,2047-2052
191

264. Lee, J. Y., Bielawska, A. E., and Obeid, L. M. (2000) Exp Cell Res
261, 303-311
265. Laethem, R. M., Hannun, Y. A., Jayadev, S., Sexton, C. J., Strum, J.
C., Sundseth, R., and Smith, G. K. (1998) Blood 91,4350-4360
266. Dbaibo, G. S., Pushkareva, M. Y., Rachid, R. A., Alter, N., Smyth, M.
J., Obeid, L. M., and Hannun, Y. A. (1998) J Clin Invest 102, 329-339
267. Panjarian, S., Kozhaya, L., Arayssi, S., Yehia, M., Bielawski, J.,
Bielawska, A., Usta, J., Hannun, Y. A., Obeid, L. M., and Dbaibo, G.
S. (2008) Prostaglandins Other Lipid Mediat 86, 41-48
268. Kim, W. J., Okimoto, R. A., Purton, L. E., Goodwin, M., Haserlat, S.
M., Dayyani, F., Sweetser, D. A., McClatchey, A. I., Bernard, O. A.,
Look, A. T., Bell, D. W., Scadden, D. T., and Haber, D. A. (2008)
Blood 111, 4716-4722
269. Liu, X., Ryland, L., Yang, J., Liao, A., Aliaga, C., Watts, R., Tan, S. F.,
Kaiser, J., Shanmugavelandy, S. S., Rogers, A., Loughran, K.,
Petersen, B., Yuen, J., Meng, F., Baab, K. T., Jarbadan, N. R., Broeg,
K., Zhang, R., Liao, J., Sayers, T. J., Kester, M., and Loughran, T. P.,
Jr. (2010) Blood 116, 4192-4201
270. Shah, M. V., Zhang, R., Irby, R., Kothapalli, R., Liu, X., Arrington, T.,
Frank, S., Lee, N. H'1 and Loughran, T. P., Jr. (2008) Blood 112, 770781
271. Kabarowski, J. H., and Witte, O. N. (2000) Stem Cells 18, 399-408
272. Rowley, J. D. (1973) Nature 243, 290-293
273. Deininger, M. W., Goldman, J. M., and Melo, J. V. (2000) Blood 96,
3343-3356
274. Ren, R. (2005) Nat Rev Cancer 5, 172-183
275. Wong, S., and Witte, O. N. (2004) Annu Rev Immunol22, 247-306
276. Karbasian Esfahani, M., Morris, E. L., Dutcher, J. P., and Wiernik, P.
H. (2006) Curf Treat Options Oncol7, 189-199
277. Quintas-Cardama, A., and Cortes, J. (2009) Blood 113, 1619-1630
278. Marley, S. 8., and Gordon, M. Y. (2005) Clin Sci (Lond) 109, 13-25
279. Sessions, J. (2007) Am J Health Syst Pharm 64, 84-9
280. Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai,
Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., and et
al. (1993) Ce1l75, 175-185
281. Skorski, T., Kanakaraj, P., Nieborowska-Skarska, M., Ratajczak, M.
Z., Wen, S. C.~ Zan, G., Gewirtz, A. M., Perussia, B., and Calabretta,
B. (1995) Blood86, 726-736
282. Lydon, N. B., and Druker, B. J. (2004) Leuk Res 28 Suppl 1, 829-38
192

283. Marin, D., Marktel, S., Sua, M., Armstrong, L., Goldman, J. M.,
Apperley, J. F., and Olavarria, E. (2002) Haemat%gica 87, 979-988
284. Ross, J. S., Schenkein, D. P., Pietrusko, R., Rolfe, M., Linette, G. P.,
Stec, J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai,
L., and Hortobagyi, G. N. (2004) Am J Clin Patho/122, 598-609
285. Spellberg, B. J., Collins, M., Avanesian, V., Gomez, M., Edwards, J.
E., Jr., Cagle, C., Applebaum, D., Fu, Y., and Ibrahim, A. S. (2007) J
Leukoc 8;0181, 632-641
286. Apperley, J. F. (2007) Lancet Oncol a, 1018-1029
287. Kantarjian, H. M., Talpaz, M., Kontoyiannis, D., Gutterman, J.,
Keating, M. J., Estey, E. H., O'Brien, S., Rios, M. B., Beran, M., and
Deisseroth, A. (1992) J Clin Onco/1 0, 398-405
288. Kantarjian, H. M., Walters, R. S., Keating, M. J., Talpaz, M.,
Andersson, B., Beran, M., McCredie, K. B., and Freireich, E. J. (1988)
Cancer 62, 672-676
289. Morris, M. J. (2006) Nat Clin Pract Onco/3, 536-537
290. Koller, C. A., and Miller, D. M. (1986) N EnglJ Med315, 1433-1438
291. Axdorph, U., Stenke, L., Grimfors, G., Carneskog, J., Hansen, J.,
Linder, 0., Ljungman, P., Lofvenberg, E., Maim, C., Simonsson, B.,
Turesson, I., Vilen, L., Uden, A. M., and 8jorkholm, M. (2002) Br J
Haemato/118, 1048-1054
292. Amarante-Mendes, G. P., Naekyung Kim, C., Liu, L., Huang, Y.,
Perkins, C. L., Green, D. R., and Shalla, K. (1998) Blood 91, 17001705
293. Maguer-Satta, V. (1998) Hematol Cell Ther 40, 233-236
294. Nica, A. F., Tsao, C. C., Watt, J. C., Jiffar, T., Kurinna, S., Jurasz, P.,
Konopleva, M., Andreeff, M., Radomski, M. W., and Ruvolo, P. P.
(2008) Cell Cycle 7,3362-3370
295. Maguer-Satta, V., Burl, S., Liu, L., Damen, J., Chahine, H., Krystal,
G., Eaves, A., and Eaves, C. (1998) Oncogene 16,237-248
296. Li, Q. F., Huang, W. R., Duan, H. F., Wang, H., Wu, C. T., and Wang,
L. S. (2007) Oncogene 26, 7904-7908
297. Wang, F. X., Dong, Z. R., Liu, Z. L., Pan, L., Luo, J. M., Zhang, X. J.,
Hao, H. L., Li, X. L., Yang, J. C., and Jiang, L. L. (2004) Zhongguo
Shi Yan Xue Ye Xue Za Zhi 12,577-583
298. Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., Obeid,
L. M., and Ogretmen, B. (2007) J BioI Chern 282, 10922-10934
299. Bonhoure, E., Lauret, A., Barnes, D. J., Martin, C., Malavaud, S.,
Kohama, T., Melo, J. V., and Cuvillier, O. (2008) Leukemia 22, 971979
193

300. Bonhoure, E., Lauret, A., Barnes, D., J.Martin, C., Malavaud,
B.Kohama, T.Melo, and J. V.Cuvillier, O. (2008) Leukemia 22, 971979
301. Ricci, C., Onida, F., Servida, F., Radaelli, F., Saporiti, G., Todoerti,
K., Deliliers, G. L., and Ghidoni, R. (2009) Br J Haemato/144, 350357
302. Ricci, C., Onida, F., and Ghidoni, R. (2006) Biochim Biophys Acta
1758,2121-2132
303. Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M.,
Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., GambacortiPasserini, C., Druker, B. J., Cortes, J., Marcucci, G., Chen, C. S.,
Verrills, N. M., Roy, D. C., Caligiuri, M. A., Bloomfield, C. D., Byrd, J.
C., and Perrotti, D. (2007) J Clin Invest 117, 2408-2421
304. Lahiri, S., Park, H., Laviad, E. L., Lu, X., Bittman, R., and Futerman,
A. H. (2009) J Bioi Chern 284, 16090-16098
305. Gotoh, A., Miyazawa, K., Ohyashiki, K., and Toyama, K. (1994)
Leukemia 8, 115-120
306. Markova, B., Albers, C., Breitenbuecher, F., Melo, J. V.,
Brummendorf, T. H., Heidel, F., Lipka, D., Duyster, J., Huber, C., and
Fischer, T. (2010) Oncogene 29,739-751
307. Bernert, J. T., and Ullman, M. D. (1981) Biochim.Biophys.Acta 666,
99-109
308. Hatch, G. M., and Vance, D. E. (1992) J.Biol.Chem. 267, 1244312451
309. Marggraf, W. D., Anderer, F. A., and Kanfer, J. (1981)
Biochim. Biophys.Acta 664, 61-73
310. Marggraf, W. D., Zertani, R., Anderer, F. A., and Kanfer, J. N. (1982)
Biochim.Biophys.Acta 710,314-323
311. Merrill, A. H., Jr., and Jones, D. D. (1990) Biochim.Biophys.Acta
Lipids Lipid Metab. 1044, 1-12
312. Ullman, M. D., and Radin, N. S. (1974) J Bioi Chern 249,1506-1512.
313. Voelker, D. R. K., and Kennedy, E. P. (1982) Biochemistry 21, 27532759
314. Luberto, C., and Hannun, Y. A. (1998) J.Biol.Chem. 273, 1455014559
315. van den Hill, A., van Heusden, G. P., and Wirtz, K. W. (1985) Biochim
Biophys Acta 833, 354-357
316. Li, Z., Hailemariam, T. K., Zhou, H., Li, Y., Duckworth, D. C., Peake,
D. A., Zhang, Y., Kuo, M. S., Cao, G., and Jiang, X. C. (2007)
Biochim Biophys Acta 1771, 1186-1194
194

317. Lafont, E., Milhas, D., Carpentier, S., Garcia, V., Jin, Z. X., Umehara,
H., Okazaki, T., Schulze-Osthoff, K., Levade, T., Benoist, H., and
Segui, B. (2009) Cell Death Differ
318. Kantarjian, H. M., Cortes, J., OIBrien, S., Giles, F. J., Albitar, M.,
Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D. A.,
Resta, D., and Talpaz, M. (2002) Blood 99, 3547-3553
319. Scherr, M., Battmer, K., Winkler, T., Heidenreich, 0., Ganser, A., and
Eder, M. (2003) Blood 101, 1566-1569
320. Ames, B. N., and Dubin, D. T. (1960) J Bioi Chern 235, 769-775
321. Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U., and Nishizuka, Y.
(1980) J BioI Chern 255, 2273-2276
322. Takai, Y., Kishimoto, A., Kikkawa, U., Mori, T., and Nishizuka, Y.
(1979) Biochern Biophys Res Commun 91, 1218-1224
323. Bikman, B. T., and Summers, S. A. J Clin Invest 121,4222-4230
324. Henry, B., Moller, C., Dimanche-Boitrel, M. T., Gulbins, E., and
Becker, K. A. Cancer Lett
325. Mullen, T. D., and Obeid, L. M. Anticancer Agents Med Chern
326. Perry, R. J., and Ridgway, N. D. (2004) J Lipid Res 45, 164-173
327. Vladychenskaya, I. P., Dergunova, L. V., and Limborska, S. A. (2002)
Biomol Eng 18 1 263-268
328. Rozhkova, A. V., Dmitrieva, V. G., Zhapparova, O. N., Sudarkina, O.
Y., Nadezhdina, E. S., Limborska, S. A., and Dergunova, L. V. (2011)
Gene 481, 65-75
329. Muller, P. Y., Janovjak, H., Miserez, A. R., and Dobbie, Z. (2002)
Biotechniques 32, 1372-1374, 1376, 1378-1379
330. Vladychenskaya, I. P., Dergunova, L. V., Dmitrieva, V. G., and
Limborska, S. A. (2004) Gene 338,257-265
331. Elferink, C. J., and Reiners, J. J., Jr. (1996) Biotechniques 20, 470477
332. Lipson, K. E., and Baserga, R. (1989) Proc Nat/ Acad Sci USA 86,
9774-9777
333. Reddy, S. T., Gilbert, R. S., Xie, W., Luner, S., and Herschman, H. R.
(1994) J Leukoc Bio/55, 192-200
334. Su, R. C., Brown, K. E., Saaber, S., Fisher, A. G., Merkenschlager,
M., and Smale, S. T. (2004) Nat Genet 36,502-506
335. Pesole, G., Mignone, F., Gissi, C., Grillo, G., Licciulli, F., and Liuni, S.
(2001) Gene 276, 73-81
336. Chen, C. Y., and Shyu, A. B. (1995) Trends Biochem Sci 20, 465-470
337. Guhaniyogi, J., and Brewer, G. (2001) Gene 265, 11-23
338. Maruyama, K., and Sugano, S. (1994) Gene 138,171-174
195

339. Schaefer, B. C. (1995) Anal Biochem 227,255-273
340. Michael Carey, S. T. S. (2001) Transcriptional Regulation in
Eukaryotes: Concepts, Strategies, and Techniques, CSHL Press
341. Liao, W. R., Hsieh, R. H., Hsu, K. W., Wu, M. Z., Tseng, M. J., Mai,
R. T., Wu Lee, V. H., and Veh, T. S. (2007) Carcinogenesis 28, 18671876
342. Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Vu, E. V.,
An, D. S., Sabatini, D. M., Chen, I. S., Hahn, W. C., Sharp, P. A.,
Weinberg, R. A., and Novina, C. D. (2003) RNA 9, 493-501
343. Luberto, C., Voo, D. S., Suidan, H. S., Bartoli, G. M., and Hannun, V.
A. (2000) J BioI Chern 275, 14760-14766
344. Rosenbauer, F., Waring, J. F., Foerster, J., Wietstruk, M., Philipp, D.,
and Horak, I. (1999) Blood 94, 4274-4281
345. Schmidt, M., Hochhaus, A., Konig-Merediz, S. A., Brendel, C., Proba,
J., Hoppe, G. J., Wittig, B., Ehninger, G., Hehlmann, R., and
Neubauer, A. (2000) J Clin Onco/18, 3331-3338
346. Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu,
S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., Roy, D. C., Valtieri,
M., Bruner-Klisovic, R., Caligiuri, M. A., Bloomfield, C. D., Marcucci,
G., and Perrotti, D. (2005) Cancer Cell 8, 355-368
347. Perrotti, D., and Neviani, P. (2006) BrJ Cancer 95, 775-781
348. Pierce, J. W., Lenardo, M., and Baltimore, D. (1988) Proc Nat! Acad
Sci USA 85,1482-1486
349. lIaria, R. L., Jr., and Van Etten, R. A. (1996) J BioI Chern 271, 3170431710
350. Hoelbl, A., Kovacic, B., Kerenyi, M. A., Simma, 0., Warsch, W., Cui,
V., Beug, H., Hennighausen, L., Moriggl, R., and Sexl, V. (2006)
Blood 107, 4898-4906
351. Samanta, A. K., Lin, H., Sun, T., Kantarjian, H., and Arlinghaus, R. B.
(2006) Cancer Res 66, 6468-6472
352. Klejman, A., Schreiner, S. J., Nieborowska-Skorska, M., Siupianek,
A., Wilson, M., Smithgall, T. E., and Skorski, T. (2002) Embo J 21,
5766-5774
353. Tao, W. J., Lin, H., Sun, T., Samanta, A. K., and Arlinghaus, R.
(2008) Oncogene 27, 3194-3200
354. Benekli, M., Baer, M. R., Baumann, H., and Wetzler, M. (2003) Blood
101 , 2940-2954

196

